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SUMMARY 
 
Diabetes mellitus is correlated with modifications in bone microarchitectural and 
mechanical strength, leading to increased bone fragility. The incretin hormones, with 
a classical effect to increase insulin secretion following food ingestion, are now 
postulated to have important direct effects on bone. As such, glucose-dependent 
insulinotropic polypeptide (GIP) has dual actions on bone cells; enhancing bone-
forming activity of osteoblasts and suppressing bone resorption by osteoclasts. The 
sister incretin of GIP, glucagon-like peptide-1 (GLP-1), is also suspected to directly 
influence bone health in a beneficial manner, although mechanism are less clear at 
present. The physiological actions of incretins are attenuated by dipeptidyl peptidase 
(DPP-4) activity and it is speculated that introduction of DPP-4 inhibitor may also 
positively affect quality of the skeleton. As such, this thesis evaluates the potential 
beneficial effects of a DPP-4 resistant GIP analogue, namely [D-Ala
2
]GIP, on 
osteoblastic-derived, SaOS-2 cells, and also preliminary in vivo studies on the impact 
of genetic deficiencies of GIPRs and GLP-1Rs on bone mineral density and content. 
Further studies characterised the beneficial effects of incretin-based therapies on 
metabolic control, bone microstructure and bone mechanical integrity in animal 
models of pharmacologically-, genetically- and environmentally-induced diabetes. 
GIP and related stable analogue increased bone-forming biomarkers in SaOS-2 cells 
and importantly, [D-Ala
2
]GIP was shown to be more potent than native GIP. 
Knockout mouse studies revealed that both GIPR and GLP-1R signaling are 
important for optimum bone mass. All diabetic mouse models displayed reduced 
bone mass, altered bone micromorphology and impairment of bone mechanical 
strength, similar to the human situation, confirming their appropriateness. The 
incretin-based therapeutics, [D-Ala
2
]GIP and Liraglutide, in streptozotocin-diabetic 
significantly increased bone matrix properties, indicating recovery of bone strength 
at the tissue level. The beneficial effects of administration of [D-Ala
2
]GIP-
oxyntomodulin on bone health in db/db mice were more prominent as the Oxm 
analogue did not only improve bone strength at tissue level, but also at whole-bone 
level. These modifications were independent of metabolic status. Twice-daily 
Exendin-4 therapy improved glycaemic control and increased work required to resist 
bone fracture in high-fat fed mice. It was also established that Sitagliptin had neutral 
effects on bone microstructure and mechanical strength in high-fat mice. In 
xv 
 
summary, these data demonstrate the negative impact of diabetes mellitus on normal 
skeleton development and bone quality. Moreover, this thesis highlights the growing 
potential of incretin-based therapies for ameliorating bone defects and improving the 
increased fragility fracture risk associated with diabetes. 
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1.0 OVERVIEW 
 
Diabetes has become a global issue as it is estimated that more than 387 million 
people worldwide are affected by this modern disease (International Diabetes 
Federation 2014b). The alarming number of diabetes cases has listed this disorder as 
the potential seventh leading cause of death in 2030 (Mathers & Loncar 2006). 
Common complications that are associated with diabetes include retinopathy 
(blindness), neuropathy (nerve damage), cardiovascular disease, stroke and 
nephropathy (kidney failure) (Diabetes UK 2014) and most recently, diabetes is also 
related to bone loss. Extensive studies on the impact of diabetes on bone have linked 
the disease to severe impairment of bone mechanical integrity, reduced bone mineral 
density (BMD) in T1DM and unaffected or even increased BMD in T2DM. 
Regardless of the inconsistencies in BMD, both types of diabetic patients have 
increased risk of fractures (Janghorbani et al. 2007, Vestergaard 2007). Early 
diagnosis and treatment of diabetes is vital to prevent long term complications that 
could lead to bone fractures and mortality in elderly people. Furthermore, the link 
between diabetes and bone fragility suggests that if blood glucose management is 
improved or if signaling pathways contributing to diabetic bone pathologies are 
corrected, overall bone quality could be enhanced, improving the increased risk of 
fracture in diabetic patients. 
 
1.1  DIABETES MELLITUS 
 
Diabetes mellitus (DM) is a metabolic disease where production of insulin is 
insufficient or body cannot effectively utilise insulin produced by pancreas.  As a 
consequence, there will be high blood glucose levels in the body. Diagnosis of 
diabetes mellitus is made when fasting plasma glucose is ≥ 126 mg/dl (7.0 mmol/l) 
or plasma glucose level is ≥ 200 mg/dl (11.1 mmol/l) measured 2 hours after 75 g-
oral glucose tolerance test (Zemmit et al. 2001). Generally, the disease is classified 
into 2 major forms; type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus 
(T2DM).  
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1.1.1 Type  1 diabetes mellitus 
 
Type 1 diabetes mellitus (T1DM), previously referred to as juvenile-onset or insulin-
dependent diabetes, is characterised by inability of the body to synthesise insulin due 
to destruction of insulin-producing pancreatic beta cells. This results in a dependency 
on exogenous insulin to stabilise blood glucose concentrations following feeding. 
The pathogenesis of this autoimmune disorder has been extensively studied in rodent 
models and humans and several key target for autoantibodies and autoreactive cells 
have been identified; insulin, glutamic acid decarboxylase (GAD), protein tyrosine 
phosphatase insulinoma antigen (IA-2), zinc transporter 8 (ZnT8) and islet glucose-
6-phosphatase catalytic subunit-related protein (IGRP) (Culina et al. 2013, Yoon & 
Jun 2005, Zhang et al. 2008). Pancreatic beta cells autoantigens together with 
lymphocytes and macrophages trigger overexpression of CD4
+
 and beta cell-specific 
cytotoxic CD8
+
 T cells (Pinkse et al. 2005) which eventually lead to the destruction 
of insulin-producing beta cells.  
 
The primary cause of T1DM is autoimmune beta-cell destruction. However, there is 
also correlation between genetic and several environmental factors in the 
pathogenesis of TIDM. Genetic components that strongly influence T1DM are 
reported to be on major histocompatibility complex human leukocyte antigen (HLA) 
alleles, which are associated with ‘protection from’ or ‘susceptibility towards’ 
T1DM. More than 90% of TIDM patients have either DR3-DQ2 or DR4-DQ8 
haplotypes, while the percentage of normal controls with these haplotypes is less 
than 40% (Atkinson & Eisenbarth 2001). These genes are known to be important 
regulators in immune response by introducing peptide antigens to T lymphocytes 
which stimulate the production of antibodies against beta-cell antigens. Further 
exposure to environmental triggers such as viruses in susceptible individuals can 
cause abnormal activation of immune system that will generate multiple 
autoantibodies to islet cells. 
 
T1DM is most prevalent in children and young people and it accounts for about 10% 
of diabetes cases worldwide (International Diabetes Federation 2014a). Statistical 
studies conducted by EURODIAB (EUROpe and DIABetes) from 1989 to 2003 
estimated that diabetes cases in children below 15 years old will rise by 70% in 2020 
4 
 
(Patterson et al. 2009). A more recent study on trends over 20-year incidence 
projected that the prevalence of Type 1 diabetes has annual increase of 3.4% 
(Patterson et al. 2012). 
 
1.1.2 Type 2 diabetes mellitus  
 
Type 2 diabetes mellitus (T2DM), previously known as adult-onset or non-insulin-
dependent diabetes, develops when beta cells do not make enough insulin or the 
insulin produced does not work appropriately. T2DM is a progressive disease and 
starts gradually with insulin insensitivity or impairment of the body’s response to 
insulin (Stumvoll et al. 2005). Compensatory mechanism in the body respond to 
insulin resistance by secreting more insulin to maintain normal glucose levels, but 
eventually pancreatic beta-cells can no longer produce sufficient insulin to maintain 
normal glucose levels. Over time, worsening insulin resistance and the decline in 
beta cell function will lead to hyperglycaemia and eventually progress to the diabetic 
state. The environmental factors that trigger T2DM are pregnancy, ageing and 
modern lifestyle (high calorie intake, obesity, physical inactivity) (Chen et al. 1988, 
Hu 2011, Stumvoll et al. 2005). Similar to T1DM, the combination of genetic 
predisposition and environmental factors contributes to the onset of insulin 
resistance and its progression to T2DM (Leahy 2005). The key genes associated with 
genetic predisposition of T2DM are TCF7L2, PPARG, KCNJ11, CAPN10, 
HHEXIIDE, MC4R, FTO and KCNQ1 (Tahrani et al. 2011, Valeriya et al. 2007).  
 
T2DM usually appears in middle-aged and older people and accounts for 90% of all 
diabetes cases (International Diabetes Federation 2014a). T2DM has become an 
epidemic as this disease progresses slowly and undetected many years before 
diagnosis is made. With increasing prevalence of obesity and T2DM, a huge burden 
is imposed on the public health-system (Diabetes UK 2012). 
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1.1.3 Existing treatment for diabetes 
 
The only therapeutic option for T1DM patients is exogenous insulin replacement 
therapy. However, T1DM complications are not always prevented by exogenous 
insulin therapy (Atkinson et al. 2014). Other important glucoregulatory hormone 
which is co-secreted with insulin by pancreatic beta cells, amylin, is also reduced in 
T1DM, leading to generation of synthetic amylin analogue, Pramlintide. Amylin 
replacement with Pramlintide improves glycaemic control by delaying gastric 
emptying and suppressing postprandial glucagon secretion (Fineman et al. 2002, 
Nyholm et al. 1999). In a long term clinical study, adjunct therapy with Pramlintide 
has been shown to provide better glycaemic control in T1DM individuals compared 
to insulin replacement alone (Ratner et al. 2004). As such, this amylin-related 
analogue was clinically approved in April 2004 by the US Food and Drug 
Administration (FDA) to be used as add-on with insulin therapy in T1DM patients 
(Ryan et al. 2005). Another option for T1DM treatment is islet-cell transplantation, 
leaving the recipients dependent on lifelong immunosuppression drugs to prevent 
organ rejection. Most importantly, the limiting factor in this type of treatment is a 
short supply of organs and until new sources of functional islets are found, the future 
for organ transplantation in T1DM treatment remains sceptical (McCall & Shapiro 
2012). 
 
Obesity is normally associated with impaired glucose tolerance and increased risk of 
developing T2DM. This is due to increased adipocyte accumulation of non-esterified 
fatty acids, hormones, inflammatory cytokines and other molecules that are involved 
in the development of insulin resistance (Kahn et al. 2006). Essentially, insulin 
resistance is improved through intensive lifestyle intervention by monitoring 
nutritient intake and regular physical activity (Tahrani et al. 2011). However, 
lifestyle changes are difficult to maintain and not sufficient to keep blood glucose 
levels normal. Consequently, oral or injectable antidiabetic drugs are often required 
to manage T2DM (International Diabetes Federation 2014a). Currently available 
T2DM treatments are summarised in Table 1.1.  
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Table 1.1 Summary of available treatment for T2DM 
 
Class Compound(s) Physiological action(s) Side effects 
 
Biguanides 
 
 
 
 
 
Sulfonylureas 
 
 
 
 
 
 
 
Meglitinides 
 
 
 
 
 
 
 
 
 
Thiazolidinediones 
 
 
 
 
 
 
 
 
 
 
 
Dipeptidyl 
peptidase-4 (DPP-
 
Metformin 
 
 
 
 
 
Glibenclamide 
/ glyburide 
Glipizide 
Glimepiride 
Gliclazide 
 
 
 
Repaglinide 
Nateglinide 
 
 
 
 
 
 
 
 
Pioglitazone 
Rosiglitazone 
 
 
 
 
 
 
 
 
 
 
Sitagliptin 
Vildagliptin 
 
Suppresses hepatic 
glucose production and 
increases insulin 
sensitivity in muscle  
 
 
Binds to sulphonylurea 
receptors causes KATP 
channels on beta-cell 
plasma membranes to 
close, influx of Ca
2+ 
and 
stimulation of insulin 
release 
 
Binds to sulphonylurea 
receptors, but at 
different binding sites 
to sulphonylurea causes 
KATP channels on beta-
cell plasma membranes 
to close, influx of Ca
2+ 
and stimulation of 
insulin release 
 
Agonise and activate 
nuclear transcription 
factor peroxisome-
proliferator-activated-
receptor-γ (PPAR-γ) in 
adipose tissue, increase 
adipogenesis, reduce 
release of fatty acids 
and increase insulin 
sensitivity in muscle 
and liver 
 
Inhibits DPP-4 action 
causes an increase in 
 
Gastrointestinal side 
effects such as diarrhoea, 
abdominal cramping 
Risk of lactic acidosis 
Vitamin B12 deficiency 
 
Hypoglycaemia 
Weight gain 
 
 
 
 
 
 
Hypoglycaemia 
Weight gain 
 
 
 
 
 
 
 
 
Weight gain 
Oedema / heart failure 
Bone fractures 
Rosiglitazone increases 
LDL-C 
 
 
 
 
 
 
 
Angio-oedema 
Association with 
7 
 
4) inhibitors 
 
 
 
Glucagon-like 
peptide-1 (GLP-1) 
receptor agonists 
 
 
 
 
 
 
SGLT2 inhibitors 
 
 
 
Saxagliptin 
Linagliptin 
Alogliptin 
 
Exendin-4 
Liraglutide 
Exenatide-
long-acting 
release (LAR) 
Lixisenatide 
Albiglutide 
 
 
Dapagliflozin 
Canagliflozin 
concentrations of native 
GLP-1 and GIP 
 
 
Bind to and agonise 
GLP-1 receptor, 
causing increase in 
glucose-dependent 
insulin secretion, 
glucagon suppression, 
slow gastric emptying 
and reduce appetite 
 
Inhibits SGLT2 action 
causes reduction in 
renal glucose 
reabsorption 
 
pancreatitits 
Long-term effect not fully 
known 
 
Gastrointestinal side 
effects such as vomiting 
Association with 
pancreatitis and medullary 
thyroid tumours in animals 
 
 
 
 
Increased risk of genital 
and urinary tract infections 
 
 
 
Adapted from (Inzucchi et al. 2012, Tahrani et al. 2011)   
 
Metformin, a biguanide, is the first-line oral therapy for T2DM treatment at present. 
Glycaemic control by this biguanide is achieved through improving hepatic and 
peripheral sensitivity to insulin, enhancing insulin-stimulated glucose uptake by 
skeletal muscle and suppressing hepatic gluconeogenesis (Krentz & Bailey 2005, 
Wiernsperger & Bailey 1999). Metformin remains the first choice as glucose levels 
are controlled without increasing body weight or increasing risk of hypoglycaemia in 
T2DM patients (Hermann et al. 1994). However, it still has side effects such as 
diarrhoea and risk of lactic acidosis (Inzucchi et al. 2012). Oral metformin does not 
have direct effect on stimulating pancreatic beta-cell insulin release and when 
metformin monotherapy is inadequate to maintain normal blood glucose levels, the 
drug is frequently combined with a sulfonylurea (Inzucchi 2002, Krentz & Bailey 
2005).  
 
Sulfonylureas, in contrast to metformin, act by directly stimulating insulin secretion 
from pancreatic islet beta cells. Sulfonylureas bind to the sulphonylurea receptor-1 
(SUR-1), a drug-binding subunit of the ATP-sensitive potassium channel on beta 
cells, causing the potassium channels to close (Ashcroft 1996). The closure of 
8 
 
potassium channels initiates a series of events; plasma membrane depolarisation, 
voltage-dependent Ca
2+
 channels are opened, increase Ca
2+
 influx and insulin 
secreted by exocytosis. Normal glucose concentration for glucose-mediated insulin 
release is around 5 mmol/l, but in the presence of sulfonylureas, this occurs even at 
low glucose concentration. Therefore, there is a potential consequence of 
hypoglycaemia with these agents (Krentz & Bailey 2005). However, as T2DM 
progresses, which is reflected by beta-cell failure, there is an inadequacy of 
sulfonylureas to lower blood glucose concentrations. Early introduction of 
exogenous insulin to sulphonylurea-treated patients has been shown to significantly 
improve glycaemic control, without causing hypoglycaemia or promoting weight 
gain (Wright et al. 2002).  
 
Meglinitides bind to non-sulfonylurea sites on SUR-l and similar to sulfonylureas, 
their binding on SUR-1 closes the ATP-regulated potasssium channels and activates 
cascades of events which lead to insulin secretion (Pfeiffer 2008). The meglitinides 
are structurally unrelated to sulfonylureas, where a member of meglinitides, 
repaglinide is derived from benzoic acid, whilst nateglinide is a phenylalanine 
derivative (Chachin et al. 2003, Fuhlendorff et al. 1998). Nateglinide has low 
binding affinity for the KATP channels and rapidly dissociates, while the binding 
affinity of repaglinide is in between the high-affinity sulphonylureas (glibenclamide 
and glimepiride) and nateglinide (Hu et al. 2000), indicating shorter duration of 
actions of meglinitides compared to sulfonylureas. The side effects of these drugs 
include weight gain and hypoglycemia (Black et al. 2009). 
 
Thiazolidinediones (TZDs) activate peroxisome proliferator-activated receptor γ 
(PPAR-γ), which closely associated with adipogenesis (Yki-Jarvinen 2004). 
Activation of PPAR-γ also increases the uptake and storage of free fatty acid 
(Bogacka et al. 2004). In addition, these insulin-sensitizing drugs regulate glucose 
levels by improving insulin sensitivity in skeletal muscle and reducing hepatic 
glucose production (Natali & Ferrannini 2006).  A recent study has also shown that a 
member of the TZDs, Pioglitazone reduces the risk of developing T2DM by 72% in 
adult with impaired glucose tolerance (DeFronzo et al. 2011). Several adverse effects 
of TZDs include increased body weight, oedema and elevated risk of bone fractures 
(Kahn et al. 2006, Schwartz et al. 2006, Yki-Jarvinen 2004).  
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Sodium–glucose-cotransporter-2 (SGLT2) inhibitors target the activity of SGLT2 by 
reducing renal glucose reabsorption and increasing urinary glucose excretion, thus 
preventing increased plasma glucose levels (Chao & Henry 2010). Due to high 
expression of SGLT2 in kidney, its inhibition plays an important role in controlling 
reabsorption of glucose in diabetes as SGLT2, facilitated by glucose tranporter type 
2 (GLUT2), has high capacity (90%) to transport glucose back into blood circulation 
(Chao & Henry 2010). This insulin-independent activity of SGLT2 inhibitors is 
compensated by SGLT1, which reabsorbs glucose at slow rate and therefore, 
minimises the risk of hypoglycaemia (Tahrani et al. 2011). Oral highly-selective 
SGLT2 inhibitor, Dapagliflozin is associated with mild risk of genital and urinary 
tract infections (List et al. 2009, Wilding et al. 2009). 
 
Newly-introduced classes of antihyperglycaemia drugs for T2DM are GLP-1R 
agonists and DPP-4 inhibitors (Nauck et al. 2009). Similar to native GLP-1, the 
binding of injectable GLP-1 mimetics to GLP-1R stimulates glucose-dependent 
pancreatic insulin release, suppresses glucagon secretion, delays gastric emptying 
and reduces appetite (Drucker et al. 2010). The main advantage of GLP-1-based 
drugs is they promote weight loss, but the stable analogues also have adverse effects 
such as nausea and vomiting (Lovshin & Drucker 2009). On the other hand, the oral 
dipeptidyl peptidase 4 (DPP-4) inhibitors stabilise circulating concentrations of 
endogenous GLP-1 and GIP from DPP-4 activity, thus prolonging bioactivity of the 
incretin hormones postprandially (Drucker & Nauck 2006). Although DPP-4 
inhibitors mediate regulation of insulin and glucagon secretion through GLP-1, the 
suppression of DPP-4 activity has neutral effect on body weight (Lovshin & Drucker 
2009). Additionally, the risk of hypoglycaemia is minimised with incretin-based 
therapies as their glucoregulatory activities only take place when there are 
abnormally high glucose concentrations in the body (Stonehouse et al. 2012). 
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1.2 BONE 
 
Bone is a dynamic organ made up of highly organised structures and consists of 
three major components; fibrous protein collagen, calcium phosphate-based 
hydroxyapatite Ca5(PO4)3(OH) and water (Weiner & Wagner 1998). The two vital 
roles of bone are to control mechanical function of the body and as storage of 
calcium and phosphate. Recently, bone has been reported to be involved in 
regulation of energy metabolism through osteocalcin and insulin interaction (Ducy 
2011). Osteocalcin, a hormone secreted by osteoblasts, has been identified as a 
positive regulator of insulin secretion, insulin resistance and energy expenditure (Lee 
et al. 2007). Remarkably, insulin signalling in osteoblasts is a positive regulator of 
osteocalcin production and activation through its ability to indirectly stimulate 
osteoclastic bone resorption (Ferron et al. 2010). Hence, interaction of osteocalcin 
and insulin has become part of a complex signalling network between bone and 
pancreas, the organ that associated with glucose homeostasis. 
 
Bone is continuously remodeled by sequential activity of osteoclasts and osteoblasts. 
Bone-resorbing cells, osteoclasts break down old bone, followed by formation of 
new bone by osteoblasts (Figure 1.1) and this coordinated process is controlled by 
various paracrine and autocrine factors (Matsuo & Irie 2008).  
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Figure 1.1 Bone remodeling 
 
 
     
 
 
 
 
 
 
 
 
 
 
 
Bone remodeling is coordinated by the activity of osteoclasts and osteoblasts through 
bone resorption and formation, respectively. A damage (microcrack) is detected by 
lining cells and signals (local factors) are released to recruit cells from blood and 
marrow into remodeling compartment. Osteoclastogenesis occurs and the 
multinucleated osteoclasts resorb bone matrix and the microcrack. This is followed 
by osteoblastic bone formation, where resorbed lacunae are refilled to the original 
level by osteoblasts. Osteoblasts, bone-forming cells; osteoclasts, bone-resorbing 
cells; osteoid, the unmineralized organic portion of bone matrix secreted by 
osteoblasts; osteocytes, the descendant of the matrix-producing osteoblast, which 
will form mature bone. Adapted from (Seeman & Delmas 2006).  
 
Throughout life, material and structural properties of bone are modulated to adapt to 
environmental and mechanical changes. Under disease conditions which alter 
molecular processes in bone, an inability to respond to these changes could lead to 
fragility and may initiate fracture. Early diagnosis or assessments of bone quality can 
prevent further bone loss and reduce the risk of bone fragility fracture. Bone quality 
and remodeling can be assessed at different scale (Table 1.2) by numerous methods 
such as radiography, histomorphometry and biomechanical test. Sections 1.2.1-1.2.4 
and 2.5-2.6 explain in greater detail the techniques and tools that are employed for 
bone assessment in animal studies. 
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Table 1.2 Physical scale and characteristics of bone that may affect overall bone 
quality 
 
Scale (m) Bone characteristics 
 
>10
-3
 
 
 
 
>10
-6
-10
-3
 
 
 
 
 
 
 
>10
-9
-10
-6
 
 
 
 
 
<10
-9
 
 
Whole bone morphology (size and 
shape) 
Bone density spatial distribution 
 
Microarchitecture 
Porosity 
Cortical shell thickness 
Lacunar number/morphology 
Remodeling cavity number, size, and 
distribution 
 
Mineral and collagen 
distribution/alignment 
Microdamage type, amount, and 
distribution 
 
Collagen structure and cross-linking 
Mineral type and crystal alignment 
Collagen–mineral interfaces 
 
 
Several important characteristics of bone that can influence whole bone mechanical 
properties and bone quality. Adapted from (Hernandez & Keaveny 2006) 
 
1.2.1 Assessment of bone mass 
 
Bone health is primarily determined by bone mass and routine practice to investigate 
this parameter involves a radiological technique. The most commonly used 
noninvasive tool to predict bone mass is dual-energy x-ray absorptiometry (DEXA). 
From DEXA scanning, bone mineral density (BMD), bone mineral content (BMC), 
fat mass and lean mass can be determined. BMC represents calcium content in bone 
which absorbs more x-ray radiation than soft tissue and protein, whilst BMD is a 
measure of average mineral content per unit area or volume of a particular bone 
segment (Cummings et al. 2002). Bone mineral content can also be assessed with x-
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ray microradiograph imaging (qXRI) and quantitatively estimated by using ImageJ 
analysis (Bassett et al. 2012). Increased BMD is commonly related to low risk of 
fracture and vice versa. However, this is not always the case as in diabetes mellitus, 
T1DM and T2DM have contradictory effects on BMD but both incur an increased 
risk of fracture. Individuals with T1DM appeared to have reduced BMD, which is in 
agreement with increased skeletal fracture risk, whilst modest increased or 
unchanged BMD in T2DM patients is surprisingly unable to protect them from bone 
fragility fractures (Vestergaard 2007). The discrepancies between BMD and fracture 
risk indicate that BMD alone does not reflect a true measure of bone quality and 
other characteristics of bone, such as microarchitecture, biomechanical strength and 
material composition of bone matrix also play a significant role in overall bone 
integrity (Hernandez & Keaveny 2006, Seeman & Delmas 2006). 
 
1.2.2  Bone microarchitecture  
  
Microscopic architecture and organisation of bone can be explored 
histomorphometrically and the methods employed include bone histomorphometry 
or high-resolution tools such as microCT. In bone histomorphometry, embedding, 
sectioning and staining of bone needs to be carried out prior to analysis. Using 
different labeling or staining protocols that are specific for molecular activities in 
bone such as resorption, formation and mineralisation, researchers can specifically 
view particular bone cell activities (Erben & Glosmann 2012). For example, 
fluorochrome labeling with alizarin red S is used to determine calcium deposition for 
bone mineralisation, whereas sirius red demonstrates the presence of collagen (Orriss 
et al. 2012). In contrast to histomorphometrical techniques, development of 
microcomputed tomography (microCT) allows for a nondestructive method of bone 
evaluation. There are three major steps in examining bone by microCT. Firstly, 
scanning of full bone which will produce X-ray projection images; secondly, 
reconstruction of 3D images of bone from a stack of projection images; and finally, 
analysis of the bone (Van‘t Hof 2012). Importantly, measurement of bone volume 
and other trabecular variables such as connectivity and frequency of thickness can be 
obtained from microCT (Chappard et al. 2011). 
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1.2.3 Biomechanical test  
 
In assessing alterations of bone quality that can lead to skeletal fragility, the main 
goal is to prevent clinical bone fracture, which principally is a mechanical event 
(Hernandez & Keaveny 2006). As such, evaluation of the two major contributors in 
biomechanical of bone, stiffness and strength are essential. Stiffness is defined by the 
ability of bone to resist deformation during loading, which is determined by elastic 
modulus, while strength is translated from bone hardness. Bone stiffness and 
hardness can be examined in rodents by numerous biomechanical techniques 
including three-point bending test and nanoindentation. The biomechanical concept 
of the three-point bending test in bone is the relationship between load applied at the 
midshaft of long bone and displacement of bone until failure, which produces a load-
displacement curve similar to well-established stress-strain curves (Turner 2006). 
From the strain-stress curve for bone, different bone variables can be obtained such 
as ultimate strength and stiffness.  
 
However, alterations of intrinsic material properties of bone can not be determined 
with three point bending. In order to provide better understanding of mechanical 
behaviour of bone, combination of three-point bending test and nanoindentation is 
employed. Nanoindentation was introduced in 1992 by Oliver and Pharr and it has 
been widely used to determine hardness and elastic modulus of materials based on an 
unloading curve produced during indentation (Oliver & Pharr 1992). One of the 
advantages of this technique is that it can measure mechanical properties of materials 
at smaller scales (below microns) and therefore, allows higher accuracy of material 
properties in matrix. Furthermore, the nanoindentation technique is independent of 
bone size and porosity, which can significantly influence bone hardness and stiffness 
(Rho et al 1997).  
 
1.2.4 Bone material properties 
 
As stated earlier, bone is mainly composed of collagen and minerals. Thus, any 
modification in matrix composition or characteristic that has negative impact on 
bone remodelling could contribute to bone fragility. Scanning electron microscope 
was first shown to be able to capture trabecular bone images in 1971 (Whitehouse et 
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al. 1971). Later, it was found that in backscattered electron mode, the density of 
mineralisation in bone was apparent and therefore could be used to determine bone 
mineral density distribution (BMDD) (Chappard et al. 2011). In this technique, back-
scattered electrons (BSEs) in the scanning electron microscope are reflected by 
atoms in the sample where high atomic-number atoms will have stronger interaction 
with the electrons and appear brighter in grey level image of the scanning electron 
microscope. The BSE signal is calibrated and standardised with carbon and 
aluminum as reference materials for grey level values, while hydroxyapatite is used 
for the measurement of calcium concentrations (Roschger et al. 1998). Alternatively, 
the characteristics of bone matrix can be investigated with Fourier transformed infra-
red (FTIR) microscopy. This technique allows examination of mineral to matrix ratio 
which reflects the degree of mineralisation of bone matrix, mineral maturity and 
crystallinity and finally collagen maturity, which is the relative ratio of pyridinium 
trivalent (mature collagen) to dehydrodihydroxylysinonorleucine divalent (new 
collagen) (Paschalis 2012).  
 
1.3 EFFECTS OF DIABETES ON THE SKELETON 
 
Bone loss can be characterised by low bone mass and damage to microstructural 
properties of bone tissue, which leads to bone fragility and increased risk of fracture. 
As such, the link between diabetes and bone impairments, along with observations of 
bone loss in diabetic animals and fracture risk in diabetic patients, requires further 
consideration.     
 
1.3.1 Hyperglycaemia and AGEs  
 
Bone loss has long been identified as a complication of diabetes. However, 
pathophysiological aspects that lead to diabetic bone abnormalities are not well 
understood, as multiple factors are involved in this disorder. A common condition 
seen in T1DM and T2DM is elevation of blood glucose levels and therefore, 
hyperglycaemia is thought to contribute to the pathogenesis of bone disorder in 
diabetes. Hyperglycaemia will initiate formation of advanced glycation end-products 
(AGEs), where important bone-related proteins such as collagen type 1 are non-
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enzymatically glycosylated, leading to alteration of their structure and bioactivity 
(Brownlee 2001, Saito & Marumo 2010).  
 
AGEs also negatively affect bone remodeling by disrupting functions of osteoblasts 
and osteoclasts. AGE-mediated attenuation of bone formation through inhibition of 
proliferation and differentiation, is seen in osteoblastic-derived rat UMR 106 cells 
(McCarthy et al. 1997). Similarly, suppression of differentiation to osteoblasts by 
AGEs is shown in human mesenchymal stem cells (Kume et al. 2005). In addition, 
apoptosis of osteoblasts is significantly stimulated by the presence of AGEs 
(Alikhani et al. 2007). Furthermore, it is found that AGE-modified proteins enhance 
bone resorptive activity as seen by an increase in the number of resorption pits in 
osteoclastic-derived cells (Miyata et al. 1997), forming a positive correlation of 
osteoclastic bone resorption activities and concentration of AGEs (Dong et al. 2011). 
Correspondingly, these studies indicate that osteoclasts response on AGEs could lead 
to further bone loss and reduced bone mechanical competency.  
 
1.3.2 Insulin  
 
In diabetes, blood glucose is not the only metabolic parameter that is altered as 
insulin levels are also negatively affected. There is mounting evidence to support a 
positive effect of insulin on bone (Cornish et al. 1996, Fulzele & Clemens 2012, 
Thrailkill et al. 2005a). Consistently, severe impairments of bone quality have been 
seen in chemically- and genetically-induced animal models of T1DM mice (Fowlkes 
et al. 2008, Thrailkill et al. 2005b). On the other hand, T2DM is associated with 
insulin resistance, excessive weight gain and increased numbers and size of 
adipocytes. Interestingly, adipocytes and osteoblasts are derived from the same 
precursor, mesenchymal stem cells (MSCs) (Figure 1.2). Previous studies have 
shown that numbers of mature osteoblasts are reduced when MSCs were stimulated 
towards adipogenesis (Lecka-Czernik et al. 2002). Conversely, suppression of 
adipogenesis was accompanied by a significant induction of osteogenesis in culture 
cells obtained from PPARγ-deficient mice (Akune et al. 2004). Therefore, bone loss 
in T2DM could be caused by less bone formation as more progenitor cells are 
differentiated in favour of adipogenesis rather than osteoblasts. However, as 
reviewed by McCabe, bone abnormalities as a result of marrow adiposity is a 
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controversial issue and more studies are required to further elucidate the connection 
between bone, adipocytes and key factors involved in the differentiation and 
maturation of MSCs (McCabe 2007).  
 
Figure 1.2 Bone marrow lineage and key determinants of cell maturation 
 
 
 
Maturation of mesenchymal stem cells involves numerous key factors such as CEBP 
(CCAAT/enhancer-binding protein), IL-6 (interleukin-6), MCSF (macrophage 
colony stimulating factor), OPG (osteoprotegerin), PPARγ (peroxisome proliferator-
activated receptor γ), RANK (receptor activator of nuclear factor-kappaB), RANKL 
(receptor activator of nuclear factor kappa-B ligand), RUNX2 (runt-related 
transcription factor 2), DLX5 and MSX1 (transcription factors). Adapted from 
(Rosen & Bouxsein 2006). 
 
1.3.3 Growth factors and cytokines 
 
There are also contributions of endocrine factors in diabetic bone loss such as 
insulin-like growth factor-1 (IGF-1) and amylin. The positive relationship of IGF-1 
and BMD has been reported previously (Rosen 2004) and therefore, it is not 
surprising to find pronounced reduction of circulating IGF-1 in diabetic patients 
(Jehle et al. 1998, Sandhu et al. 2002, Teppala & Shankar 2010). On the other hand, 
inactivation of amylin, a peptide co-secreted with insulin by pancreatic beta-cells, is 
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associated with low bone mass and increased osteoclastic activity (Dacquin et al. 
2004). Furthermore, increases in bone strength and bone formation biomarker, 
osteocalcin have been demonstrated in T1DM diabetic rats treated with amylin 
agonist (Horcajada-molteni et al. 2001), indicating the importance of amylin in bone 
regulation. 
 
Conflicting data has been published on the participation of adipokines (e.g leptin and 
adiponectin) and cytokines (e.g osteoprotegerin) in bone regulation under diabetic 
conditions. For instance, leptin-deficient obese diabetic (ob/ob) mice exhibit severe 
bone impairments, and improvement in bone mass was seen with administration of 
leptin (Steppan et al. 2000). Similarly, leptin treatment increases bone mechanical 
properties in normal mice (Cornish et al. 2002), indicating the anabolic effect of 
leptin on bone. However, in clinical human studies, unchanged or increased serum 
leptin concentrations are observed in diabetic individuals (Alexopoulou et al. 2006, 
Luna et al. 1999). Bone-related protein, osteoprotegerin (OPG) is known to have 
positive effect on bone by inhibiting excessive osteoclastogenesis and in line with 
that, genetically modified mice lacking OPG gene have been shown to have elevated 
osteoclast numbers and activity (Nakamura et al. 2003). In the contrary, serum OPG 
levels are significantly increased in T1DM children (Galluzzi et al. 2005), suggesting 
a negative correlation of OPG and bone. These contradictions could be due to 
comparisons made on different models (mouse vs human) and the limited data 
available in this area. As such, further investigations are needed to explore the 
possible effects of adipokines and cytokines in diabetic bone abnormalities. 
 
1.3.4 Bone impairments in animal models of diabetes 
 
One particular model of animals extensively used in the laboratory is mouse. The 
high degree of similarity between mouse and human genetics (more than 95% of 
human genomes conserved in the mouse) has increased the value of mouse models 
for research on human disorders (The Jackson Laboratory 2015). Detrimental effects 
of diabetes on bone quality have also been vastly investigated in rodent models of 
diabetes.  Diabetes can develop in animals either spontaneously- or through genetic 
modifications or induction of diabetes based on experimental protocols. Thrailkill 
and colleagues showed that trabecular and cortical bone were severely compromised 
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in spontaneous nonobese diabetic (NOD) mice as assessed by microCT and three-
point bending tests (Thrailkill et al. 2005b). The modifications in microstructure and 
bone strength contributed to an impairment of bone formation as seen by reductions 
of bone formation biomarkers and formation of new bone. In addition to trabecular 
bone loss, a more recent study reported increases in bone marrow adiposity and 
adipocyte-related proteins, whilst osteoblast-specific osteocalcin was reduced in 
NOD mice (Botolin & McCabe 2007).     
 
Bone abnormalities have also been investigated in several frequently used 
genetically-induced rodent models of diabetes such as obese Zucker (fa/fa) rats, 
obese diabetic (ob/ob) mice and diabetic (db/db) mice. These diabetic models exhibit 
gross weight gain, hyperglycaemia and hyperinsulinemia due to impairments in 
leptin signaling (Rees & Alcolado 2005). Homozygous mutation of the leptin gene 
(ob gene) in ob/ob mice or defective leptin receptor in db/db mice and obese Zucker 
rats severely affects bone microstructure and bone strength. Obese diabetic (ob/ob) 
mice have shorter femoral bone compared to normal mice and densitometry and 
histomorphometry analysis reveal reduced bone mass, cortical thickness, and 
trabecular bone volume in the diabetic mice (Hamrick et al. 2004, Matsunuma et al. 
2004, Steppan et al. 2000). Similar findings are observed in Zucker rats (Tamasi et 
al. 2003). Additionally, reductions in whole-femur BMD and BMC as well as whole-
bone biomechanical properties were reported in db/db mice (Ealey et al. 2006). 
Further studies by Williams and colleagues found not only alterations of mechanical 
properties at the organ-level, but also changes in material properties of bone matrix 
in leptin receptor-deficient db/db mice (Williams et al. 2011).   
 
Streptozotocin (STZ) is a glucosamine-nitrosourea analogue and when introduced 
into the body, it is taken up by pancreatic beta cells, causing cell death. Due to the 
toxicity of STZ to insulin-producing islets beta cells, this compound has been widely 
used, either as single high dose or multiple low doses, to induce hyperglycaemia and 
insulin deficiency in normal rodents (Lu et al. 1998). Defective bone formation is 
consistently seen in STZ-induced diabetic rodents (Coe et al. 2013, Fowlkes et al. 
2008, Motyl & McCabe 2009). Additionally, multiple low-dose STZ-injected mice 
demonstrate increased bone marrow adiposity which is accompanied by increased 
expression of adipocyte biomarkers and reductions in markers for bone formation 
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(Botolin et al. 2005). In terms of the biomechanical consequences of diabetes, 
diabetic bones require less load and energy absorption to reach failure (Reddy et al. 
2001), emphasising a reduction in biomechanical integrity.  
 
Other models of T2DM can be obtained through high-fat dietary feeding. The intake 
of high-fat diet, which mimics Westernised diet, can cause metabolic disturbances 
and lead to obesity, insulin resistance and hyperinsulinemia (Zhang et al. 2009). 
With regards to bone, conflicting results are reported on the bone mass of high-fat 
dietary-induced diabetic mice (Halade et al. 2010, Ionova-Martin et al. 2010, Patsch 
et al. 2011), which possibly due to different type of high-fat diet used in the studies. 
In agreement with reduced bone mass in high-fat fed mice, Halade et al. found that 
bone marrow adipocytes were significantly increased (Halade et al. 2010), whilst 
Patsch et al. reported a reduction in bone volume as assessed by microCT (Patsch et 
al. 2011).  Studies by Ionova-Martin et al. observed significant reductions in 
parameters of microstructural and biomechanical strength, despite increased bone 
quantity and mass in high-fat diet group (Ionova-Martin et al. 2010). In general, the 
studies agree that high fat feeding has adverse effects on overall bone quality.  
 
1.3.5 Bone mineral density and fracture risk in human diabetes 
 
Recent meta-analysis of discrepencies in BMD and fracture risk conclude that 
regardless of BMD (decreased, unchanged, elevated), DM patients are associated 
with increased risk of fractures (Janghorbani et al. 2007, Vestergaard 2007). 
However, the relative fracture risk is higher in T1DM than T2DM. The majority of 
studies in T1DM consistently report the reduction of BMD in T1DM patients (Rakel 
et al. 2008) and in line with that, T1DM individuals are more susceptible to bone 
fragility fracture (Vestergaard 2007). Cross-sectional studies of the relationship 
between BMD and increased fracture risk are mostly related to the lower spine, and 
although there are limited reports on T1DM-associated bone fragility at other sites 
(Hampson et al. 1998, Miazgowski & Czekalski 1998), most of these studies 
demonstrate a pattern towards increased fracture risk (Vestergaard 2007). T2DM 
individuals have normal-to-increased BMD when measured at femoral neck, 
vertebral, distal tibia, humerus and radius (De Liefde et al. 2005, Petit et al. 2010, 
Schwartz et al. 2000) and persistently high BMD is seen even after correction for 
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body composition compared to age-matched healthy subjects. Despite elevated 
BMD, T2DM patients still have increased bone fragility fracture (Vestergaard 2007).    
 
Several factors limit the usefulness of these studies such as duration and severity of 
diabetes, assessment of different types of bone markers and different methods for 
measurement of bone density (Epstein & LeRoith 2008). Furthermore, in view of 
risk of fractures, BMD should not be the only aspect that is considered (Moseley 
2012) as diabetes-related extraskeletal factors, such as neuropathy and retinopathy 
could contribute to the elevated rate of falling as a result of increased postural 
instability and impaired eye-sight (Schwartz et al. 2002). As a consequence of the 
first fall, diabetic patients may exhibit reduced bone competency and therefore, may 
be prone to further bone fracture.  
 
1.4 INCRETIN EFFECT 
 
The incretin effect is described as the difference in insulin secretion after glucose 
ingestion or intravenous glucose infusion. The term was first introduced when the 
oral administration of glucose was observed to induce elevated insulin release 
compared with the same amount of glucose given intravenously (Nauck et al 1986). 
The incretin effect is considered as an important event in controlling blood glucose 
homeostasis as insulin response from this effect is estimated to account for 50% to 
70% of total insulin release (Nauck et al. 2011). In response to food ingestion, 
incretin hormones are released into circulating blood and enhance glucose-mediated 
insulin secretion from pancreatic beta-cells. The two gut hormones that have been 
identified to control the enteroinsular axis are glucose-dependent insulinotropic 
polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) (Baggio & Drucker 2007). 
Although other gastrointestinal hormones can stimulate insulin release and lower 
blood glucose concentrations, only GIP and GLP-1 are physiologically relevant 
(McIntosh et al. 2009).  
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1.5 GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE (GIP) 
 
GIP was isolated from crude extracts of porcine small intestine and initially known 
as gastric inhibitory polypeptide for its ability to inhibit the secretion of gastric acid 
in dogs (Pederson et al. 1975). Further studies with purified GIP demonstrated the 
stimulatory effect of GIP on insulin release in humans and animals. The incretin 
effect of GIP was considered more important as the insulinotropic action was seen at 
physiological levels compared to its inhibitory action in gastric acid release which 
only occurred at pharmacological levels. Therefore, it is renamed as glucose-
dependent insulinotropic polypeptide (Baggio & Drucker 2007).  
 
1.5.1 Synthesis, secretion and signaling 
 
GIP is a 42-amino acid peptide synthesised within K-cells, which are abundant in the 
upper duodenum and proximal jejunum of small intestine. The human GIP gene 
comprises of 6 exons (Figure 1.3A) with most of the sequences for GIP in exon 3. 
The GIP sequence is highly conserved for human and shares more than 90% 
similarity in amino acids sequence with mouse, rat, porcine and bovine GIP (Baggio 
& Drucker 2007). Bioactive GIP is processed from ProGIP, a prohormone precursor 
of 153 amino acids (as shown in Figure 1.3) and the enzyme responsible for the post-
translational processing is prohormone convertase (PC) 1/3. PC1/3-mediated 
cleavage of the ProGIP sequence occurs at single arginine residues, leaving 
biologically active GIP(1-42) along with N-terminal and C-terminal signal peptides 
(Ugleholdt et al. 2006).  
 
Basal GIP concentrations for healthy humans is around 0.01 nmol/l and the peak 
value of GIP level reached within 60 min after nutrient intake, increases by 10 to 15-
fold (Visboll et al. 2001). GIP binds to the GIP receptor (GIPR), a member of the 
seven-transmembrane domain-spanning receptor which belongs to G-protein coupled 
receptor (GPCR) family (Usdin et al. 1993).  
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Figure 1.3 : Structures of ProGIP  
 
 
 
Structures of (A) ProGIP gene, (B) mRNA, and (C) GIP protein. Adapted from 
(Baggio & Drucker 2007). 
 
1.5.2 Pancreatic actions 
 
The main role of GIP is as incretin hormone that regulates glucose homeostasis. 
Upon nutrient intake, GIP is secreted by K-cells, binds to its receptors on islet beta-
cells of pancreas and subsequently enhances glucose-mediated insulin secretion. 
Activation of GIPR signaling increases cAMP levels and inhibits KATP channels. 
Inhibition of ATP-sensitive potassium channels leads to influx of Ca
2+
 and 
stimulation of insulin secretion by exocytosis (Ding & Gromada 1997). Binding of 
GIP to its G-protein couple receptor also activates cAMP-mediated 
phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB) and MAP kinase 
signaling pathways which are closely associated with promotion of proliferation, 
differentiation and inhibition of apoptosis in beta cells (Ehses et al. 2003, Trumper et 
al. 2001, Trumper et al. 2002).  
 
1.5.3 Extrapancreatic actions 
 
The primary physiological action of GIP is in pancreas. However, the widespread 
expression of GIPRs in other tissues such as in adrenal cortex, brain, heart, lung, 
pituitary, adipose and bone suggests wider extrapancreatic actions of GIP in the body 
(Figure 1.4) (Baggio & Drucker 2007). GIP is suggested to participate in fat 
metabolism from the observations that obese humans (Creutzfeldt et al. 1978, Salera 
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et al. 1982) and ob/ob mice (Flatt et al. 1983) had increased concentrations of plasma 
GIP. In agreement, there is evidence of functional GIPRs in primary adipocytes and 
the adipose cell line 3T3-L1 (Rupert et al. 1998). Additionally, a more recent study 
in isolated adipocytes demonstrated that GIP dose-dependently stimulates 
lipogenesis (Omar et al. 2013).  
 
In addition to adipose tissue, extrapancreatic effects of GIP have also been shown in 
the brain. GIPR mRNA and its specific binding sites are detected in several regions 
of the brain such as cerebral cortex and hippocampus, including old factorybulb 
(Kaplan & Viagna 1994, Usdin et al. 1993), indicating a direct role of GIP in 
regulating brain function. Administration of exogenous GIP in rats and incubation of 
GIP with cultured adult hippocampal progenitor cells has been demonstrated to 
stimulate the proliferation of hippocampal progenitor cells (Nyberg et al. 2007). In 
agreement, the same group of researchers reported that genetic deficiency of the 
GIPR reduced the number of new proliferating cells by 50%. GIP-overexpressing 
transgenic mice display better memory recognition than wild type mice (Ding et al. 
2006) and consistent with this finding, administration of a stable GIP analogue for 
28 days improved cognitive function in high-fat fed diabetic mice with cognitive 
dysfunction (Porter et al. 2011). Collectively, these observations show that GIP 
positively influences brain function.   
 
With regards to bone, functional GIPRs were revealed on bone-forming cells, the 
osteoblasts and bone-resorbing cells, the osteoclasts (Bollag et al 2000, Zhong et al 
2007). GIPRs were also expressed on osteocytes (Bollag et al 2001) and cultured 
bone marrow stromal cells (BMSCs) (Ding et al. 2008). The expression and potential 
osteoprotective effects of GIP on bone will be further discussed in Section 1.8. 
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Figure 1.4: GIP actions on specific tissues 
 
 
 
The effects of GIP are mediated by direct interaction with GIPRs on specific tissues. 
Taken from (Baggio & Drucker 2007). 
 
1.5.4 DPP-4 and GIP metabolism 
 
GIP is secreted immediately after food intake. However, the endogenous peptide has 
a short half-life due to the action of the ubiquitous enzyme dipeptidyl peptidase-4 
(DPP-4). Active GIP in rodents is reported to have a half-life of less than 2 min 
(Kieffer et al. 1995) while in humans, GIP has a half-life of around 5-7 min (Deacon 
et al. 2000). DPP-4 is a specialized serine protease that cleaves penultimate residues 
from the N-terminal of bioactive proteins that contain alanine or proline residues at 
position 2 (Mentlein et al. 1993). Thus, DPP-4 inactivates biologically active GIP by 
cleaving at its first two N-terminal amino acids (Tyr
1
-Ala
2
), leaving the N-terminally 
truncated metabolite, GIP(3-42) (Kieffer et al. 1995). DPP-4-facilitated cleavage of 
active GIP(1-42) eliminates insulinotropic activity, but receptor affinity is only 
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reduced by fourfold (Deacon et al. 2006). Inhibition of DPP-4 action by specific 
DPP-4 inhibitor has previously been shown to reduce degradation of exogenous GIP, 
resulting in increased levels of intact GIP in plasma (Deacon et al. 2001, Deacon et 
al. 2002). In addition to rapid degradation by DPP-4, GIP is also subjected to renal 
extraction through kidney filtration (Meier et al. 2004). In order to overcome the 
inactivation of GIP by DPP-4, structurally-modified DPP-4 resistant GIP molecules 
are developed. Furthermore, promoting the adherence of long-acting GIP agonists to 
serum proteins will delay renal clearance and improve the bioactivity of GIP.    
 
1.5.5 Structurally-modified stable GIP agonists 
 
In order to harness the insulinotropic properties of GIP, substantial numbers of DPP-
4 resistant GIP molecules have been developed. One of the pharmacological 
approaches is through modifying the N-terminal amino acid residues of GIP to 
prevent DPP-4-mediated degradation, hence prolonging bioactivity of circulating 
GIP (Irwin & Flatt 2009). Several Tyr
1
-substituted GIP molecules that have been 
generated and tested include N-acetyl, N-Fmoc, N-gluticol, N-pyroglutamyl and N-
palmitate groups. These analogues have been shown to be resistant to DPP-4 and 
have enhanced bioactivity compared to native GIP in vitro (O’Harte et al. 2000, 
Gault et al. 2002, O’Harte et al. 2002). In addition, synthesis and characterisation of 
novel Ala
2
-modified GIP analogues has also been carried out and these include 
[Abu
2
]GIP, [Gly
2
]GIP, [Sar
2
]GIP, [Ser
2
]GIP and [D-Ala
2
]GIP. However, only 
[Gly
2
]GIP, [Ser
2
]GIP and [D-Ala
2
]GIP have notable biological activity and 
antihyperglycaemic properties compared to native GIP (Hinke et al. 2002, Gault et 
al. 2003a).  
 
Although N-terminally-protected GIP analogues are resistant to DPP-4-mediated 
inactivation, these molecules are still susceptible to in vivo renal filtration. Therefore, 
in order to prolong the pharmacodynamic profile of GIP, a C-16 palmitate fatty-acid 
(PAL) chain is attached covalently to the Lys
16
 or Lys
37
 residue of the GIP peptide. 
The fatty-acid GIP derivatives that have been developed to date are GIP(Lys
37
PAL), 
GIP(Lys
16
PAL), N-AcGIP(Lys
37
PAL), N-AcGIP(Lys
16
PAL),                                  
N-pGluGIP(Lys
37
PAL) and N-pGluGIP(Lys
16
PAL) (Irwin et al. 2005a, Irwin et al. 
2005b, Irwin et al. 2006a). The attachment of C-16 fatty acid protects the GIP-
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modified molecules from being degraded by DPP-4, whilst biological and 
insulinotropic activities are significantly enhanced compared to native GIP peptide 
(Irwin & Flatt 2009). In comparison of efficacy of different long-acting GIP 
analogues, a previous study has shown that the biological activity of stable fatty-acid 
GIP derivatives is similar to stable non-fatty acid GIP molecule (Irwin et al. 2006b), 
indicating an equal effectiveness of the DPP-4 resistant molecules.  
 
1.6 GLUCAGON-LIKE PEPTIDE-1 (GLP-1) 
 
Glucagon-like peptide-1 (GLP-1), along with its sister incretin, GIP, are responsible 
for incretin effect. In 1983, a study with GIP-lacking rat gut extracts found that 50% 
incretin activity was preserved in these extracts (Ebert et al. 1983). It was then 
suggested that GIP only partially accounting for the incretin effect and that there are 
other gut factors which carry similar insulinotropic properties to GIP. Sharing 50% 
sequence of glucagon, GLP-1 together with GLP-2 were later identified from the 
sequence of hamster preproglucagon (Bell et al. 1983). Subsequent work on their 
potential insulinotropic action revealed the ability of GLP-1 to stimulate insulin 
secretion from the isolated perfused rat pancreas (Mojsov et al. 1987) and later was 
shown to be one of hormones that accounts for incretin effect.  
 
1.6.1 Synthesis, secretion and signaling 
 
GLP-1 is one of the products of the proglucagon gene which has 6 exons and the 
entire GLP-1 coding sequence is within exon 4 (Figure 1.5A).  The proglucagon 
gene is expressed not only in pancreatic α-cells but also in L-cells of the intestine 
and central nervous system. Posttranslational processing of proglucagon will 
generate different peptides, depending on where the gene is expressed. While in 
pancreas, proglucagon is cleaved by prohormone convertase PC2 to produce 
glucagon (GLUC), glicentin-related polypeptide (GRPP), intervening peptide-1 (IP-
1) and major proglucagon fragment (MPGF) (Rouille et al. 1997a). As a major 
product of proglucagon in alpha-cells, glucagon is known to play its role by 
counteracting insulin action to maintain normal glucose levels. However, the actual 
roles of other post-translational products remain largely unknown.  
 
28 
 
Figure 1.5: Structures of proglucagon  
 
 
 
Structures of (A) the proglucagon gene, (B) mRNA, and (C) protein. (D) 
Posttranslational processing of proglucagon in the pancreas generates Glicentin-
related polypeptide (GRPP), glucagon (GLUC), intervening peptide-1 (IP-1), and 
major proglucagon fragment (MPGF), whereas the products in the intestine and brain 
are glicentin, oxyntomodulin (OXM), intervening peptide-2 (IP-2), and GLP-1 and 
GLP-2. Adapted from (Baggio & Drucker 2007). 
 
In the intestine and central nervous system, the 180-amino acid proglucagon peptide 
liberates oxyntomodulin, glicentin, GLP-1, intervening peptide-2 (IP-2) and GLP-2 
(Figure 1.5D). GLP-1 is the major product of proglucagon gene in the intestine and it 
is one of the important glucoregulatory hormones that control glucose homeostasis. 
In addition to GLP-1, oxyntomodulin is also released postprandially and the peptide 
is believed to exert its effects by binding to both GLP-1 and glucagon receptors 
(Pocai 2012). Activation of glucagon receptor increases blood glucose concentration, 
whilst simultaneous GLP-1R activation counteracts this effect, thus balancing 
glucose metabolism in the body. Oxyntomodulin is recently speculated to have 
therapeutic potential for diabetes and obesity for its dual actions in improving 
glucose homeostasis and lowering body weight (Pocai 2014). Similar to GIP, 
processing of proglucagon precursor to GLP-1 is dependent on prohormone 
convertase PC1/3. Proglucagon is initially cleaved to glicentin and the major 
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proglucagon fragment (MPGF). Subsequent cleavage of MPGF at the monobasic site 
Arg
77
 and the dibasic site Arg
109
-Arg
110
 releases GLP-1 (Rouille et al. 1997b). 
 
Fasting plasma concentrations of biologically active GLP-1 in humans is normally in 
a range of 5-10 pmol/L and increases approximately 2- to 3-fold following food 
intake (Vilsboll et al. 2001). The secretion of GLP-1 follows biphasic pattern where 
early phase takes 10-15 minutes and the subsequent later phase takes much longer, 
around 30-60 min (Herrmann et al. 1995). Upon release, GLP-1 binds to its 
heterotrimeric receptor, a member of G-protein-coupled receptor (GPCR) 
superfamily (Mayo et al. 2003) and activates adenylate cyclase. The activation of 
adenylyl cyclase is followed by a rise in cAMP levels and direct inhibition of KATP 
channels which leads to elevation of intracellular Ca
2+
 concentration, and 
subsequently, stimulation of insulin release (Gromada et al. 1998).  
 
1.6.2 Pancreatic actions 
 
The primary physiological action of GLP-1 in the pancreas is to stimulate insulin 
release from islet beta-cells in a glucose dependent manner (Mojsov et al. 1987). 
Two different signaling pathways are involved in GLP-1-mediated cAMP-activated 
insulin release, either through PKA or Epac2 or cAMP-independent 
phosphatidylinositol-3 kinase (PI-3K)/protein kinase C (PKC) signaling pathways 
(Baggio & Drucker 2007). In addition, activation of GLP-1R signaling enhances 
transcription of the insulin gene and biosynthesis of insulin, thus preventing 
exhaustion of insulin stores (Drucker et al. 1987, Wang et al. 1997). GLP-1-mediated 
insulin gene transcription and synthesis occur through pancreas duodenum 
homeobox 1 (PDX-1), an essential transcription factor for pancreatic and beta cell 
function by upregulating PDX-1 expression and binding to the insulin gene (Wang et 
al. 1999). GLP-1 also strongly suppresses glucagon secretion from pancreatic alpha-
cells (Holst et al. 2011) and its inhibitory action is likely mediated through 
stimulation of the glucagon inhibitor, somatostatin and somatostatin subtype receptor 
2 (SSTR2) in pancreatic cells (de Heer et al. 2008).  
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1.6.3 Extrapancreatic actions 
 
Several other tissues have been shown to express GLP-1Rs, such as the heart, brain, 
liver, intestinal tract, muscle and adipose tissue (Dunphy et al. 1998, Merchenthaler 
et al. 1999, Wei & Mojsov 1996). As shown in Figure 1.6, wide distribution of 
GLP-1Rs throughout the body is an indication that GLP-1 possesses several 
extrapancreatic actions. Indeed, glucoregulatory activity of GLP-1 does not only 
take place in pancreas, but also in other tissues by reducing hepatic glucose 
production in liver and increasing glucose uptake in muscle and adipose tissue 
(Baggio & Drucker 2007, Larsson et al. 1997). In the brain, activation of GLP-1R 
signaling enhances neurogenesis, reduces apoptosis and protects neuronal function 
(Perry et al. 2002, Perry et al. 2003). Moreover, improvements in learning and 
memory activities were observed in rodents when treated with stable GLP-1 
mimetics (During et al. 2003, Porter et al. 2010). Therefore, GLP-1 could be useful 
in the treatment of neurodegenerative disorders (Holscher 2012).  
 
Protective properties of GLP-1 have also been demonstrated in isolated and intact 
rat heart (Bose et al. 2005) and GLP-1 was also shown to improve ventricular 
performance and myocardial glucose uptake in dogs (Nikolaidis et al. 2004). 
Although there are limited data available, several recent studies postulate that GLP-
1 affects bone in a beneficial manner. The potential osteoprotective actions of GLP-
1 will be explained in further detail in Section 1.8. 
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Figure 1.6: GLP-1 actions on specific tissues 
 
 
 
GLP-1 exerts its effects by directly binding to GLP-1Rs on pancreas, stomach, brain 
and heart. However, GLP-1 acts through indirect mechanisms in liver, fat and 
muscle. Adapted from (Baggio & Drucker 2007).  
 
 
1.6.4 DPP-4 and GLP-1 metabolism 
 
There are several forms of GLP-1 secreted in vivo that include GLP-1(1-37), GLP-
1(1-36)amide, but only GLP-1(7-37) and GLP-1(7-36)amide are thought to be 
biologically active (Baggio & Drucker 2007). Both bioactive GLP-1 molecules 
appear to have similar potency in stimulating insulin secretion (Orskov et al. 1993) 
with significant amouts of GLP-1(7-36)amide found in circulation system of humans 
(Orskov et al. 1994). GLP-1 is rapidly secreted into blood circulation following 
feeding. However, the half-life of intact GLP-1 is short, around 2 min (Kieffer et al. 
1995), due to the activity of DPP-4.  Native GLP-1 contains alanine at position 2 and 
therefore is a substrate for DPP-4. The specific cleavage of DPP-4 at N-terminal 
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dipeptides from GLP-1 produces GLP-1(9-36)amide and GLP-1(9-37) with 
abolished insulinotropic activities (Mentlein et al. 1993, Kieffer et al. 1995). Similar 
to GIP, GLP-1 can also be eliminated from circulation by renal filtration (Meier et al. 
2004). The short half-life of GLP-1 has prompted generation of stable long-acting 
forms of GLP-1 (Knudsen et al. 2000).  
 
1.6.5 Structurally-modified stable GLP-1 agonists 
 
In order to harness the higly significant glucose-lowering and insulin-releasing 
properties of GLP-1, numerous structurally modified GLP-1R agonists have been 
generated and tested for their therapeutic potential. These GLP-1 analogues possess 
modification of amino acid residues at N-terminus of the peptide, producing GLP-1R 
molecules that are resistant to DPP-4 activity (Deacon et al. 1998). Furthermore, 
biological activity of GLP-1 can be prolonged by delaying renal filtration and this 
can be achieved through fatty acid derivatisation (Green & Flatt 2007). 
 
1.6.6 Exendin-4 
 
Exendin-4 (Exenatide / Byetta) is a naturally occurring 39 amino acid peptide 
isolated from the saliva of the lizard Heloderma suspectum (Eng et al. 1992). 
Exendin-4 exhibits roughly 53% similarity in structure to mammalian GLP-1 and it 
is resistant to DPP-IV action due to the presence of a glycine residue at position 2 in 
place of alanine (Drucker & Nauck 2006). As a result, Exendin-4 remains in blood 
circulation longer than native GLP-1 (Parkes et al. 2001). Exendin-4 mimics GLP-1 
actions by enhancing insulin secretion in a glucose-dependent manner, reduces 
glucagon release, decreases food intake and slows gastric emptying (Nielsen et al. 
2004).  
 
Exenatide is the synthetic form of exendin-4 and it was the first GLP-1 mimetic 
approved by US Food and Drug Administration (FDA) in 2005 as an alternative for 
the treatment of T2DM (Drucker & Nauck 2006). Exenatide is administered twice 
daily at a dose of 5 - 10 µg and postprandial and fasting plasma glucose is markedly 
reduced in patients with T2DM receiving subcutaneous Exenatide (Koltermann et al. 
2003). In addition, improvement in glucose levels was observed when Exenatide was 
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used as an adjunctive therapy in diabetic patients who had poor glycaemic control 
with metformin and/or sulfonylurea combinations (DeFronzo et al. 2005, Fineman et 
al. 2003, Kendall et al. 2005). 
 
1.6.7 Liraglutide 
 
Liraglutide (NN2211, Victoza) is an effective GLP-1 analogue and has high 
sequence homology (approx. 97%) to native GLP-1. Liraglutide differs from native 
GLP-1 sequence at lysine 26 and 34, where lysine 26 has an addition of C-16 free 
fatty acid via a γ-glutamic acid spacer while at position 34, lysine is substituted by an 
arginine residue (Knudsen et al. 2000). The additional acyl chain in Liraglutide 
promotes non-covalent binding of the GLP-1 mimetic to serum protein albumin and 
prevents renal clearance, thus prolonging its action (Knudsen et al. 2000). Similar to 
Exenatide, Liraglutide binds to and fully activates GLP-1Rs to glucose-dependently 
stimulate the release of insulin and subsequent reduction in blood glucose 
concentrations (Lovshin & Drucker 2009).  
 
The half-life of Liraglutide is about 13 h and therefore, it is suitable for once-daily 
subcutaneous administration in humans (Agerso et al. 2002, Degn et al. 2004, 
Knudsen et al. 2000). In 2009, approval was obtained from the European Medicines 
Agency to clinically use Liraglutide in T2DM treatment, and this was followed by 
the US Food and Drug Administration in early 2010 (Peterson & Pollom 2010). 
Several clinical studies of tolerability and efficacy of Liraglutide have been 
conducted and it was demonstrated that once-daily subcutaneous administration of 
Liraglutide at a dose of 0.6-1.8 mg was well tolerated (Neumiller & Campbell 2009). 
Additionally, Liraglutide can also be used as monotherapy or in combination with 
other glucose-lowering agents, such as metformin and/or a sulphonylurea, in poorly 
controlled T2DM patients (Neumiller & Campbell 2009).  
 
1.6.8 Newly-approved/developed GLP-1 therapeutics 
 
A structurally-modified form of the Exenatide molecule, Lixisenatide is one of the 
latest drugs approved by the European Medicines Agency in early 2013 for the 
management of T2DM. This molecule is a synthetic version of Exendin-4 and it 
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differs from Exendin-4 by having deletion of one proline residue and an addition of 
six lysine molecules at the C-terminus (Barnett 2011). Once-daily administration of 
Lixisenatide monotherapy or as adjunct therapy with metformin or sulfonylureas has 
been shown to significantly improve postprandial blood glucose levels in 
inadequately controlled T2DM individuals (Fonseca et al. 2012, Horowits et al. 
2013). Similar to Exenatide and Liraglutide, monotherapy of Lixisenatide has 
common gastrointestinal adverse effects such as vomiting and nausea with low 
numbers of treatment-associated hypoglycaemic problems reported (Christensen et 
al. 2011). 
 
Two once-weekly GLP-1 derivatives that have been recently approved are Exenatide 
extended-release and Albiglutide. Exenatide long-acting release (LAR) (Bydureon) 
contains exenatide in poly(lactic-co-glycolic) microspheres (Tharakan et al. 2011) 
which is gradually released by diffusion of the microspheres. The long-acting release 
property of the once-weekly Exenatide derivative provides a continuous exposure to 
Exenatide and elicits sustained improvements in glycaemic control and body weight 
(Bergenstal et al. 2010, Buse et al. 2010). Exenatide LAR was authorized for 
marketing in January 2012 by FDA and is taken at a dose of 2 mg / week (Lund et al. 
2014, Neumiller 2012). On the other hand, Albiglutide consists of two molecules of 
GLP-1 fused to human serum albumin and this molecule is resistant to DPP-4 
degradation through substitution of alanine for glycine at position 2 of the GLP-1 
peptides (Lund et al. 2011). In an evalution test for efficacy with three different 
dosing regimes, pronounced improved glycaemic control and modest weight loss 
were demonstrated with weekly administration of Albiglutide (Rosenstock et al. 
2009), making this sustained-release GLP-1R agonist suitable for less frequent 
dosing as compared to existing T2DM treatment. In April 2014, Albiglutide 
(Tanzeum) was approved to be used once weekly by FDA at a dose of 30-50 mg 
(GlaxoSmithKline 2015).  
 
Taspoglutide has α-aminoisobutyric acid residues replacing Ala8 and Gly35 in human 
GLP-1(7-36)amide (Dong et at. 2010). The molecule exhibits enhanced stability, 
thus higher potency in vivo compared to native GLP-1 (Sebokova et al. 2010). 
Although a clinical study comparing once-weekly administration of Taposglutide to 
twice-daily Exenatide demonstrated significantly improved glycemic control in 
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T2DM patients, the use of this long-acting agonist has limitations due to its side 
effects (Rosenstock et al. 2013).  
 
1.7 DPP-4 INHIBITORS 
 
Another attractive therapeutic strategy for diabetes is through DPP-4 inhibition 
(Holst & Deacon 1998). As mentioned, DPP-4 inactivates native GLP-1(7-36)amide 
and GIP(1-42) by cleaving the alanine residue at position 2 of these peptides, leaving 
the truncated forms GLP-1(9-36)amide and GIP(3-42) (Baggio & Drucker 2007). 
Hence, inhibition of DPP-4 activity by DPP-4 inhibitors prevents the degradation of 
biologically active incretins and prolongs insulinotropic action of endogenous GLP-1 
and GIP (Green et al. 2006). Several DPP-4 inhibitors are already clinically 
available, namely Sitagliptin, Vildagliptin, Saxagliptin and Linagliptin (Duez et al. 
2012).  
 
Vildagliptin (Galvus), Sitagliptin (Januvia), Saxagliptin (Onglyza) and Linagliptin 
(Tradjenta) are orally available and highly selective inhibitors of DPP-4. Once-daily 
administration of Sitagliptin for a period time of 24 weeks reduced HbA1c 
concentrations and postmeal plasma glucose levels of type 2 diabetic patients whose 
glucose tolerance was inadequately controlled by diet and exercise (Aschner et al. 
2006). Additionally, Sitagliptin used as an adjunct to ongoing metformin or 
thiazolidinedione therapy improved glycaemic control in type 2 diabetic subjects 
(Charbonnel et al. 2006, Rosenstock et al. 2006).  
 
Vildagliptin was introduced in the UK in 2008, a year later than Sitagliptin, and is is 
administered twice daily at a dose of 50 mg orally. Vildagliptin monotherapy or in 
conjuction with metformin or insulin therapy significantly reduced HbA1c in type 2 
diabetic patients (Bosi et al. 2007, Fonseca et al. 2007, Pratley et al. 2006). 
Vildagliptin improves glycaemic control in pre-diabetic or impaired glucose 
tolerance patients by increasing postprandial plasma level of biologically active 
GLP-1 and GIP and pancreatic beta-cell sensitivity to glucose, as well as suppressing 
glucagon secretion (Rosenstock et al. 2008). Saxagliptin is the third DPP-4 inhibitor 
approved for clinical use in 2009 and used as an add-on therapy at a dose of 5 mg 
with metformin or thiazolidinedione therapy (DeFronzo et al. 2009, Hollander et al. 
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2009). The introduction of Linagliptin was in 2011, and similar to other DPP-4 
inhibitors, glycaemic control is improved with Linagliptin monotherapy or in 
combination with other oral glucose-lowering agent (Duez et al. 2012, Gomis et al. 
2012). 
 
DPP-4 inhibitors offer several advantages over existing diabetes therapies. Firstly, 
enhancement of insulin secretion and suppression of glucagon release follow a 
glucose-dependent manner, thus there less risk of hypoglycaemia (Herman et al. 
2005). Furthermore, no weight gain was observed in type 2 diabetes patients treated 
with DPP-4 inhibitors (Barnett 2006, Karasik et al. 2008, Rosenstock et al. 2008). 
Lastly, long-term inhibition of DPP-4 has beneficial effects on islet beta-cell mass 
and function as seen in diabetic mice (Mu et al. 2006, Pospisilik et al. 2003, Reimer 
et al. 2002).  
 
1.8 FUNCTION OF INCRETINS ON BONE 
 
Bone formation and breakdown are closely related to nutrient intake and it has been 
shown that with meal ingestion, biomarkers for bone resorption are reduced 
(Henrikson et al. 2003), suggesting a link between gut and bone regulation. GIP and 
GLP-1 are secreted in response to food ingestion and since gastrointestinal hormone 
levels change upon food intake, it is suspected that incretins may play a role in bone 
turnover. GIP has direct action on bone as GIPR mRNA and protein are present in 
normal bone cells (osteoblast and osteoclast) and progenitor bone cells (Bollag et al. 
2000, Bollag et al. 2001, Ding et al. 2008, Zhong et al. 2007). 
 
Similar to the pancreas, the binding of GIP to GIPR on osteoblast has been shown to 
increase cAMP and Ca
2+
 concentrations and subsequently elevate the expression of 
bone formation biomarkers, collagen type 1 and alkaline phosphatase activity 
(Bollag et al. 2000), suggesting positive action of GIP on bone formation. GIP has a 
role in proliferation of osteoblasts as it was observed to have stimulatory effect on 
the release of transforming growth factor-β (TGF-β) and 3H-thymidine incorporation 
in osteoblastic-derived cells (Zhong et al. 2003). Investigation of potential 
osteoprotective effects of GIP using primary mouse osteoblasts and osteoblastic-like 
SaOS-2 cells found that pretreatment with GIP significantly reduced the percentage 
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of apoptotic cells (Tsukiyama et al. 2006). Furthermore, GIP may be involved in the 
early process of osteogenesis by promoting osteoblastic differentiation of bone 
marrow stromal cells (Ding et al. 2008). There is limited information on GIP actions 
on bone-resorbing osteoclast cells. However, GIP has been reported to inhibit 
osteoclast activity and differentiation in vitro (Zhong et al. 2007), indicating a role of 
GIP in reducing bone resorption.  
 
Rodent models of GIPR knockout have reduced bone size and lower bone mass as 
well as a decrease in bone formation biomarkers compared with the wild type (Xie et 
al. 2005). Bone histomorphometrical analyses in GIPR-deficient mice demonstrated 
that the reduction in bone mass was due to increased multinucleated osteoclasts, 
which are responsible for active bone resorption (Tsukiyama et al. 2006). In 
agreement, bone mass, bone size and biomarkers for bone formation were shown to 
be increased in GIP-overexpressing transgenic mice, whilst bone resorption 
biomarkers were decreased (Xie et al. 2007). These observations were in harmony 
with in vitro data that reported a stimulatory effect of GIP on osteoblasts and 
inhibitory effect on osteoclasts. In addition, using five different techniques of bone 
assessment, a recent study found that microstructure and strength of bones in mice 
lacking GIPRs were compromised and these findings support the beneficial effects 
of GIP on bone (Mieczkowska et al. 2013). Importantly, it was shown earlier that 
administration of GIP prevented bone loss in ovariectomized rats (Bollag et al. 
2001), while a more recent study found that rats injected with a stable GIP analogue 
appeared to have increased tissue material properties at the cortical bone level 
(Mabilleau et al. 2014).  
 
Conflicting data on the expression of GLP-1Rs on bone cells has been published 
(Bollag et al. 2000, Mabilleau et al. 2013, Nuche-Berenguer et al. 2010b). However, 
the inconsistencies may result from the use of different cell lines. Nevertheless, 
GLP-1 is speculated to affect bone turnover in a beneficial manner as GLP-1R-
deficient mice have reduced bone mass and bone mineral density, whilst bone 
resorption biomarkers appeared to be significantly increased (Yamada et al. 2008). 
The same researchers also found that level of calcitonin was reduced and proposed 
that GLP-1-mediated bone turnover is mediated through a calcitonin-dependent 
pathway. Recently, bone quality in mice lacking GLP-1Rs function was further 
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assessed and it was revealed that these mice had reduced cortical bone strength due 
to alterations of cortical thickness and bone material properties (Mabilleau et al. 
2013). Other studies demonstrated that bone formation biomarkers were elevated 
after 3-day subcutaneous administration of GLP-1 or the GLP-1R agonist, Exendin-4 
in streptozotocin-induced and insulin-resistant diabetic rats (Nuche-Berenguer et al. 
2009, Nuche-Berenguer et al. 2010a), supporting earlier findings that suggested the 
positive effects of GLP-1 on bone.    
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1.9 AIMS OF THESIS 
 
The primary aim of this thesis was to investigate the impact of diabetes on bone and 
to characterise the effects of long-acting anti-diabetic incretin analogues on 
metabolic control, bone strength and quality in diabetes. 
 
The specific objectives of this thesis were : 
 
1. To demonstrate the positive effects of native GIP and [D-Ala2]GIP on human 
osteoblastic SaOS-2 cells. 
 
2. Preliminary assessment of metabolic control, bone mineral density and bone 
mineral content in mice lacking GIP and/or GLP-1 receptors. 
 
3. To investigate the effects of [D-Ala2]GIP and Liraglutide treatment on bone 
mass and cortical mechanical strength in chemically-induced insulin-
deficient diabetic mice. 
 
4. To assess the effects of the triple-acting [D-Ala2]GIP-Oxyntomodulin agonist 
on cortical bone strength at whole- and tissue-level in genetically-induced 
C57 BL/KsJ diabetic (db/db) mice.  
 
5. To determine the effects of Exendin-4 and Sitagliptin administration on bone 
microarchitecture and quality in high-fat fed diabetic mice. 
 
6. To provide evidence to support the use of incretin-based therapies for bone 
abnormalities in diabetes. 
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General Materials and Methods 
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2.1  PEPTIDES 
 
2.1.1  Synthesis of peptides 
 
Peptides used in these studies were all purchased from GL Biochem Ltd. (Shanghai, 
China), whilst DPP-4 inhibitor was purchased from ApexBio Technology (Houston, 
TX, USA) with >95% purity. The peptides used were native GIP(1-42), GLP-1(7-
36)amide, [D-Ala
2
]GIP(1-42), [D-Ala
2
]GIP-Oxm, Liraglutide, Exendin-4 and the 
DPP-4 inhibitor was Sitagliptin phosphate monohydrate.  
 
2.1.2  Identification and characterisation 
 
All peptides were identified and characterised by matrix-assisted laser 
desorption/ionisation-time of flight mass spectrometry (MALDI-TOF MS). Peptide 
solution 1.5 µl was individually dispensed into different wells of a 100-well stainless 
steel MALDI plate and allowed to dry at room temperature. Matrix solution 1.5 µl; 
10 mg/ml α-cyano-4-hydroxycinnamic acid in acetonitrile (Sigma-Aldrich, UK), was 
added to the dried peptides and the mixture was again left to dry at room 
temperature. The molecular mass of the peptides were determined using a Voyager-
DE BioSpectrometry Workstation (PerSeptive BioSystems, Framingham, MA, USA) 
and recorded as mass-to-charge (m/z) ratio vs percentage intensity of peak. Table 2.1 
lists the peptides used together with their theoretical and experimental mass. 
 
2.2  CELL CULTURE 
 
2.2.1  SaOS-2 cells 
 
The SaOS-2 cell line was obtained from ATCC. Cells were cultured in MEM alpha 
medium (1x) without phenol red (Gibco, Invitrogen) supplemented with 10% of fetal 
bovine serum (FBS) (Lonza) and 1% of penicillin/streptomycin (5000 U/ml, 5000 
µg/ml) (Gibco, Invitrogen). All cells were maintained in sterile tissue culture flasks 
in a controlled atmosphere (37
o
C, 5% CO2/95% air). When cells were in confluence, 
they were washed with hanks buffer saline solution (HBSS) and trypsinised. Trypsin 
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was removed by centrifuging cells/trypsin mixture at 900 rpm for 5 min and cells 
were resuspended with fresh media. 
 
Table 2.1 : Identification and characterisation of peptides by MALDI-TOF MS 
  
Peptide 
MALDI-TOF MS 
Theoretical mass (Da) Experimental mass (Da) 
GIP(1-42) 4983.60 4983.36 
(D-Ala
2
)GIP(1-42) 4983.60 4984.32 
GLP-1(7-36)amide 3297.68 3297.04 
Liraglutide 3751.30 3752.64 
(D-Ala
2
)GIP-Oxm 4473.00 4472.29 
 
2.3  ANIMALS 
 
Animal models of incretin receptor knock-out (KO) as well as chemically-, 
genetically- and environmentally-induced diabetic rodents were employed in these 
studies. All experiments were non-blind studies and performed in accordance with 
the UK Animals (Scientific Procedures) Act 1986. 
 
2.3.1  GIPR KO mice 
 
Female GIPR KO mice (kindly provided by Professor Bernard Thorens from 
University of Lausanne, Switzerland) were derived from the C57BL/6J background 
as outlined previously (Preitner et al. 2004). These mice were individually housed in 
an air-conditioned room at 22 ± 2 with 12 h light : 12 h dark cycle and had free 
access to standard rodent chow (10% fat, 30% protein, 60% carbohydrate) and 
drinking water. 
 
2.3.2  GLP-1R KO mice 
 
Male GLP-1R KO mice (obtained from Dr DJ Drucker from University of Toronto, 
Canada) were derived from the C57BL/6J colony and individually kept in an air-
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conditioned room at 22 ± 2 with 12 h light : 12 h dark cycle and had free access to 
standard rodent chow (10% fat, 30% protein, 60% carbohydrate) and drinking water. 
 
2.3.3  Double incretin receptor (DIR) KO mice 
 
Female DIR KO mice (kindly given by Professor Bernard Thorens from University 
of Lausanne, Switzerland) were individually caged in an air-conditioned room at 22 
± 2 with 12 h light : 12 h dark cycle and had free access to standard rodent chow 
(10% fat, 30% protein, 60% carbohydrate) and drinking water. The C57BL/6J 
genetic background and characteristics of these mice are described previously 
(Preitner et al. 2004). 
 
2.3.4  NIH Swiss mice 
 
Male NIH Swiss mice (8 weeks, Harlan Ltd., Blackthorn, UK) were housed 
individually in an air-conditioned room at 22 ± 2 with 12 h light : 12 h dark cycle 
and had free access to standard rodent chow (10% fat, 30% protein, 60% 
carbohydrate) and drinking water. 
 
2.3.5  C57 BL/KsJ diabetic (db/db) mice 
 
Male db/db mice (11 weeks, Harlan LTD., Blackthorn, UK) were caged individually 
in an air-conditioned room at 22 ± 2 with 12 h light : 12 h dark cycle and had free 
access to standard rodent diet (10% fat, 30% protein, 60% carbohydrate) and 
drinking water. 
 
2.3.6  High-fat fed NIH Swiss mice 
 
Male NIH Swiss mice (Harlan Ltd., Blackthorn, UK) were housed individually in an 
air-conditioned room at 22 ± 2 with 12 h light : 12 h dark cycle and had free access 
to drinking water and high fat diet (45% fat, 20% protein, 35% carbohydrate; Special 
Diet Service, Essex, U.K.) for 15 weeks prior to start of studies.  
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2.3.7  Collection of blood samples 
 
Blood samples were obtained from the cut tips of the tail vein of conscious mice and 
collected into fluoride coated microvette blood tubes (Sarstedt, Germany). The 
samples were immediately centrifugated using a microcentrifugate (Beckman 
Instruments, Galway, Ireland) for 3 min at 13 000 g. The separated plasma was 
aliquoted into 500 μl eppendorf tubes and kept at -20oC prior to analysis. 
 
2.3.8  Intraperitoneal glucose tolerance test 
 
Pre-injection blood collections were taken (0 min) in 18 h fasted mice before 
intraperitoneal injection of glucose (18 mmol/kg bw). Blood was then collected at 
15, 30 and 60 min post-injection and immediately were centrifuged with a 
microcentrifuge (Beckman Instruments, Galway, Ireland) at 13 000 g for 3 min. 
Supernatants were then aliqouted into 500 μl eppendorf tubes and stored at -20oC for 
subsequent plasma glucose and insulin measurements. 
 
2.3.9  Intraperitoneal insulin sensitivity test 
 
Blood glucose levels were initially recorded using an Ascencia glucose meter (Bayer 
Contour) at 0 min in non-fasted mice. Bovine insulin (25 or 50 U/kg bw in 0.9% 
saline) was then intraperitoneally administered and blood glucose sampled at 30 and 
60 min post-injection. 
 
2.4  IN VIVO BIOCHEMICAL ANALYSIS 
 
2.4.1  Plasma glucose determination 
 
Plasma glucose concentrations were determined by the glucose oxidase method 
using Analox analyser GM-9 with Analox instruments glucose reagent. Glucose 
oxidase catalyses the oxidation of glucose to gluconic acid and the rate of oxygen 
consumption is directly proportional to concentration of glucose in the sample. The 
analyser was calibrated with 8 or 25 mmol/l glucose standard until it achieved a 
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stable reading of the standard used and 5 μl of samples was injected into it. The 
reading was then recorded. 
 
2.4.2  Plasma insulin determination 
 
Plasma insulin concentrations were determined by a modified dextran-coated 
charcoal radioimmunoassay (RIA). The methodology for insulin RIA is described 
below. 
 
Iodinated bovine insulin 
 
Iodogen solution was made by dissolving 100 µg/ml of 1,3,4,6-tetrachloro-3α,6α-
diphenylglycoluril in dichloromethane, followed by dispense of the solvent (100 µl) 
into Eppendorf tubes. The tubes were left in a fume hood with a stream of helium to 
allow evaporation of the solvent and leaving a uniform layer of iodogen at the 
bottom of the tubes. Bovine insulin solution (125 µg/ml) was prepared by diluting a 
1 mg/ml solution of bovine insulin (in 10 mM HCl) with 500 mM phosphate buffer. 
20 µl of the bovine insulin solution and 5 µl of Na
125
I (100 mCi/ml stock) was added 
to the iodogen-coated Eppendorf tubes and left on ice with gentle agitation for 15 
min. The iodogen reaction was stopped by removing the reaction mixture into a fresh 
Eppendorf tube with an addition of 500 µl of 50 mM sodium phosphate buffer. The 
solution was kept on ice prior to HPLC separation. 
 
HPLC separation was carried out using a VydaC8 analytical column (4.6 x 250 mm) 
and the mobile phases used were 0.12% (v/w) TFA (in purified H2O) and 0.1% TFA 
(in 70% acetonitrile-30% purified H2O). The separation programme was set for 67 
min and 1 ml fractions were collected by fraction collector (Frac-110, LKB). 5 µl 
from each fraction was aliquoted into LP3 tubes and radioactivity counts were 
assessed using a gamma counter (Perkin Elmer Wallac Wizard 1470 Automatic 
Gamma Counter). The fractions with highest counts were kept for antibody-binding 
tests and then pooled together to be used as the 
125
I-labelled tracer in the insulin 
radioimmunoassay.   
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Modified dextran-coated charcoal radioimmunoassay 
 
Radioimmunoassay stock buffer was prepared by adding an acidic solution of 40 
mmol/l sodium dihydrogen orthophosphate to 40 mmol/l of basic disodium hydrogen 
orthophosphate (containing 0.3% (w/v) sodium chloride and 0.02% (w/v) 
thimerosal) to achieve a solution with pH 7.4 and stored at 4
o
C until use. On the day 
of experimentation, working RIA buffer was made up by dissolving bovine serum 
albumin (0.5 g/100 ml) in stock RIA buffer pH 7.4. Insulin standards were prepared 
by serial dilutions (0.039 to 20 ng/ml concentration) from frozen rat insulin stock (40 
ng/ml) in working RIA buffer. 180 µl of working RIA buffer was added to 20 µl of 
unknown plasma samples in LP3 tubes to give a total of 200 µl of unknown sample 
per tube. Guinea pig insulin antibody was later diluted in working RIA buffer to 
achieve approximately 40% insulin label binding and 100 µl of the antibody was 
added to the unknown (duplicate) and standard (triplicate) samples, followed by the 
addition of 100 µl of 
125
I-labelled insulin (approximately 10,000 cpm/100 µl in 
working assay buffer) into all samples.  
 
All tubes were incubated at 4
o
C for 48 hours to allow antibody binding reactions to 
take place. After which, the separation of free from bound 
125
I-labelled was achieved 
by adding 1 ml of working dextran-coated charcoal (stock dextran-coated charcoal 
(5% charcoal solution) diluted with stock RIA buffer in 1:5 dilution) to all tubes 
(except the total tubes of the standards). All tubes were vortexed and incubated for 
20 minutes at 4
o
C in a cooled centrifugal machine (Beckmann Coulter) and then 
centrifugated for 20 min at 2500 rpm. The supernatant was discarded and free 
(unbound) 
125
I-labelled tracer absorbed to black charcoal pellet remained in the 
tubes. Radioactivity in the tubes was counted using a gamma counter (Perkin Elmer 
Wallac Wizard 1470 Automatic Gamma Counter. The total counts (from total tube) 
minus radioactivity counts of unbound 
125
I-labelled tracer were inversely 
proportional to insulin present in the unknown samples and standards. The insulin 
concentration in the unknown samples was determined from a rat insulin standard 
curve as shown in Figure 2.1. 
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Figure 2.1 Typical standard curve of rat insulin standards for insulin 
immunoassay 
 
 
 
2.5  MEASUREMENT OF BODY COMPOSITION, BONE MINERAL 
DENSITY AND MINERAL CONTENT BY DUAL-ENERGY X-RAY 
ABSORPTIOMETRY (DEXA) SCANNING 
 
DEXA scanning uses x-ray beams of two different energy levels that pass through 
the whole body where both energies are absorbed by bones and soft tissues. A 
radiation detector records reduction in intensity of the x-ray beam and attenuation of 
high and low energy are calculated. The ratio of attenuation of the two energies 
allows separation of bone and soft tissues as well as lean and fat mass. Bone mineral 
density (BMD, g/cm
2
), bone mineral content (BMC, g), lean mass (g), fat mass (g) 
and percentage of total fat were measured by a Lunar PIXImus dual-energy X-ray 
absorptiometry (DEXA) scanner (Inside Outside Sales, Wisconsin, U.S.A.). Mice 
were anaesthetised with isoflurane and pentabarbitol sodium (10 μl/g bw) and then 
placed on a specimen tray. The animals were exposed to low energy X-rays and a 
high-resolution picture (0.18 x 0.18 mm pixel size) is captured of the x-rays hitting a 
luminescent panel. The whole body was scanned and regions of interest (ROIs), as 
shown in Figure 2.2, were analysed as described previously (Xie et al. 2005). Quality 
control was performed on daily intervals before acquiring data and calibration of the 
DEXA machine was performed using the phantom provided by the manufacturer. 
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Figure 2.2 Animal images from DEXA scanning and its region of interest (ROI) 
 
 
 
Figure 2.2A shows total region, whole body (in green) excluding the head (in red) 
Figure 2.2B shows femoral region 
Figure 2.2C shows lumbar or lower spine region  
Figure 2.2D shows tibial region 
 
2.6 ASSESSMENT ON BONE STRENGTH AND QUALITY 
 
Tibias and femurs were cleaned of tissue and then, extracted femurs were stored in 
ethanol 70, while excised tibias were kept in a fixative (75% ethanol 95, 10% 
formaldehyde 37 or 40 and 15% distilled water) for 24 h, followed by in absolute 
acetone and stored at 4
o
C until required for microstructural and mechanical strength 
assessment. Five techniques that were then employed; X-ray microcomputed 
tomography (microCT), quantitative X-ray imaging (qXRI), three-point bending test, 
A B 
C D 
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quantitative back-scattered electron imaging (qBEI) and nanoindentation (Figure 
2.3). 
 
Figure 2.3 General representation of experimental design for excised bones 
 
Excised bones 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.6.1  Quantitative x-ray imaging (qXRI) 
 
Bone mineral content at cortical or trabecular bone was evaluated using quantitative 
x-ray imaging which is based on the absorption of x-rays by mineral content in the 
bone matrix.  The x-ray images of femurs were recorded using a Faxitron MX20 
digital radiograph (Edimex, Angers, France) with 4 x magnification at 26 kV. A 1.5-
mm thick steel plate and polyester plate were used as standards and aligned together 
 
 
Tibia Femur 
microCT qXRI 
Three-point 
bending 
Embedding of bone in PMMA 
and sectioning 
 
Nanoindentation 
qBEI 
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with femurs each time x-ray images were captured (Figure 2.4). Images obtained in 
16-bit DICOM files were processed by stretching the histogram from grey level 0 
(represented by polyester) to grey level 255 (represented by steel) and saved in tiff 
format. Using 16-color lookup table of ImageJ (National Institute of Health, 
Bethseda, MD), the frequency of occurrence of grey level at trabecular or cortical 
bone was calculated and mean grey level (GLmean) and absorbing mineral density 
(AMD) which represent mineral density were determined as previously described 
(Bassett et al. 2012, Mabilleau et al. 2015, Mieczkowska et al. 2013). Trabecular 
bone was measured at the metaphysis (starting just below growth plate and 2 mm 
down), whilst cortical was measured at the midshaft (3 mm below growth plate until 
the beginning of crest).  
 
Frequency of occurrence of i grey level (Fi) ; 
 







t
i
i
N
N
F 100  
 
Ni = number of pixels with the i grey level  
Nt = total number of pixels 
 
The distribution of frequency represented by grey level was plotted and using the 
following formula, the mean grey level (GLmean) was obtained ; 
 



100
ii
mean
GLF
GL  
 
GLi = value of the i grey level 
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Figure 2.4 Normal and x-ray images from x-ray radiograph 
 
 
 
Figure 2.4A shows normal image of two standards and a femur 
Figure 2.4B shows an x-ray image of steel (GL = 255), polyester (GL = 0) and bone 
 
2.6.2 X-ray microcomputed tomography (µCT) 
 
Bone mass and microstructural morphology of tibia were assessed using a high-
resolution Skyscan 1172 microtomograph (Bruker-Skyscan, Kontich, Belgium) 
which was hequipped with an X-ray tube working at 50 kV/100 µA. Bones were 
individually placed in water-cointaining Eppendorf tubes to keep the sample 
hydrated and in order to maintain the specimen at stationary condition in the tube, a 
damp sponge was positioned at both ends of bone in the tube. The Eppendorf tubes 
were aligned at the central scanner axis on a carbon bed in the sample’s chamber 
prior to scanning process in the x-ray chamber. Using a fixed pixel size of 9 µm, 
rotation step set at 0.3
o
 and exposed with a 0.5 mm aluminium filter, bones were 
scanned cross-sectionally and distally to produce a series of 2D projection images. 
This was followed by 3D reconstruction of bones from the projection images 
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obtained after removing noise background and interactive thresholding using 
NRecon software.  
 
CTAn software (release 1.11.4.2, Bruker) was then employed to measure trabecular 
parameters in the volume of interest (VOI) that was located at tibia metaphysis 
which is approximately 0.5 mm below growth plate on a height of 2 mm. Variables 
that were assessed with microCT included; BV/TV (bone volume / trabecular 
volume, %), Tb.Th (trabecular bone thickness, mm), Tb.N (numbers of trabecular 
bone, 1/mm) and Tb.Sp (trabecular separation, mm). The measurements were 
perfomed according to guidelines on bone microstructure proposed by the American 
Society for Bone and Mineral Research (Bouxsein et al. 2010). 
 
Assessment was also done on cortical bone thickness (Ct.Th, in µm) and cross-
sectional moment of inertia (CSMI, in mm
4
) by measuring the diameter of cortical 
bone (B.Dm, in mm) and bone marrow (Ma.Dm, in mm) at 3-4 mm below the 
growth plate using lab-made routine ImageJ software (National Institute of Health, 
Bethseda, MD), as previously explained (Libouban et al. 2008). The measurements 
were conducted according to guidelines on bone histomorphometry proposed by the 
American Society for Bone and Mineral Research (Dempster et al. 2013).  
 
Cortical variables were calculated using the following formula; 
 
 
2
..
.
DmMaDmB
ThCt

  
 
    44 ...
64
DmMaDmBDmBCSMI 

 
 
Where 
B.Dm = the diameter of bone 
Ma.Dm = the diameter of bone marrow  
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Figure 2.5 Setup of microCT 
 
 
 
 
 
Figure 2.5A shows the microtomography system which consists of sample and x-ray 
chambers.  
Figure 2.5B shows how tubes containing bones aligned on a carbon bed in sample 
chamber 
Figure 2.5C shows the scout view of bones in x-ray chamber  
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2.6.3 Three-point bending test 
 
Mechanical properties of femoral bones were assessed by three-point bending test 
using an Instron-5942 3-point bending machine (Instron, U.S.A.). Prior to 
experimental day (24 h), bones were rehydrated in saline at room temperature. 
Femurs were positioned horizontally with the anterior side facing upward, on top of 
a pair of rounded grips (10 mm apart) as supports (Figure 2.6B). Using a control 
panel, vertically-moving crosshead was slowly brought down to the midshaft of the 
specimen and a pressing force was applied to the femur until the bone breaks. A 
loading speed of 2 mm min
-1 
was employed and the load and time taken until bone 
failure was recorded by the captor. The load-time curve was converted to a force-
displacement curve (Figure 2.7), measured by Bluehill 3 software. Mechanical 
properties derived from the curve were ultimate load, ultimate displacement, 
stiffness and work to failure as published previously (Turner 2006). 
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Figure 2.6 : Setup of the three-point bending machine 
 
 
   
  
 
Figure 2.6A shows three-point bending instrument connected to a computer with 
Bluehill 3 software that is responsible for measuring mechanical properties of bone. 
Figure 2.6B shows the position of femur on 10 mm-apart grips and a moving 
crosshead. 
Figure 2.6C shows control panel of the three-point bending instrument that allows 
vertical movement of load and captor. 
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Figure 2.7 Representative of force-displacement curve for three-point bending 
test 
 
 
 
As specimen is subjected to an increasing force, displacement initially increases 
linearly with the load. However, after a critical value of applied force is reached 
(yield point), bone undergoes deformation with a relatively small increase in the 
applied load until it reaches the maximum value. Formation of cracks from 
innumerable microcracks at midshaft of bone results in lower force required to keep 
bone elongating further, until it finally breaks. Mechanical properties derived from 
this graph were extrinsic stiffness represented by the slope of linear region of the 
curve; total absorbed energy (area under the curve); maximum load (peak of the 
curve on y-axis), maximum displacement (displacement at maximum force); yield (a 
transition point, above which force begins to cause permanent damage to bone) and 
the post-yield energy (area under the curve after yield point).   
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2.6.4    Nanoindentation 
 
Measurement of mechanical strength of whole bone was performed by three-point 
bending tests while mechanical properties of bone matrix were investigated by 
nanoindentation (Mabilleau et al. 2013, Mieczkowska et al. 2013). Blocks of 
embedded bone were polished with a DiaPro Nap-B diamond particle using Struers 
Tegramin-30 machine (Struers, Denmark) prior to experimental day and left in saline 
(NaCl, w/v, 0.9%) for rehydration overnight. The polished block was placed on a 
stable platform and using microscope, an indentation area 3 mm below the growth 
plate which is equivalent to cortical bone area was selected. Once the indentation 
area was chosen, the block was transferred under the indenter. 12 indentations were 
positioned in cortical bone using NHT-TTX (CSM instrument, Peseux, Switzerland) 
which was equipped with a Berkowitch pyramidal diamond probe as an indenter. A 
loading/unloading rate of 40 mN/min was applied to the bone and produced 
indentations that were 900 nm in depth. In order to prevent creeping of bone 
material, load was maintained for 15 s at its maximum rate. Depending on properties 
of bone matrix, maximum force applied to reach the required depth reflected the 
hardness of the bone. The variables derived from this test were maximum force, 
indentation modulus, hardness and dissipated energy as described previously (Oliver 
& Pharr, 1992).   
 
Hardness is calculated from this equation; 
 
p
IT
A
F
H max  
  
Where 
Fmax is the maximum force 
Ap is the projected contact area 
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Figure 2.8 The nanoindentation system 
 
  
 
Figure 2.8A shows the position of PMMA block on a stable platform and under the 
indenter.  
Figure 2.8B shows the pyramidal indentation as an impact of Berkowitch diamond 
probe on cortical bone. 
 
Indentation modulus is the initial slope of the unloading section of the curve and 
obtained from the equation below; 
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Where 
Ei = Elastic modulus of the indenter (1141 GPa) 
Er = Reduced modulus of the indentation contact 
vi = Poisson’s ratio of the indenter (0.07) 
vs = Poisson’s ratio of the sample 
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Figure 2.9 Typical force-displacement curve for nanoindentation 
 
 
 
The curve illustrates the different period of time during indentation. During loading, 
a probe is touching and penetrating bone where there is a combination of elastic and 
deformation properties. When maximum penetration is achieved (900 nm), there is a 
15 s plateau phase maintained to avoid creeping deformation or plasticity. 
Subsequently at the unloading phase, the probe is retracted and the curve reflects 
elasticity of the sample.  Mechanical parameters obtained from this curve are 
hardness (a measure of resistance to permanent deformation), indentation modulus 
(initial slope of unloading curve), maximum force (load that reached maximum 
penetration) and dissipated energy (area between loading and unloading curves).  
 
2.6.5  Quantitative backscattered electron imaging (qBEI) 
 
Scanning electron microscope scans sample using a focused beam of electrons which 
interact with atoms in the specimen and produce various signals. These signals carry 
information on the composition or topography at the surface of the sample and 
produce an image. Back-scattered electron (BSE) is one of these signals where 
beams of electrons are reflected from the sample and the signal is closely related to 
the atomic number (Z) of the specimen. From assessment on quantitative 
backscattered electron imaging and in combination with ImageJ software (National 
Institute of Health, Bethseda, MD), bone mineral density distribution (BMDD) can 
be determined (Mieczkowska et al. 2013, Roschger et al. 1998).  
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Prior to the experimental day, polymethylmethacrylate blocks were polished with 
DiaPro Nap-B diamond particles (Struers, Denmark) to get 1-µm finishing and then 
coated with carbon. The blocks were observed with a scanning electron microscope 
(EVO LS10, Carl Zeiss Ltd., Nanterre, France) (Figure 2.10A) which was equipped 
with a five quadrant semi-conductor backscattered electron detector and at least four 
images were taken from the cortical bone area. The electron microscope was 
operated at 20 keV with a 250 pA probe current at working distance of 15 mm. 
Calibration of the backscattered electron signal (grey scale) was achieved using pure 
carbon (Z = 6, mean grey level = 25), pure aluminium (Z = 13, mean grey level = 
225) and pure silicon (Z = 14, mean grey level = 253) as standards (Micro-analysis 
Consultants Ltd., St. Ives, UK).  
 
The adjustments in brightness and contrast of those reference materials established a 
correlation of atomic number (Z)(y-axis) and BSE gray level (x-axis). Using 
hydroxylapatite, Ca10(PO4)6(OH)2 (Z = 14.06) composition, the BSE gray level 
histogram was converted to weight percentage of calcium. The integrity of the 
instrument was checked every 15 min by imaging these standards. The region of 
interest was imaged at 200x magnification (0.5 µm per pixel) and Using ImageJ 
software, change in grey levels distribution, also known as bone mineral density 
distribution (BMDD) was determined from 3 parameters; Capeak which reflects the 
most frequent calcium content of the bone area, Camean which is the mean calcium 
content of the bone area obtained from area under the curve and Cawidth which is the 
heterogeneity of mineralisation measured at 50% of maximum Ca level. 
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Figure 2.10 Representative of scanning electron microscope (A), PMMA blocks 
(B) and scanning image of trabecular bone (C) 
 
 
 
  
 
Figure 2.10A shows scanning electron microscope system that was used in 
quantitative backscattered electron imaging technique 
Figure 2.10B shows proximal longitudinal section of embedded bone in 
polymethylmethacrylate (PMMA) blocks 
Figure 2.10C shows microarchitectural image of trabecular bone captured by 
scanning electrom mocroscope 
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2.7  STATISTICAL ANALYSIS 
 
Results are expressed as mean ± SEM together with number of observations. Values 
were compared by repeated measures ANOVA or one-way ANOVA with Student- 
Tukey or New-Keuls post hoc test or two-tailed unpaired t-test using GraphPad 
Prism 5. A P value of < 0.05 was considered to be statistically significant. 
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Chapter 3 
 
Effects of GIP peptides on SaOS-2 
cells in vitro and genetic 
deficiencies of GIP and/or GLP-1 
receptors on bone mass in vivo 
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3.1 SUMMARY 
 
Glucose-dependent insulinotropic polypeptide (GIP) is a 42-amino acid incretin 
peptide that regulates blood glucose levels by stimulating insulin secretion following 
food intake. GIP receptors (GIPRs) are predominantly found in pancreas however 
recently, the presence of active GIPRs has been revealed on bone cells. The 
physiological actions of GIP are limited as the molecule is rapidly degraded by 
dipeptidyl peptidase 4 (DPP-4). In order to circumvent DPP-4 activity, stable GIP 
peptides have been developed. This study investigated the effects of native GIP, and 
a long-acting GIP analogue namely [D-Ala
2
]GIP, on biomarkers of bone formation, 
alkaline phosphatase (AlkP) activity and cyclic adenosine monophosphate (cAMP) 
generation in human osteoblastic-like SaOS-2 cells. Preliminary in vivo studies on 
the effects of GIP and its sister incretin, glucagon-like peptide 1 (GLP-1) on bone 
were also carried out by assessing bone mineral density (BMD) and bone mineral 
content (BMC) in mice lacking GIP and/or GLP-1 receptors. SaOS-2 cells were 
incubated with GIP peptides (10
-12
 - 10
-6
 M) for 8 h and both native GIP and [D-
Ala
2
]GIP significantly stimulated IGF-1 secretion (1.2-1.4-fold, P < 0.01) at all 
concentrations tested. In harmony, both peptides significantly (1.1-1.3-fold, P < 0.01 
to P < 0.001) induced TGF-β release, but only [D-Ala2]GIP was effective at the 
lowest concentration (10
-12
 M) tested. Native GIP and [D-Ala
2
]GIP significantly 
increased (1.6-2.3-fold, P < 0.05 to P < 0.01) cAMP production, with [D-Ala
2
]GIP 
being more potent. AlkP activity in SaOS-2 cells was enhanced after 24 h incubation 
with [D-Ala
2
]GIP (1.1-fold, 10
-10
 – 10-6 M, P < 0.01) and native GIP (1.1-fold, 10-6 
M, P < 0.01) when compared to control cultures. Moreover, following 48 and 72 h 
incubation, [D-Ala
2
]GIP was significantly (P < 0.05 to P < 0.001) more potent than 
native GIP in terms of augmenting AlkP activity at all concentrations examined. 
Further investigation of the effects of GIP on bone density and content revealed that 
GIPR KO mice had significantly reduced (P < 0.01) total BMD as well as at femur 
(P < 0.001) and tibia (P < 0.01) BMD. In parallel, BMC at those regions was also 
decreased (P < 0.05 to P < 0.001). BMD and BMC in GLP-1R KO mice were not 
significantly different compared to normal mice. The absence of both incretin 
receptors markedly decreased (P < 0.05) BMD and BMC at the femur while only 
BMD was significantly reduced (P < 0.01) at the tibia. The data demonstrates that 
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GIP has clear anabolic effects on bone cells and this is supported by the appearance 
of impaired bone quality in GIPR- and double incretin receptor-deficient mice.  
 
3.2 INTRODUCTION 
 
Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 
(GLP-1) are released in response to food ingestion. The primary effect of these 
hormones is to enhance the secretion of insulin in a glucose-dependent manner and 
hence, control postprandial glucose concentrations. Interestingly, previous studies 
reveal the presence of functional GIP receptors, but not GLP-1 receptors on bone 
(Bollag et al. 2000, Zhong et al.2007), suggesting a direct action of GIP on skeleton. 
GIPRs are predominantly found in pancreatic tissue, however the expression of GIP 
receptors are also detected in other tissues such as bone (Baggio & Drucker 2007). 
 
The first evidence of GIP receptors on bone was reported in normal rat bone as well 
as in established human osteoblastic-like osteosarcoma cell lines, the SaOS-2 and 
MG-63 (Bollag et al. 2000). Previous studies have shown that exposure to GIP 
results in an increase in bone-forming biomarkers, collagen type 1 expression and 
alkaline phosphatase activity from osteoblast-derived cells (Bollag et al. 2000). 
Furthermore, a lower percentage of apoptotic bone cells was seen in the presence of 
GIP in vitro (Tsukiyama et al 2006), indicating the protective effects of GIP on bone 
cells. Further examination in GIPR KO mice found that deficiencies in GIPR 
signalling not only reduced bone size and mass, but also detrimentally affected bone 
microarchitecture and strength (Xie et al. 2005). Conversely, increased bone mass 
was seen in transgenic mice with overexpression of GIP (Xie et al. 2007). A more 
recent study demonstrated that the reduction of bone strength in GIPR-deficient mice 
is associated with alterations of material properties of bone matrix (Mieczkowska et 
al. 2013).  
 
Bone remodeling is a complex process which involves communication between 
osteoblasts and osteoclasts, where old bone is removed by osteoclasts and 
replacement of new bone by osteoblasts (Matsuo & Irie 2008). Although extensive 
studies have been conducted in determining the effects of GIP on osteoblastic cells, 
much less information is available on the effects of GIP on bone-resorbing osteoclast 
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cells. GIP has been shown to inhibit osteoclast activity and differentiation (Zhong et 
al. 2007) and in agreement with these findings, bone-resorbing biomarkers were 
reduced in GIP-overexpressing transgenic mice (Xie et al. 2007), indicating the 
positive action of GIP in reducing bone resorption. Similar to its glucoregulatory 
action in pancreas, GIP exerts its effects on bone through activation of cAMP- and 
Ca
2+
-dependent pathways (Bollag et al. 2000). Collectively, these studies show that 
GIP has dual actions on bone turnover by enhancing bone formation and reducing 
bone resorption. 
 
GIP has only short half-life in rodents and humans (Deacon et al. 2000, Kieffer et al. 
1995). The intact biologically active peptide is rapidly degraded by dipeptidyl 
peptidase 4 (DPP-4). To circumvent this, DPP-4-resistant GIP molecules with 
prolonged bioactivity have been developed (Hinke et al. 2002, Irwin et al. 2005a). 
[D-Ala
2
]GIP is recognised as an enzyme-resistant GIP agonist which improves 
glucose tolerance and insulin release in high-fat fed mice (Hinke et al. 2002, Lamont 
& Drucker 2008). This study was undertaken to investigate and characterise the 
potential beneficial effects of stable [D-Ala
2
]GIP on the release of TGF-β and IGF-1, 
cAMP production and alkaline phospahatase activity in human osteoblastic-derived 
SaOS-2 cells as compared to native GIP(1-42). Effects of genetic deficiencies of 
GIPRs and GLP-1Rs on metabolic parameters, total and regional bone mineral 
density (BMD) and bone mineral content (BMC) were also assessed. 
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3.3  MATERIALS AND METHODS 
 
3.3.1 Peptides 
 
Native GIP(1-42) and [D-Ala
2
]GIP(1-42) were purchased from GL Biochem Ltd. 
(Shanghai, China) and the peptides were characterised by MALDI-TOF mass 
spectrometry as described in Section 2.1.2. Identity of the peptides was confirmed by 
comparing values for experimental mass obtained from MALDI-TOF and calculated 
theoretical masses. 
 
3.3.2  Maintenance of SaOS-2 cells 
 
SaOS-2 cells were maintained as described in Section 2.2.1. Culture medium was 
changed every 3 days and the cells were utilised at 80% confluency. The assays were 
run in duplicate and repeated 2-3 times according to previous studies (Bollag et al. 
2000, Zhong et al. 2003).  
 
3.3.3 Animals and study design 
 
3.3.3.1 GIPR KO mice 
 
In order to characterise the mice, glucose tolerance tests (18 mmol/kg bw glucose 
alone or in combination with 25 nmol/kg bw GIP) were performed on GIPR KO and 
respective control mice (from C57BL/6J colony) as explained in Section 2.3.8. 
Following GTT, mice were anaesthetised with isoflurane and pentabarbitol sodium 
(10 μl/g b.w) and the whole body was scanned using DEXA imaging.  
 
3.3.3.2 GLP-1R KO mice 
 
Glucose tolerance tests (18 mmol/kg bw glucose alone or in combination with 25 
nmol/kg bw of GLP-1) were conducted as described in Section 2.3.8. GLP-1R KO 
mice and its controls (both from the C57BL/6J background) were then injected with 
isoflurane and pentabarbitol sodium (10 μl/g b.w) prior to whole body scanning by 
DEXA imaging.  
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3.3.3.3 Double Incretin receptor (DIR) KO mice 
 
Mice were characterised from glucose tolerance tests (18 mmol/kg bw glucose alone 
or in combination with GIP or GLP-1 (each at 25 nmol/kg bw)) as outlined in 
Section 2.3.8. All mice were administered with isoflurane and pentabarbitol sodium 
(10 μl/g bw) prior to DEXA scanning.  
 
3.3.4 Measurement of TGF-β 
 
SaOS-2 cells were seeded at a density of 2 x 10
5
 cells/well and incubated in media 
supplemented with 10% FBS until confluent. 24 h prior to addition of GIP peptides, 
media was changed with fresh 0.1% FBS-containing media. On the day of 
experimentation, media was removed and 1 ml of GIP peptides (10
-12
 - 10
-6
 M) was 
added to each well. Plates were then incubated for 8 h. After which, media was 
collected and TGF-β released in the supernatant measured using a TGF-β 
Immunoassay kit (Quantikine, R&D Systems). The concentrations of TGF-β were 
calculated from a standard curve of recombinant human TGF-β ranging from 0 to 
2000 pg/ml.    
 
3.3.5 Measurement of IGF-1 
 
SaOS-2 cells were seeded at a density of 2 x10
5
 cells/well in 6-well plates and 
allowed to reach confluency in 10% FBS-containing media. Media was changed with 
fresh media supplemented with 0.1% FBS 24 h prior to addition of various peptides. 
Media was removed, followed by an addition of 1 ml of GIP peptides (10
-12
 - 10
-6
 
M). Plates were then incubated at 37
o
C for 8 h. After which, media was collected and 
IGF-1 released in the supernatant measured using IGF-1 Immunoassay kit 
(Quantikine, R&D Systems). The concentrations of IGF-1 in the samples was 
determined from a standard curve of recombinant human IGF-1 in the range of 0 - 60 
ng/ml.   
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3.3.6 Measurement of bone alkaline phosphatase activity 
 
SaOS-2 cells were seeded at a density of 1 x 10
5
 cells/well in 6-well plates and 
cultured for 72 h in growth media. 24 h prior to addition of peptides, media was 
replaced with 2% FBS-containing media.  Cells were incubated with varying 
concentrations of GIP or related analogue (10
-6 
- 10
-12 
M) in media supplemented 
with 2% FBS, 1% penicillin/streptomycin. After the desired incubation period (24, 
48 or 72 h), cells were washed 3 times with PBS (Oxoid, England). 250 µl of 0.2% 
Nonidet-40 (NP-40) (Sigma) was then added into each well and plates were left on 
an orbital shaker for 10 min. Cells were then scraped using a cell scraper (Costar). 
The cellular material was homogenized by 3 cycles of freeze (-70
o
C)-thawing 
(37
o
C). The mixture of cells/0.2% NP-40 was collected in 500 μl eppendorf tubes 
and snap-frozen in liquid nitrogen. The tubes were then placed on a shaker for 16 h 
at 4
o
C and for a final disruption and homogenisation of cells, contents of the tubes 
were sonicated using a Soniprep 150 Plus ultrasonic disintegrator for 15s. The 
sonicated samples were then centrifugated (15 min, 13000g, 4
o
C) and supernatant 
was collected for alkaline phosphatase activity and total protein contents as 
previously explained (Mahoney et al. 2008).  
 
3.3.6.1  Alkaline phosphatase determination 
 
Samples (50 µl) were added to 96-well plates in duplicate and alkaline phosphatase 
activity was indirectly determined using 4-methyl umbelliferyl phosphate (Sigma) as 
the substrate. After incubation for 30 min at 37
o
C, the reaction was stopped by the 
addition of 100 µl of 0.6 M Na2CO3 (Sigma-Aldrich). Alkaline phosphatase cleaves 
the phosphate group of the non-fluorescent 4-methylumbelliferyl phosphate (MUP) 
and generates highly fluorescent and stable 4-methyl umbelliferone (MU). 
Fluorescence was measured at excitation wavelength of 360 nm and an emission 
wavelength of 450 nm (with cut off 435 nm) using a FlexStation 3 (Molecular 
Devices). Alkaline phosphatase activity was then calculated from a standard curve 
(0-1000 pmol) of 4-methyl umbelliferone (Aldrich).  
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3.3.6.2  Total protein determination 
  
Total protein content in samples used to assay alkaline phosphatase activity was 
determined using the bicinchoninic acid (BCA) protein assay kit (Pierce). Briefly, 25 
μl of sample and standard were added to a 96-well plate in duplicate and 200 μl of 
reagent AB (50:1) added. The plates were incubated at 37
o
C for 30 min and left for 5 
min at room temperature. The plates were spectrophotometrically read at 562 nm 
using a microplate reader (Molecular Devices) and total protein content was 
calculated according to a bovine serum albumin standard curve (0-1500 µg/ml).  
Alkaline phosphatase activity was normalised against total protein content per well 
and was expressed as pmol 4-MU/µg protein. 
 
3.3.7 Measurement of cyclic AMP 
 
SaOS-2 cells were seeded at a density of 5 x 10
4
 cells in 96-well plates and cultured 
in α-MEM 1X media (Invitrogen) supplemented with 10% FBS (Lonza), penincillin 
and streptomycin for 24h to allow attachement to plate. Prior to experimentation, 
cells were washed with HBSS (Invitrogen). Cells were then incubated with various 
concentrations (10
-12
-10
-6
 M) of GIP and longer-acting GIP, [D-Ala
2
]GIP 
supplemented with 200 µM of 3-isobutyl-1-methylxanthine (IBMX). The plate was 
left for 40 min at 37
o
C and after that, cells were washed 3 times with 150 µl of PBS. 
Cells were then lysed with 150 µl cell lysis buffer (R&D Systems) and a freeze (-
20
o
C)-thaw (37
o
C) cycle was carried out. The contents were then collected into 500 
µl eppendorf tubes and centrifugated at 600 g for 10 min (4
o
C). Supernatants were 
collected and cAMP was measured using a cAMP assay kit (R&D Systems). The 
concentration of cAMP was calculated from a standard curve of cAMP ranging from 
0 to 240 pmol/ml.  
 
3.3.8 Measurement of plasma glucose concentration 
 
Plasma glucose was determined using an Analox GM-9 glucose analyser as 
explained in Section 2.4.1.  
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3.3.9 Measurement of body composition, bone density and mineral content by 
DEXA scanning 
 
Unconcious mice were placed on a specimen tray of the DEXA scanner and the 
whole body was scanned. Bone mineral density (BMD), bone mineral content 
(BMC), lean mass, fat mass and percentage of total fat were measured as explained 
in Section 2.5.  
 
3.3.10 Statistical analysis 
 
Data were analysed using repeated measures one-way or two-way ANOVA with 
Newman-Keuls post hoc tests or two-tailed t-tests using PRISM 5.0. Data are 
expressed as mean ± S.E.M and a P value < 0.05 was considered statistically 
significant. 
 
3.4 RESULTS 
 
3.4.1  Dose-dependent effects of native GIP and [D-Ala
2
]GIP on TGF-β1 and 
IGF-1 release from SaOS-2 cells 
 
Native GIP and [D-Ala
2
]GIP dose-dependently stimulated TGF-β release from 
SaOS-2  cells (Figure 3.1). As compared to control, [D-Ala
2
]GIP significantly 
induced TGF-β release at all concentrations tested (10-12 – 10-6 M, P < 0.01) while 
stimulatory effect of native GIP was seen only at higher concentration (10
-10
 – 10-6 
M, P < 0.01). Similarly, IGF-1 was also shown to increase in the presence of native 
GIP and [D-Ala
2
]GIP (Figure 3.2). Both native and stable GIP demonstrated to 
induce higher IGF-1 release than control incubations at all concentrations employed 
(10
-12
 – 10-6 M, P < 0.01). However, the stimulatory effect on TGF-β and IGF-1 
release was not significantly different between native and long-acting GIP.  
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3.4.2  Dose-dependent effects of native GIP and [D-Ala
2
]GIP on alkaline 
phosphatase activity in SaOS-2 cells 
 
Both GIP(1-42) and [D-Ala
2
]GIP enhanced AlkP activity during a 24 h incubation in 
SaOS-2 cells (Figure 3.3). Long-acting [D-Ala
2
]GIP increased alkaline phosphatase 
activity at concentrations of 10
-10
 M and above (P < 0.05) while native GIP was only 
effective at 10
-6
 M (P < 0.01) compared to controls. No significant differences were 
observed between GIP(1-42) and [D-Ala
2
]GIP in stimulating alkaline phosphatase 
activity during 24 h incubation time. Stimulation by both GIP peptides continued to 
elevate the activity of alkaline phosphatase during 48 and 72 h incubations. 
Compared to respective control, 48 and 72 h exposure of SaOS-2 to [D-Ala
2
]GIP 
significantly increased the activity of the bone-related protein at all concentrations 
tested (Figure 3.4 & 3.5). Native GIP demonstrated increased alkaline phosphatase 
activity only at 10
-8
 M (P < 0.01) and higher concentrations after 48 h and the lowest 
effective concentration after 72 h incubation was 10
-10
 M (P < 0.05). There were 
significant differences seen in bone-specific alkaline phosphatase activity at all 
concentrations employed between native GIP and [D-Ala
2
]GIP after 48 h (P < 0.01) 
and 72 h (P < 0.01) incubation periods (Figure 3.4 & 3.5). 
 
3.4.3  Dose-dependent effects of native GIP and [D-Ala
2
]GIP on cAMP 
production in SaOS-2 cells 
 
As shown in Figure 3.6, native GIP and [D-Ala
2
]GIP significantly stimulated cAMP 
production in SaOS-2 cells compared to controls. The lowest effective concentration 
of [D-Ala
2
]GIP was 10
-8
 M (P < 0.05) while for native GIP this was 10
-6
 M (P < 
0.01). [D-Ala
2
]GIP significantly enhanced cAMP generation at concentration of 10
-6
 
M (P < 0.05) when compared to GIP(1-42).  
 
3.4.4  Comparison of body composition in GIPR, GLP-1R, DIR KO and 
normal mice 
 
Body weight and percentage total fat mass (Figure 3.7 & 3.10) of GIPR- and GLP-
1R-deficient mice not significantly different compared to normal mice. Similar to the 
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single KO mice, the absence of both incretin receptors had no significant effect on 
body weight and total fat mass in DIR KO mice (Figure 3.13).  
 
3.4.5 Comparison of glucose tolerance in GIPR, GLP-1R, DIR KO and 
normal mice 
 
Intraperitoneal administration of glucose alone modestly reduced the glycaemic 
excursion and plasma glucose AUC in GIPR KO mice compared to normal controls 
(Figure 3.8). In the presence of exogenous GIP, normal mice had a significant 
reduction (37% decrease, P < 0.05) in plasma glucose AUC values, whilst it was 
unchanged in GIPR-deficient mice. As shown in Figure 3.11, deficiency in GLP-1R 
signalling significantly impaired glucose tolerance as seen by a notable increase (2.6 
fold, P < 0.001) in plasma glucose AUC values of GLP-1 KO mice compared to wild 
type mice. Glucose supplemented with GLP-1 significantly reduced (32% decrease, 
P < 0.05) plasma glucose AUC value in normal mice, but not in GLP-1R KO mice. 
Similarly, DIR KO mice exhibited a significant elevation (1.5 fold, P < 0.05) in 
plasma glucose level when given glucose load compared to sex- and age-matched 
controls (Figure 3.14). Wild type mice received exogenous GIP or GLP-1 had 
noticeable reductions (30-57% decrease, P < 0.05) in plasma glucose AUC values, 
while the parameter was unchanged in DIR KO mice.   
 
3.4.6 Comparison of bone mineral density and mineral content in GIPR, GLP-
1R, DIR KO and normal mice 
 
As shown in Figure 3.9, bone mineral density (BMD) and bone mineral content 
(BMC) as assessed by DEXA were lowered in GIPR knockout (KO) mice when 
measured as total as well as at femur, lumbar and tibia areas. Significant reductions 
were seen in total (BMD: 8% decrease, P < 0.01; BMC: 13% decrease, P < 0.05), 
femur (BMD: 16% decrease, P < 0.001; BMC: 15% decrease, P < 0.001) and tibia 
(BMD: 14% decrease, P < 0.01; BMC: 15 decrease, P < 0.001) of GIPR-deficient 
mice. In contrast, deficiencies in GLP-1Rs did not adversely affect either parameter 
and although total BMC appeared to be reduced, the reduction did not reach 
statistical significance (Figure 3.12). Total, femoral, lumbar and tibial BMD (Figure 
3.15A) were all decreased in DIR KO mice with significant reductions only found at 
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femur (8% decrease, P < 0.05) and tibia (27% decrease, P < 0.01). No differences 
were observed at total, lumbar and tibial BMC but femoral BMC was markedly 
reduced in DIR KO mice (11% decrease, P < 0.05, Figure 3.15B). 
 
3.5 DISCUSSION 
 
Bone turnover is controlled by numerous hormones and growth factors through both 
endocrine and paracrine signaling. Following food ingestion, bone resorption 
biomarkers are rapidly changed (Henriksen et al. 2003), suggesting a role of the 
gastrointestinal tract (GIT) in bone remodeling. Glucose-dependent insulinotropic 
polypeptide (GIP) is one of hormones released from the GIT and in addition, GIP 
receptors are found on bone cells (Bollag et al. 2000, Zhong et al. 2007), suggesting 
a direct role of GIP on bone. Although GIP receptors are widely distributed, most 
studies on GIP are focus on its potential to stimulate glucose-mediated pancreatic 
insulin release. To date, only a few studies have been carried out to establish the 
effects of GIP on bone and the mechanism of action of GIP on the skeleton remain 
largely unknown. 
 
The potential of GIP as therapeutic peptide is restricted by the fact that it is a 
substrate for dipeptidyl peptidase 4 (DPP-4) and once release into circulating blood, 
DPP-4 cleaves alanine residue at second position of biologically intact GIP, 
generating the truncated metabolite of GIP, GIP(3-42), with no biological activity 
(Baggio & Drucker 2007). In order to circumvent DPP-4 action, several N-
terminally-protected GIP analogues have been generated (Hinke et al. 2002, Irwin et 
al. 2005a). From a series of N-terminal modifications of GIP peptide, [D-Ala
2
]GIP 
has been identified as one of the most promising analogues (Hinke et al. 2002). The 
potential anabolic effect of native GIP on bone cells has been shown in earlier 
studies (Bollag et al. 2000, Bollag et al. 2001, Zhong et al. 2007). However, the 
effects of prolonged activation of the GIPR by stable GIP molecules on the skeleton 
are less well known.  
 
Receptor binding studies have shown the presence of GIP receptors on osteoblastic-
like cell lines, namely SaOS-2 and MG-63 (Bollag et al. 2000) and therefore, the 
SaOS-2 cell line was chosen in this study. Previously, GIP was reported to stimulate 
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transforming growth factor-β (TGF-β) release from osteoblastic-derived cells the 
MG-63 (Zhong et al. 2003). TGF-β is a product of osteoblasts and found abundantly 
in bone matrix (Robey et al. 1987). TGF-β plays an important role in bone formation 
by stimulating osteoblastic proliferation and differentiation of MSCs (Filvaroff et al. 
1999, Janssens et al. 2005, Lee et al. 2002, Tang et al. 2009). As expected, TGF-β 
concentrations significantly increased in the presence of native GIP and its stable 
analogue in SaOS-2 cells. However, the stimulatory effect of GIP was only observed 
at lower concentrations (10
-10
 M) in our study, probably due to the longer incubation 
period employed as compared to previous studies. In line with its prolonged half-life, 
[D-Ala
2
]GIP significantly stimulated TGF-β release at the lowest concentration 
tested (10
-12
 M), indicating enhanced bioactivity. 
 
Another growth factor that is found in bone matrix is insulin-like growth factor-1 
(IGF-1). The role of IGF-1 in bone is not limited to stimulation of preosteoblastic 
proliferation and differentiation (Giustina et al. 2008; Xian et al. 2012), but also to 
enhanced production of bone matrix and bone mineralisation (Zhang et al. 2002), 
leading to a further increase in osteoblastic function and bone formation. Similar to 
TGF-β release, 8-hour incubation of SaOS-2 cells with native GIP and [D-Ala2]GIP 
resulted in significant elevations of IGF-1 levels in comparison to control cultures. 
However, there were no significant differences seen in stimulatory effects of the two 
GIP peptides in terms of IGF-1 secretion.   
 
Osteoblastic-related protein, alkaline phosphatase is widely used as a biomarker for 
bone formation (Eastell & Hannon 2008). In our study, alkaline phosphatase activity 
appeared to increase following 24 h incubation with GIP peptides. When the 
incubation period was extended to 48 and 72 h, the dose-dependent stimulatory 
effect of [D-Ala
2
]GIP on alkaline phosphatase activity was at least 30% more 
prominent than native GIP. Interestingly, beneficial effect of [D-Ala
2
]GIP appeared 
less prominent at 72, as opposed to 48 h incubations. A similar pattern on alkaline 
phosphatase activity was seen when GIP was incubated for 6 days with the 
osteoblastic-like MG-63 cell line (Bollag et al. 2000). One possible explanation for 
this is cell death which could be due to exhaustion of the alkaline phosphatase 
signaling pathway. However, a cell viability assay was not conducted to confirm 
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this. Alkaline phosphatase is an osteoblastic-related protein actively involved in bone 
mineralisation by reducing extracellular inorganic pyrophosphate, a suppressor of 
hydroxyapatite crystals (Golub & Boesze-Battaglia 2007, Hessle et al. 2002). The 
fact that GIP can significantly induce alkaline phosphatase activity, indicates the 
hormone could regulate bone mineralisation. 
 
The GIPR is a member of the seven-transmembrane domain-spanning receptors, also 
known as G-protein coupled receptor (GPCR) superfamily and activation of the 
receptor by its ligand stimulates adenylyl cyclase, which subsequently increases 
intracellular cAMP levels (Baggio & Drucker 2007). Threrefore, it is not surprising 
to see that in the presence of GIP, cAMP generation was enhanced in osteoblastic-
derived cells, as previously reported (Bollag et al. 2000). Consistent with this earlier 
study, we found dose-dependent increases in cAMP levels in cultured SaOS-2 cells 
with both GIP peptides at concentration as low as 10
-8 
M. Furthermore, the cAMP 
response to the DPP-4 resistant [D-Ala
2
]GIP was noticeably increased (approx. 28% 
increase) at 10
-6 
M compared to native GIP, further confirming increased potency of 
[D-Ala
2
]GIP. Unline native GIP, modification at the N-terminal of [D-Ala
2
]GIP  
protects this analogue from DPP-4 activity. The increase in [D-Ala
2
]GIP stability 
permits longer GIP receptor activation and as a result, there is a significant rise in 
cAMP production at higher [D-Ala
2
]GIP concentration. 
 
We used mice that were genetically deficient in GIP, GLP-1 or both receptors to 
assess the effects of incretins on bone in vivo. Assessment of body composition 
found that body weight and fat content were not affected in mice lacking either 
GIPRs, GLP-1Rs or both receptors. Intraperitoneal administration of glucose 
induced modest reduction in the glycaemic excursion in GIPR KO mice compared to 
normal littermates. In agreement with previous observations, GLP-1R and DIR KO 
mice exhibited a significant impairment of glucose homeostasis (Preitner et al. 2004, 
Scrocchi et al. 1996). In the present study, GIPR KO mice had better glucose 
tolerance than GLP-1R KO mice when compared with their respective controls. The 
reason could be that there is a compensatory mechanism of insulin secretion in GIPR 
KO mice, as previously reported (Pamir et al. 2003). In order to confirm the genetic 
background of the KO mice, glucose supplemented with either GIP and/or GLP-1 
was intraperitoneally injected into wild type and KO mice.  
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Bone mineral density (BMD), measured by DEXA, is frequently used to determine 
bone health and it represents bone mass of that particular individual (Cummings et 
al. 2002). In the present study, suppression of GIPRs alone clearly altered BMD and 
BMC in mice when measured at total bone and at regions of interest. Importantly, 
similar observations have been seen in age-matched GIPR KO mice from a different 
genetic background in a previous study (Xie et al. 2005) and this is further 
strengthened by recent findings that observed reduced mechanical properties of bone 
matrix in GIPR-deficient mice on the same background as mice in the current study 
(Mieczkowska et al. 2013). In the study done by Xie et al., serum biomarkers were 
also assessed and it was found that osteocalcin and alkaline phosphatase levels were 
significantly reduced in mice lacking GIPR. Osteocalcin is produced by osteoblasts 
(Lee et al. 2000) and a reduction in osteocalcin levels indicates that osteoblast 
activity is reduced, which in turn reflects a decrease in rate of bone formation. As 
discussed earlier, alkaline phosphatase plays an important role in bone mineralisation 
(Golub & Boesze-Battaglia 2007) and reduction in alkaline phosphatase 
concentrations shows less mineralisation of bone. Therefore, inactivation of GIPR 
signaling causes disruption in the molecular processes of bone formation, leading to 
bone impairments as seen in GIPR KO mice. 
 
On the other hand, deficiency in GLP-1Rs appeared to have no effect on BMD and 
BMC in our study. In contrast, previous studies reported that bone densitometry, 
morphology and mechanical properties were modified in mice lacking GLP-1Rs, 
leading to reduced bone strength (Mabilleau et al. 2013, Yamada et al. 2008). 
However, bone quality is determined not only by bone mass, but also on the 
microstructural and material properties of bone matrix (Seeman & Delmas 2006). 
Thus, investigation of bone morphology and mechanical strength in other studies 
confirm the positive effects of GLP-1R signaling on bone integrity. According to 
Yamada and colleagues, modifications in bone quality of GLP-1R-deficient mice 
were due to enhanced bone resorbing activity as demonstrated in increased number 
of osteoclasts and elevated markers for bone resorption, deoxypyridinoline (Yamada 
et al. 2008). Single KO of either GIPR or GLP-1R diminished bone 
microarchitecture and strength by attenuating bone formation or enhancing bone 
resorption. Therefore, it would be expected that simultaneous inactivation of both 
incretin receptors signaling pathways would severely compromise skeletal integrity, 
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as observed by pronounced reductions of bone mass in DIR KO mice in the present 
study. 
 
In the present study, we conclude that GIP has beneficial effects on osteoblastic 
cells. In addition, the presence of functional GIP and GLP-1 receptors is essential to 
maintain normal bone remodeling as bone impairments were demonstrated in mice 
lacking incretin receptors. Diabetes is linked to bone loss (Vestergaard 2011) and 
this leads to subsequent complications such as fracture. GIPRs are expressed on 
bone, forming a direct interaction of GIP to bone cells and it would be interesting to 
examine the effects of DPP-4-resistant GIP analogues on bone strength and quality 
in animal models of diabetes. Although the presence of its receptors on bone cells is 
uncertain, the sister incretin of GIP, glucagon-like peptide-1 (GLP-1) is also 
suspected to positively regulate bone turnover. Furthermore, GLP-1R-deficient mice 
appear to have reductions in bone mass and bone mineral density, increased bone 
resorption as well as reduced mechanical properties and bone strength (Mabilleau et 
al. 2013, Yamada et al. 2008). Therefore, it would be interesting to assess the 
possible impact of clinically established GLP-1 mimetics on bone microstructure and 
strength in animal model of diabetes.  
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Figure 3.1: Effect of increasing concentrations of GIP peptides on TGF-β 
release from SaOS-2 cells 
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SaOS-2 cells were grown in 0.1%-FBS-containing media and stimulated with 
indicated concentrations of peptides. Cultures were incubated for an additional 8 h 
and TGF-β levels were measured using recombinant human TGF-β Immunoassay 
kit. Values are mean ± SEM for n=4 and experiment was repeated twice. **P < 0.01, 
***P < 0.001 compared with control group. 
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Figure 3.2: Effect of increasing concentrations of GIP peptides on IGF-1 release 
from SaOS-2 cells 
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SaOS-2 cells were grown in 0.1%-FBS-containing media and stimulated with 
indicated concentrations of peptides. Cultures were incubated for an additional   and 
IGF-1 levels were measured using recombinant human 1GF-1 Immunoassay kit. 
Values are mean ± SEM for n=4 and experiment was repeated twice.  ***P < 0.001 
compared with control group. 
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Figure 3.3: 24 h stimulation of alkaline phosphatase activity by various 
concentrations of GIP peptides in SaOS-2 cells 
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SaOS-2 cells were grown in 6-well plates and stimulated with indicated 
concentrations of peptides. After 24 h, the reaction was stopped and AlkP production 
was indirectly measured using 4-methyl umbelliferyl phosphate as substrate. The 
values were normalised against total amount of protein/well using BCA protein kit. 
Values are mean ± SEM for n=6 and experiment was repeated three times. *P < 
0.05, **P < 0.01, *** P< 0.001 vs control. 
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Figure 3.4: 48 h stimulation of alkaline phosphatase activity by various 
concentrations of GIP peptides in SaOS-2 cells 
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SaOS-2 cells were grown in 6-well plates and stimulated with indicated 
concentrations of peptides. After 48 h, the reaction was stopped and AlkP production 
was indirectly measured using 4-methyl umbelliferyl phosphate as substrate. The 
values were normalised against total amount of protein/well using BCA protein kit. 
Values are mean ± SEM for n=6 and experiment was repeated three times. **P < 
0.01, ***P < 0.001 vs control; 
Ψ
P < 0.05, 
ΨΨ
P < 0.01, 
ΨΨΨ
P < 0.001 vs native GIP. 
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Figure 3.5: 72 h stimulation of alkaline phosphatase activity by various 
concentrations of GIP peptides in SaOS-2 cells 
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SaOS-2 cells were grown in 6-well plates and stimulated with indicated 
concentrations of peptides, with replenishment of fresh media every 24 h. After 72 h, 
the reaction was stopped and AlkP production was indirectly measured using 4-
methyl umbelliferyl phosphate as substrate. The values were normalised against total 
amount of protein/well using BCA protein kit. Values are mean ± SEM for n=6 and 
experiment was repeated three times. *P < 0.05, **P < 0.01, ***P < 0.001 vs 
control; 
Ψ
P < 0.05, 
ΨΨ
P < 0.01vs native GIP. 
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Figure 3.6: Effects of different concentrations of GIP peptides on cAMP 
generation in SaOS-2 cells  
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SaOS-2 cells were seeded and induced with different concentrations of GIP peptides 
for 40 min. cAMP release was then measured using a commercially available cAMP 
assay kit. Values are mean ± SEM for n=4 and experiment was repeated twice. *P < 
0.05, **P < 0.01 vs control. 
Ψ 
P < 0.05 vs GIP. 
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Figure 3.7 : Body weight and percentage of total fat in normal and GIPR KO 
mice 
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Body weight (A) and total fat (B) of 27 week-old mice was measured by dual energy 
X-ray absorption before necropsy. Values are expressed as mean ± S.E.M for 5 mice 
per group.  
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Figure 3.8 : Comparison of glucose tolerance in normal and GIPR KO mice  
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Plasma glucose concentrations (A) were measured prior to and after intraperitoneal 
administration of glucose alone (18 mmol/kg, control) or in combination with GIP 
(25 nmol/kg body weight) in normal and GIPR KO mice. Plasma glucose AUC 
values (determined by using mean value at 0 min as a baseline) for 0-60 min post-
injection are also shown (B). Injection time is indicated by the arrow (0 min). Values 
are mean ± SEM for 5 mice. *P < 0.05 compared with normal glucose alone. 
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Figure 3.9 : Comparison of (A) bone mineral density and (B) bone mineral 
content of total bone area, femur, tibia and lumbar regions in normal and GIPR 
KO mice  
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BMD and BMC were measured by dual energy X-ray absorption before necropsy. 
Values are mean ± SEM for 5 mice. *P < 0.05, **P < 0.01, ***P < 0.001 compared 
with normal group. 
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Figure 3.10 : Body weight and percentage of total fat in normal and GLP-1R 
KO mice 
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Body weight (A) and total fat (B) of 43 week-old mice was measured by dual energy 
X-ray absorption before necropsy. Values are expressed as mean ± S.E.M for 4 mice 
per group.  
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Figure 3.11 : Comparison of glucose tolerance in normal and GLP-1R KO mice  
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Plasma glucose concentrations (A) were measured prior to and after intraperitoneal 
administration of glucose alone (18 mmol/kg, control) or in combination with GLP-1 
(25 nmol/kg body weight) in normal and GLP-1-r KO mice. Plasma glucose AUC 
values (determined by using mean value at 0 min as a baseline) for 0-60 min post-
injection are also shown (B). Injection time is indicated by the arrow (0 min). Values 
are mean ± SEM for 4 mice. *P < 0.05, ***P < 0.001 compared with normal + 
glucose alone, 
ΔΔΔ
P < 0.01 compared with normal + glucose + GLP-1. 
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Figure 3.12 : Comparison of (A) bone mineral density and (B) bone mineral 
content of total bone area, femur, tibia and lumbar regions in normal and GLP-
1R KO mice  
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BMD and BMC of were measured by dual energy X-ray absorption before necropsy. 
Values are mean ± SEM for 4 mice. 
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Figure 3.13 : Body weight and percentage of total fat in normal and DIR KO 
mice 
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Body weight (A) and total fat (B) 29 week-old mice was measured by dual energy 
X-ray absorption before necropsy. Values are expressed as mean ± S.E.M for 4-5 
mice per group.  
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Figure 3.14 : Comparison of glucose tolerance test in normal and DIR KO mice 
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Plasma glucose concentrations (A) were measured prior to and after intraperitoneal 
administration of glucose alone (18 mmol/kg, control) or in combination with GIP or 
GLP-1 (each at 25 nmol/kg body weight) in normal and DIR KO mice. Plasma 
glucose AUC values (determined by using mean value at 0 min as a baseline) for 0-
60 min post-injection are also shown (B). Injection time is indicated by the arrow (0 
min). Values are mean ± SEM for 4-5 mice. *P < 0.05 compared with normal + 
glucose alone; 
Δ
P < 0.05, 
ΔΔ
P < 0.01 compared with respective normal group. 
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Figure 3.15 : Comparison of (A) bone mineral density and (B) bone mineral 
content of total bone area, femur, tibia and lumbar regions in normal and DIR 
KO mice 
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BMD and BMC were measured by dual energy X-ray absorption before necropsy. 
Values are mean ± SEM for 4-5 mice. *P < 0.05, **P < 0.01 compared with normal 
group.  
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Chapter 4 
 
Recovery of cortical bone strength 
at the tissue level by [D-Ala2]GIP 
and Liraglutide in streptozotocin-
induced insulin-deficient diabetic 
mice 
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4.1 SUMMARY 
 
Impaired insulin production has adverse effects on bone integrity, consequently there 
is increased bone fracture risk in diabetic individuals. There is now accumulating 
evidence suggesting that the gut hormones, glucose-dependent insulinotropic 
polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) play a role in the 
maintenance of bone strength and quality. This study assessed the effects of 
subchronic administration of the stable incretin receptor mimetics, [D-Ala
2
]GIP and 
Liraglutide, on metabolic control and bone structural integrity in streptozotocin 
(STZ)-induced insulin-deficient diabetic mice. STZ (150 mg/kg bw) was used to 
induce diabetes (blood glucose level > 12 mmol/l), five days prior to commencement 
of treatment intervention. Diabetic mice then received once-daily i.p injection of 
saline (0.9% w/v NaCl), [D-Ala
2
]GIP or Liraglutide (each at 25 mmol/kg bw) for 21 
days. [D-Ala
2
]GIP and Liraglutide had no effects on body weight, water intake, non-
fasting plasma glucose and insulin concentrations. Although no significant 
differences were seen in plasma glucose concentrations compared to saline STZ 
controls, glucose tolerance had a tendency to be improved in [D-Ala
2
]GIP- and 
Liraglutide-treated mice. This slight improvement was due to a significant 
augmentation of glucose-stimulated plasma insulin levels in mice that received either 
[D-Ala
2
]GIP (2.3-fold, P < 0.05) or Liraglutide (3.3-fold, P < 0.01). On the other 
hand, treatment with [D-Ala
2
]GIP and Liraglutide did not affect insulin sensitivity in 
diabetic mice. In general, streptozotocin-induced diabetic mice displayed severe 
impairments of cortical bone as seen through reductions of cortical mineral content, 
cortical thickness and mechanical properties of whole bone and bone matrix, whilst 
trabecular bone was unaffected. Treatment with [D-Ala
2
]GIP or Liraglutide did not 
affect whole body or individual bone masses. Similarly, no changes were seen in 
mineral content of cortical and trabecular bone in diabetic mice when assessed by 
qXRI. Parameters for trabecular bone microstructure as determined by microCT 
were unchanged with [D-Ala
2
]GIP or Liraglutide therapy. Three-point bending tests 
revealed no dramatic changes in whole-bone strength between treated and nontreated 
diabetic mice. However, defects in mechanical tissue properties of diabetic mice as 
examined by nanoindentation were ameliorated by [D-Ala
2
]GIP and Liraglutide 
where there were increases observed in hardness (35-49% increase, P < 0.01), 
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indentation modulus (31% increase, P < 0.001), maximum load (35-43% increase, P 
< 0.001) and dissipated energy (41% increase, P < 0.01) compared to diabetic 
controls. Importantly, mechanical tissue responses were elevated to levels similar to 
normal mice. Nonetheless, the improvements in intrinsic material properties were 
independent of bone mineralisation. In conclusion, three-week administration of 
long-acting incretin hormones improved glucose tolerance and enhanced recovery of 
cortical bone strength at the tissue-level in STZ-induced insulin-deficient diabetic 
mice.  
 
4.2  INTRODUCTION 
 
Insulin deficiency has detrimental effects on bone, resulting in higher bone fragility 
as reported in diabetes (Hofbauer et al. 2007). A role for gastrointestinal tract (GIT) 
in controlling bone turnover has been suggested as serum markers for bone 
resorption are reduced following feeding (Henriksen et al. 2003). Glucose-dependent 
insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are two gut 
hormones suspected to be implicated in bone turnover. GIP and GLP-1 are incretin 
peptides that regulate postprandial glucose homeostasis by enhancing glucose-
mediated insulin release from islet beta-cells (Yabe & Seino 2011). However, native 
GIP and GLP-1 are rapidly degraded by dipeptidyl peptidase-4 (DPP-4), resulting in 
a short half-life (approx. 3-5 minutes) (Baggio & Drucker 2007). In order to protect 
them from DPP-4 activity, stable GIP and GLP-1 analogues have been synthesised 
(Hinke et al. 2002, Irwin et al. 2005a, Knudsen et al. 2000, O’Harte et al. 2002).  
 
The GLP-1-based mimetic drug, Liraglutide is an established antidiabetic drug 
already available on the market since 2010 (Peterson & Pollom 2010). Liraglutide 
exhibits 97% sequence homology to human GLP-1 and it differs from native GLP-1 
through substitution of Lys
34 
with Arg and addition of C-16 acyl chain at Lys 
position 26 (Knudsen et al. 2000). This GLP-1 agonist is proven to be resistant to 
DPP-4 and not subjected to renal clearance through its ability to bind to albumin. 
Therefore, it is suitable for once daily administration (Agerso et al. 2002, Knudsen et 
al. 2000). There is also growing interest in targeting sister incretin of GLP-1, GIP, as 
potential therapeutic agent for management of T2DM. Several N-terminally 
protected GIP peptides have been developed and examined for glucose-lowering and 
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insulin-releasing activities, and [D-Ala
2
]GIP has been reported to be one of the most 
promising molecule (Hinke et al. 2002). 
 
Interestingly, GIPRs and GLP-1Rs are widely distributed outside the pancreas, 
suggesting their extrapancreatic actions (Baggio & Drucker 2007). Functional GIPRs 
are evidenced on bone cells that are responsible for bone formation and bone 
resorption, osteoblasts and osteoclasts, respectively (Bollag et al. 2000, Zhong et al. 
2007). Deficiencies of GIPR signalling in mice resulted in significant reductions of 
bone mass, reduced biomarkers for bone formation and increased bone resorption 
biomarkers (Tsukiyama et al. 2006, Xie et al. 2005). In parallel, decreased bone 
resorption biomarkers were seen in transgenic mice overexpressing GIP (Xie et al. 
2007). Furthermore, GIP inhibited pit formation by mature osteoclasts and as a 
result, osteoclastic bone resorptive activity was reduced (Zhang et al. 2007). 
Collectively, the data from Chapter 3 and previous studies suggested the anabolic 
role of GIP in enhancing bone formation and inhibiting bone resorption. Therefore, 
GIP may present a therapeutic approach for bone-related diseases (Irwin et al. 2010). 
Despite inconsistencies in previous studies on the expression of GLP-1Rs on bone 
(Bollag et al. 2000, Mabilleau et al 2013, Nuche-Berenguer et al. 2010a), bone 
histomorphometrical analyses found increased numbers of osteoclasts and bone 
resorption activity in GLP-1R-deficient mice (Yamada et al. 2008). Further 
examination showed that genetically-modified GLP-1R knockout mice exhibited 
significantly lowered material properties and consequently, reduced bone strength 
compared to normal mice (Mabilleau et al. 2013). Taken together, the data indicate 
the importance of GLP-1 and GLP-1R signaling on normal bone function.  
 
In Chapter 3 of this thesis, native GIP and [D-Ala
2
]GIP have been shown to have 
anabolic effects on bone in vitro and genetic deficiencies in incretin receptors lead to 
alterations of BMD and BMC. Based on previous studies, it is suggested that incretin 
therapies not only improve glucose homeostasis in diabetes but additionally, they 
could improve diabetic bone abnormalities. Furthermore, it would be interesting to 
identify the main target of gut hormones on bone and characterise their impact on 
bone regulation. Therefore, in the present study, we employed [D-Ala
2
]GIP and 
Liraglutide to examine the effects of once-daily administration on metabolic 
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parameters and more importantly on bone microstructure, cortical geometry and 
bone strength in STZ-induced insulin-deficient diabetic mice. 
 
4.3 MATERIALS AND METHODS 
 
4.3.1 Synthesis of (D-Ala
2
)GIP and Liraglutide 
  
[D-Ala
2
]GIP and Liraglutide were purchased from GL Biochem Ltd. (Shanghai, 
China) at 97.4% and 95.8% purity, respectively. The peptides were characterised by 
MALDI-TOF mass spectrometry (Table 2.1) as described in Section 2.1.2. 
  
4.3.2 Animals and study design 
  
The chronic effect of the GIPR agonist, [D-Ala
2
]GIP and the GLP1R mimetic, 
Liraglutide on metabolic control and bone quality were examined in streptozotocin 
(STZ)-induced diabetic mice. Young male NIH Swiss mice (n=30, 8 weeks old) 
initially received 150 mg/kg bw of STZ in citrate buffer to develop diabetes. Normal 
mice (n=6) were also injected with citrate buffer alone. 6 days post-STZ 
introduction, the mice were divided into three groups (n=10) and started receiving 
once daily injection of [D-Ala
2
]GIP or Liraglutide (each at 25 nmol/kg bw) or saline 
vehicle (0.9% NaCl) for 21 days, whilst normal mice received saline vehicle (0.9% 
NaCl) once daily for the same period of time. Body weight, food consumption, fluid 
intake, non-fasting blood glucose and insulin concentrations were monitored at 
regular intervals. Intraperitoneal glucose tolerance test (18 mmol/kg bw, 18-h fast) 
and non-fasting insulin sensitivity test (25 U/kg bw) were performed at the end of 
the study as outlined in Section 2.3.8 and 2.3.9, respectively. No adverse effects 
were seen following administration of [D-Ala
2
]GIP and Liraglutide. All experiments 
were carried out according to UK Home Office Regulations (UK Animals Scientific 
Procedures Act 1986). 
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4.3.3 Measurement of plasma glucose and insulin 
 
Plasma glucose was determined using an Analox GM-9 glucose analyser as 
explained in Section 2.4.1, while insulin RIA was carried out as described in Section 
2.4.2 to determine plasma insulin concentrations.   
 
4.3.4 Measurement of body composition, bone density and mineral content by 
DEXA scanning 
 
Unconcious mice were placed on a specimen tray of DEXA scanner and the whole 
body was scanned. Bone mineral density (BMD), bone mineral content (BMC), lean 
mass, fat mass and percentage of total fat of ROIs were determined as explained in 
Section 2.5.  
 
4.3.5 Assessment of bone quality and strength 
 
Bone microarchitectural and mechanical strength tests were carried out on excised 
femurs or tibias from all groups of mice at the end of the study.  
 
 4.3.5.1 Quantitative X-ray Imaging (qXRI) 
  
Each femur was scanned and imaged together with two standards, 1.5 mm-thick steel 
and polyester which represent grey level 255 and 0, respectively. Bone mineral 
content was determined as detailed in Section 2.6.1. 
 
4.3.5.2 X-ray microcomputed tomography (µCT) 
   
Tibias were positioned and scanned as described in Section 2.6.2 and parameters that 
were obtained from the assessment were trabecular bone mass, trabecular bone 
thickness, numbers of trabecular bone, trabecular separation, cortical bone diameter, 
bone marrow diameter, cortical thickness and cross-sectional moment of inertia. 
 
 
 
100 
 
4.3.5.3 Three-point bending test  
 
Femurs were individually kept in test tubes containing saline (NaCl, 0.9%) for 
rehydration and left overnight at 4
o
C. The test was carried out as described in 
Section 2.6.3 and four mechanical properties were evaluated; ultimate load, ultimate 
displacement, stiffness and total absorbed energy (work-to-failure). 
 
4.3.5.4  Nanoindentation 
 
Prior to experimentatation, polymethylmethacrylate blocks were polished with 
diamond particles to obtain a smooth surface and the blocks were then left in saline 
(NaCl, 0.9%) at 4
o
C for 15 h. Nanoindentation was performed as outlined in Section 
2.6.4 and maximum force, hardness, indentation modulus and dissipated energy were 
computerized from force-penetration depth curve. 
 
4.3.5.5 Quantitative backscattered electron imaging (qBEI) 
 
The polymethylmethacrylate blocks were polished with diamond particles, followed 
by carbon-coating process. Subsequently, the blocks were observed under scanning 
electron microscope as detailed in Section 2.6.5. 
 
4.3.6 Statistical analysis 
 
Data were analysed using repeated measures one-way or two-way ANOVA with 
Tukey post hoc tests or two-tailed t-tests using PRISM 5.0. Data are expressed as 
mean ± S.E.M and a P value < 0.05 was considered statistically significant. 
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4.4 RESULTS 
 
4.4.1  Effects of once-daily administration of [D-Ala
2
]GIP or Liraglutide on 
metabolic parameters in streptozotocin-induced diabetic mice. 
 
As shown in Figure 4.1, body weight of diabetic mice significantly decreased (30% 
decrease, P < 0.001) from day 4 post-STZ injection compared to normal mice. 
Neither [D-Ala
2
]GIP nor Liraglutide administration altered body weight of STZ-
induced diabetic mice (Figure 4.1). As compared to lean mice, diabetic mice 
demonstrated increased cumulative food intake which appeared significant (P < 
0.05) on day 18 while water intake continued to increase (P < 0.05) from day 4 
onwards. No differences were observed in food intake (Figure 4.2) and water intake 
(Figure 4.3) in saline-, Liraglutide- and [D-Ala
2
]GIP-treated diabetic mice. STZ 
treatment significantly increased plasma glucose levels (5-fold, P < 0.001, Figure 
4.4A) and the increase was accompanied by a significant reduction in insulin 
concentrations (4-fold, P < 0.001, Figure 4.4B) compared to lean littermate mice. 
Treatment with [D-Ala
2
]GIP or Liraglutide for 21 days did not improve non-fasting 
plasma glucose concentrations and insulin levels compared to untreated STZ mice 
(Figure 4.4).  
 
4.4.2 Effects of once-daily administration of [D-Ala
2
]GIP or Liraglutide on 
glucose tolerance and glucose-induced plasma insulin release in streptozotocin-
induced diabetic mice. 
 
Daily administration of [D-Ala
2
]GIP or Liraglutide induced no significant effects on 
glycaemic response at every time point tested following glucose loading (Figure 
4.5A). Although overall improvements in glucose tolerance were observed, as seen 
by the reduction of plasma glucose AUC (0-60 min) in diabetic mice treated with [D-
Ala
2
]GIP or Liraglutide, the differences did not reach statistical significance. On the 
other hand, plasma insulin concentration in response to glucose loading significantly 
increased 15 minutes post-injection in Liraglutide- treated mice compared to saline 
control group (48% increase, P < 0.05, Figure 4.6A). No differences were seen in 
plasma insulin levels at any time point in mice treated with [D-Ala
2
]GIP compared 
to the control group (Figure 4.6A). Overall plasma insulin response as measured by 
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integrated AUC (0-60 min) were augmented in mice treated with [D-Ala
2
]GIP (57% 
increase, P < 0.05) and Liraglutide (70%  increase, P < 0.01) compared with saline 
controls (Figure 4.6B). 
 
4.4.3 Effects of once-daily administration of [D-Ala
2
]GIP or Liraglutide on 
insulin sensitivity in streptozotocin-induced diabetic mice. 
 
Treatment with [D-Ala
2
]GIP or Liraglutide had no significant effect on blood 
glucose concentrations following exogenous administration of insulin (Figure 4.7). 
The overall effect, shown from blood glucose AUC (0-60min) values, was enhanced 
in mice receiving [D-Ala
2
]GIP or Liraglutide. However, the beneficial effect was not 
significant compared to saline-treated diabetic controls (Figure 4.7B). 
 
4.4.4  Effects of [D-Ala
2
]GIP and Liraglutide on total body fat, bone mineral 
density (BMD) and bone mineral content (BMC) in streptozotocin-induced 
diabetic mice. 
 
Once daily administration of [D-Ala
2
]GIP or Liraglutide for 21 days had no 
significant effect on percentage of total body fat compared to streptozotocin-induced 
diabetic mice (Figure 4.8). All three STZ groups exhibited decreased total body fat 
mass (55 - 60% decrease, P < 0.001) compared to lean mice. Total BMD and BMC 
were not significant in all four groups, whilst BMD and BMC at specific bone 
regions of interest appeared to be slightly decreased in diabetic mice compared to 
normal littermates, but the differences did not reach significance (Figure 4.10-4.12). 
Total as well as BMD and BMC at femur, tibia and lumbar regions in mice injected 
with [D-Ala
2
]GIP or Liraglutide showed no differences compared with saline-treated 
diabetic and normal mice (Figure 4.9-4.12).  
 
4.4.5 Effects of [D-Ala
2
]GIP and Liraglutide on femoral mineral content in 
streptozotocin-induced diabetic mice. 
 
Femoral mineral content, represented by mean grey level, was determined by 
quantitative x-ray imaging at cortical (Figure 4.13) and trabecular (Figure 4.14) 
bone. Grey level at cortical bone in diabetic mice was significantly decreased (9% 
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decrease, P < 0.01, Figure 4.13B) compared to normal littermates. However, there 
were no significant differences seen in GLmean values between [D-Ala
2
]GIP-, 
Liraglutide- and saline-treated STZ mice. As seen in Figure 4.14A, trabecular bone 
in STZ-induced diabetic mice was slightly modified. However, bone mineral content 
was not significantly different in diabetic and normal mice (Figure 4.14B). 
Additionally, no apparent changes were observed with [D-Ala
2
]GIP or Liraglutide 
treatment (Figure 4.14).  
 
4.4.6 Effects of [D-Ala
2
]GIP and Liraglutide on trabecular bone morphology 
and cortical bone geometry in streptozotocin-induced diabetic mice. 
 
Trabecular bone morphology and cortical bone geometry were investigated using 
high resolution microCT. Trabecular bone volume, thickness, numbers and 
separation were not affected by STZ-induced diabetes as there were no significant 
differences between STZ-treated and normal mice (Figure 4.15). [D-Ala
2
]GIP and 
Liraglutide therapy did not change these parameters. On the other hand, cortical bone 
appeared to be altered in diabetic mice. Diabetic control mice had increased diameter 
of bone marrow (18% increase, P < 0.05, Figure 4.16B) accompanied by reduction in 
cortical thickness (17% decrease, P < 0.001, Figure 4.16C) as compared to normal 
mice. Cortical bone diameter was unchanged, whilst CSMI values were lowered, but 
not significant in STZ-mice. Once daily administration of [D-Ala
2
]GIP or 
Liraglutide over 21 days had no effect on cortical diameter, thickness or CSMI, 
whilst bone marrow diameter in Liraglutide-treated diabetic mice was slightly 
reduced compared to diabetic mice that received saline vehicle (Figure 4.16B). 
 
4.4.7 Effects of [D-Ala
2
]GIP and Liraglutide on whole-bone mechanical 
properties in streptozotocin-induced diabetic mice. 
 
As assessed by three-point bending test, diabetic mice demonstrated reduced 
ultimate force, ultimate displacement, stiffness and work-to-failure but only the 
differences in ultimate force (20% decrease, P < 0.01, Figure 4.17A) and stiffness 
(22% decrease, P < 0.01, Figure 4.17C) were significant compared to lean 
littermates. None of the parameters investigated were markedly different in [D-
Ala
2
]GIP-,  Liraglutide- and saline-treated diabetic groups (Figure 4.17). 
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4.4.8 Effects of [D-Ala
2
]GIP and Liraglutide on nanomechanical properties of 
cortical bone matrix in streptozotocin-induced diabetic mice. 
 
As compared to normal mice, a significant reduction was seen in hardness (30% 
decrease, P < 0.01), indentation modulus (18% decrease, P < 0.001), maximum load 
(24% decrease, P < 0.001) and dissipated energy (20% decrease, P < 0.05) of cortical 
bone in STZ-induced diabetic controls. Treatment with Liraglutide or [D-Ala
2
]GIP 
increased hardness (35-49% increase, P < 0.01, Figure 4.18A), indentation modulus 
(31% increase, P < 0.001, Figure 4.18B), maximum load (35-43% increase, P < 
0.001, Figure 4.18C) and dissipated energy (39% increase, P < 0.01, Figure 4.18D) 
compared to control diabetic mice. Furthermore, elevations in all four parameters in 
treated diabetic mice reached levels similar to lean littermates (Figure 4.18).  
 
4.4.9 Effects of [D-Ala
2
]GIP and Liraglutide on bone mineral density 
distribution in streptozotocin-induced diabetic mice. 
 
All three variables of bone mineral density distributions; Capeak, Camean and Cawidth at 
cortical parts of the tibia in diabetic mice were similar to lean controls. Treatment 
with [D-Ala
2
]GIP or Liraglutide had no significant effects on BMDD (Figure 4.19). 
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4.5 DISCUSSION 
 
Bone loss in insulin-deficient diabetic patients can lead to severe complications such 
as bone fracture and mortality (Gulcelik et al. 2011, Zhokouskaya et al. 2014). 
Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 
(GLP-1) are well-known incretin hormones that are involved in the regulation of 
glucose homeostasis postprandially (Yabe & Seino 2011). The primary action of 
these peptides is on pancreas to glucose-dependently stimulate islet beta-cell insulin 
secretion which leads to reduction of blood glucose concentrations after food 
ingestion (Baggio & Drucker 2007). The widespread expression of incretin receptors 
in brain, adipose tissue and bone (Bollag et al. 2000, Goke et al. 1995, Usdin et al. 
1993, Yip et al. 1998, Zhong et al. 2007) suggests multiple actions of incretins at 
extrapancreatic sites. However, biological actions of incretins are limited as the gut 
hormones are rapidly inactivated by DPP-4 enzyme (Baggio & Drucker 2007). In 
order to protect against N-terminal cleavage of incretins, structurally modified 
incretin agonists have been developed (Hinke et al. 2002, Irwin et al. 2005a, 
Knudsen et al. 2000, O’Harte et al. 2002).  
 
In Chapter 3, native GIP and its stable analogue [D-Ala
2
]GIP were shown to have 
positive effects on stimulating bone-formation biomarkers. Additionally, initial 
assessment of bone quality found that animal model of incretin KO mice had altered 
bone mass. These findings supported previous studies that showed deficiencies in 
GIPR function resulted in reduced bone microarchitecture and strength 
(Mieczkowska et al. 2013, Xie et al. 2005). On the other hand, less studies on GLP-1 
action on bone have been published. To date, GLP-1 is believed to positively affect 
bone as GLP-1R-deficient mice were observed to have higher bone-resorbing 
activity and impaired bone quality (Mabellieau et al. 2013, Nuche-Berenguer et al. 
2009, Yamada et al. 2008). In view of these observations, the present study 
examined the effects of once-daily administration of long-acting [D-Ala
2
]GIP and 
Liraglutide peptides on metabolic parameters, bone micromorphology and bone 
strength and quality in streptozotocin-induced insulin-deficient diabetic mice. 
 
Streptozotocin (STZ) is a chemical that is toxic to pancreatic beta cells (Lenzen 
2008) and is extensively used to induce hyperglycaemia and hypoinsulinemia in 
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mouse (Coe et al. 2013) and rat (Horcajada-Molteni et al. 2001) models. In line with 
observations from other studies, STZ introduction leads to hyperglycaemia and 
hypoinsulinemia 2 days post STZ delivery, and glucose and insulin levels remained 
extremely high and low, respectively, compared to lean mice. Body weight was also 
reduced in STZ-treated rodents (Graham et al. 2011, Lu et al. 1998, Motyl & 
McCabe 2009) and in agreement with previous reports, the reduction in body weight 
resulted from a decrease in fat mass (Coe et al. 2013). Loss of body weight was 
however independent of water and food intake as both parameters continued to 
elevate until the end of experimental period and this is consistent with diabetic 
hyperphagia and polydipsia.  
 
Once daily intraperitoneal administration of [D-Ala
2
]GIP or Liraglutide for 21 days 
had no effect on body weight or feeding behavior in diabetic mice. This is not 
surprising as a high single dose of STZ used in our protocol causes rapid beta-cell 
destruction which is unlikely to be corrected by the relatively short period of 
treatment employed. Additionally, there were no changes in non-fasted plasma 
glucose and insulin levels in STZ-induced diabetic mice, as opposed to other studies 
which reported improved glycaemic excursion with Liraglutide and [D-Ala
2
]GIP 
therapy (Porter et al. 2010, Porter et al. 2011). This could simply be due to frequency 
of drug administered and different level of severity of diabetic model employed. As 
such, other studies used twice-daily injection in high-fat dietary induced obesity and 
insulin resistance mice, whilst our study opted for once-daily treatment in more 
severe model of STZ-induced diabetes.  
 
Glucose tolerance had tendency to be improved as seen by reductions of plasma 
glucose concentrations and significantly augmented glucose-induced plasma insulin 
levels after 21 days administration of Liraglutide or [D-Ala
2
]GIP in diabetic mice. 
However, due to the extremely high plasma glucose concentrations (approx. 25 
mmol/l) in 18-h fasted STZ-induced diabetic mice, significant glucose-stimulated 
plasma insulin release was insufficient to fully alleviate hyperglycaemia. Non-fasted 
plasma insulin concentrations were seemingly low throughout the experimental 
period (Figure 4.4). However, higher levels of plasma insulin were observed when 
an exogenous glucose load was intraperitoneally administered (Figure 4.6) at the end 
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of the study, suggesting glucose-dependent insulin-stimulating effect of these 
analogues. Indeed, Liraglutide has previously been shown to improve beta cell mass 
and function (Tamura et al. 2015). Although not as effective as GLP-1 agonist, [D-
Ala
2
]GIP has a tendency to also increase beta cell mass (Maida et al. 2009). Unlike 
human beta-cells, murine pancreatic beta cells also have the potential to regenerate 
following STZ administration (Bonner-Weir et al. 1981, Wang et al. 1994) which 
could partially explain the increase in insulin production observed in STZ-induced 
diabetic mice when compared to db/db mice. 
 
As reported previously, rodent models of STZ-induced diabetes display bone loss 
(Botolin & McCabe 2007, Coe et al. 2013, Horcajada-Molteni et al. 2001, Nyman et 
al. 2011). In our study, initial assessment of bone was performed using DEXA and 
similar to previous observations, bone loss was seen in diabetic mice. Although the 
differences in bone mineral density and content did not reach significance, BMD and 
BMC were clearly reduced at femoral, tibial and lumbar regions of mice with 
pharmacologically induced diabetes in comparison to normal controls. In line with 
what we have seen in DEXA scanning, GLmean which represents mineral content 
was also reduced at cortical, but not trabecular bone of diabetic mice. Insulin has 
anabolic effects on bone (Cornish et al. 1996, Thomas et al. 1998) and it is most 
likely that hypoinsulinemia in STZ-induced diabetic mice leads to bone defects. In 
addition, hyperglycaemia is associated with formation of advanced glycation end 
(AGE) products (Saito & Marumo 2010) and AGEs are reported to inhibit the 
function of bone-forming osteoblast cells and induce bone resorption activities by 
osteoclasts, resulting in excessive boss loss (Alikhani et al. 2007, McCarthy et al. 
1997, Miyata et al. 1997, Yamagishi 2011).  
 
In contrary to available literature (Nyman et al. 2011), only cortical bone was 
severely affected in streptozotocin-induced diabetic mice. An explanation for this 
could be the different duration of diabetes in each study. Bones were excised and 
preserved after 4 weeks of hyperglycaemia in the current study, whilst the minimum 
duration of diabetic bones examined in aforementioned study was 10 weeks. In the 
present study, cortical bone thickness was significantly reduced and this reduction 
was accompanied by a significant increase in bone marrow diameter with an 
unchanged outer bone diameter. However, Nyman and colleagues did not assess 
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bone marrow diameter in their study. Yet, others propose that diabetic bone loss is 
due to an increase in bone marrow adiposity which was supported by elevations in 
biomarkers of adipocytes in mouse models of STZ-induced diabetes (Botolin et al. 
2005). More importantly, adipocyte volume in bone marrow was also reported to 
increase in osteoporotic human bone in iliac crest bone biopsies (Justesen et al. 
2001), indicating the similarity in rodent and human bone loss. Therefore, the 
changes in cortical geometry in this study were probably due to less bone formation, 
resulting from enhanced differentiation of progenitors of mesenchymal stem cells to 
bone marrow adipogenesis. In addition to changes in cortical thickness, CSMI, 
which is a biomechanical indicator of the ability of bone to resist bending, was also 
reduced in diabetic mice (Nyman et al. 2011). Similarly, a modest reduction in 
resistance of cortical bone to bending was seen in our work study. Chronic 
administration of [D-Ala
2
]GIP did not improve bone microstructure and morphology 
in STZ-induced diabetic mice. However, the diameter of bone marrow was slightly 
improved with Liraglutide therapy.  
 
Bone integrity is characterised by both bone quantity and strength. While quantity of 
bone is dependent on skeletal mass, bone strength is defined by a combination of all 
factors that contribute to resistance in skeletal fracture, such as microstructure, 
geometry as well as quality of minerals and collagens (Licata 2009). Assessment of 
bone microstructure with microCT revealed defective cortical bone, with unaffected 
trabecular bone in diabetic mice. Apart from improvement in marrow diameter by 
Liraglutide, neither [D-Ala
2
]GIP nor Liraglutide therapy had favourable effects on 
the other variables measured for microstructure and morphology. Therefore, further 
examination by three-point bending and nanoindentation were done to assess the 
biomechanical properties of cortical bone in diabetic mice. At the whole-bone level, 
STZ-induced diabetic mice had alterations in mechanical properties and this was 
shown by the reductions of ultimate force and stiffness. In parallel, size-independent 
material properties of bone matrix were also reduced in diabetic mice as compared to 
normal littermates. The abnormalities in bone strength are not surprising as 
hyperglycaemia provides a suitable condition for irreversible non-enzymatic 
modifications of bone collagen, which in turn alter bone matrix structural and 
mechanical properties and can lead to high bone fragility (Saito & Marumo 2010).  
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Treatment with [D-Ala
2
]GIP or Liraglutide for 21 days did not induce noticeable 
changes of size-dependent mechanical properties measured of cortical long bone in 
diabetic mice. In contrast, material properties at the tissue-level were restored to lean 
control levels by [D-Ala
2
]GIP and Liraglutide. Our findings are consistent with a 
previous study that observed increased bone material properties with another stable 
GIP analogue, N-AcGIP, in rats and that the primary target of GIP is at cortical bone 
(Mabilleau et al. 2014). Insulin deficiency contributes to bone loss and we 
hypothesised that augmented insulin concentrations by GIP and GLP-1 may have 
beneficial effects on bone. However, daily circulating insulin levels were very low 
and not improved by the treatments in this experiment. Therefore, we can say that 
the beneficial effects of [D-Ala
2
]GIP or Liraglutide on bone are independent of the 
insulin axis. These improvements were also not dependent on calcium deposition, as 
bone mineral density distribution was similar in treated and nontreated diabetic mice.  
 
One could argue that duration of the study should be extended to observe more 
significant effects on bone microarchitecture. The opportunity to study STZ diabetic 
mice depends on the extent of beta cell destruction, which indicates severity of 
diabetes and its complications. In the present study, single injection of high-dose 
STZ was used to initiate immediate insulin-producing beta cell destruction and to 
demonstrate clear effects of insulin-deficient diabetes to bone. Due to the rapid onset 
and severity of beta cell loss in this experimental model, it was not possible to keep 
STZ diabetic mice for longer period without implementing insulin therapy, which 
itself may affect bone. Additionally, potential effects of STZ on incretin function 
need to be considered. GLP-1 and GIP primarily enhances insulin release from beta 
cells and the destruction of islet beta cells by STZ indirectly reduces the capacity of 
incretins in stimulating insulin production. Apart from that, no evidence for a direct 
toxicity of STZ on incretins has been reported. In the present study, treatment started 
on day 6 after STZ introduction and due to a short biological half-life of STZ (5-15 
min) (Eleazu et al. 2013), this glucoseamine derivative may have been fully 
metabolised when incretin-based analogues were administered.    
 
As mentioned earlier, there are multiple factors that influence bone strength such as 
bone mass, microstructure, morphology, mineralisation and organic phase. As the 
first four factors were not improved in our study, changes in organic status which 
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was not assessed in this study could be the reason of recovery of material properties 
of bone matrix. Indeed, a previous study found that increased tissue-level mechanical 
properties of bone were accompanied by increased collagen maturity by N-AcGIP 
(Mabilleau et al. 2014). However, the exact mechanism by which GIP regulates bone 
mineral and organic materials is still unknown. On the other hand, activation of 
GLP-1R was reported to modulate bone through a calcitonin-pathway in rodent 
(Yamada et al. 2008) and interestingly, calcitonin has been previously shown to 
inhibit the expression and activity of proteins responsible for extracellular matrix 
degradation (Sondergaard et al. 2006). Therefore, it is possible that improvements in 
bone matrix hardness and stiffness seen with Liraglutide therapy in our study could 
be due to calcitonin.  
 
In this study, we reveal that STZ-diabetic mice exhibited impaired cortical geometry 
as well as reduced bone mechanical properties, ultimately resulting in low bone 
strength. It was also demonstrated that both stable incretin peptides had no effect on 
cortical mass and micromorphology in diabetic mice. However, a recovery process 
in bone strength was seen through improvement of intrinsic tissue material properties 
in STZ-induced diabetic mice treated with [D-Ala
2
]GIP and Liraglutide. With 
regards to GIP and GLP-1 analogues employed, both [D-Ala
2
]GIP and Liraglutide 
had equal potential in optimising bone quality at the tissue level. Additionally, it 
would be interesting to investigate the osteoprotective effects of prolonged and 
simultaneous activation of GIP and GLP-1 receptors in genetically-induced animal 
models of diabetes. 
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Figure 4.1 : Effects of once daily administration of  [D-Ala
2
]GIP or Liraglutide 
on body weight in STZ-induced diabetic mice 
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Body weight was measured at 2-3 day intervals, starting 6 days prior to STZ delivery 
(150 mg/kg b.w, indicated by the arrow) until 26 days post STZ-injection. Mice were 
treated once daily with saline vehicle (0.9%, w/v, NaCl), [D-Ala
2
]GIP or Liraglutide 
(each at 25 nmol/kg b.w) for 21 days (horizontal black bar). Lean littermates were 
used for comparative purposes. Values are mean ± S.E.M for 6-8 mice. ***P < 0.001 
compared with saline normal group. 
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Figure 4.2 : Effects of once daily administration of [D-Ala
2
]GIP or Liraglutide 
on cumulative food intake in STZ-induced diabetic mice 
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Food intake was measured at 2-3 day intervals, starting 6 days prior to STZ delivery 
(150 mg/kg b.w, indicated by the arrow) and until 26 days post-STZ injection. Mice 
received daily treatment with saline vehicle (0.9%, w/v, NaCl), [D-Ala
2
]GIP or 
Liraglutide (each at 25 nmol/kg b.w) for 21 days (horizontal black bar). Lean 
littermates were used for comparative purposes. Values are mean ± S.E.M for 6-8 
mice. *P < 0.05, **P < 0.01 compared with saline normal group. 
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Figure 4.3 : Effects of once daily administration of [D-Ala
2
]GIP or Liraglutide 
on fluid intake in STZ-induced mice 
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Water intake was measured at 2-3 day intervals, starting 6 days prior to STZ delivery 
(150 mg/kg b.w, indicated by the arrow) until 26 days post-STZ injection. Mice were 
injected once daily with saline vehicle (0.9%, w/v, NaCl), [D-Ala
2
]GIP or 
Liraglutide (each at 25 nmol/kg b.w) for 21 days (horizontal black bar). Lean 
littermates were used for comparative purposes. Values are mean ± S.E.M for 6-8 
mice. *P < 0.05, ***P < 0.001 compared with saline normal group. 
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Figure 4.4 : Effects of once daily administration of [D-Ala
2
]GIP or Liraglutide 
on non-fasting plasma glucose (A) and insulin (B) in STZ-induced diabetic mice 
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Mice were injected once daily with saline vehicle (0.9%, w/v, NaCl), [D-Ala
2
]GIP or 
Liraglutide (each at 25 nmol/kg b.w) for 21 days (horizontal black bar). Lean 
littermates were used for comparative purposes. Blood was collected 3 days prior to 
STZ delivery (indicated by arrow) and every 5 days thereafter. Values are expressed 
as mean ± S.E.M for 6-8 mice. ***P < 0.001 compared with saline normal group. 
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Figure 4.5 : Effects of once daily administration of [D-Ala
2
]GIP or Liraglutide 
on glucose tolerance in STZ-induced diabetic mice 
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Tests were conducted following 21 days once daily treatment with saline (0.9%, w/v, 
NaCl), [D-Ala
2
]GIP or Liraglutide (each at 25 nmol/kg b.w). A) Glucose alone (18 
mmol/kg b.w) was administered at time 0 (indicated by the arrow) in 18 h fasted 
mice and plasma glucose concentrations prior to and 15, 30 and 60 min after glucose 
administration were recorded. Plasma glucose AUC values (determined by using 
mean value at 0 min as a baseline) are also shown (B). Values are mean ± S.E.M for 
6-8 mice per group.  
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Figure 4.6 : Effects of once daily administration of [D-Ala
2
]GIP or Liraglutide 
on glucose-induced insulin release in STZ-induced diabetic mice 
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Tests were conducted following 21 days once daily treatment with saline (0.9%, w/v, 
NaCl), [D-Ala
2
]GIP or Liraglutide (each at 25 nmol/kg b.w). A) Glucose alone (18 
mmol/kg b.w) was administered at time 0 (indicated by the arrow) in 18 h fasted 
mice and plasma insulin concentrations prior to, and 15, 30 and 60 min after glucose 
administration were recorded. Plasma insulin AUC values (determined by using 
mean value at 0 min as a baseline) are also shown (B). Values are mean ± S.E.M for 
6-8 mice per group. *P < 0.05, **P < 0.01 compared with saline STZ-induced 
diabetic group. 
117 
 
Figure 4.7 : Effects of once daily administration of [D-Ala
2
]GIP or Liraglutide 
on insulin sensitivity in STZ-induced diabetic mice 
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Tests were performed after once daily treatment with saline (0.9%, w/v, NaCl), [D-
Ala
2
]GIP or Liraglutide (each at 25 nmol/kg b.w) for 21 days. A) Insulin (25 U/kg 
b.w) was administered at time 0 (indicated by the arrow) in non-fasted mice and 
plasma glucose concentrations prior to, and 15, 30 and 60 min after glucose 
administration were recorded. B) Plasma glucose AUC values (determined by using 
mean value at 0 min as a baseline) for 0-60 min post-injection. Values represent the 
means ± S.E.M for 6-8 mice per group.  
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Figure 4.8 : Effects of once daily administration of [D-Ala
2
]GIP or Liraglutide 
on total body fat as measured by DEXA scanning in STZ-induced diabetic mice 
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Body fat was measured by dual energy X-ray absorption after once daily 
administration of saline (0.9%, w/v, NaCl), [D-Ala
2
]GIP or Liraglutide (each at 25 
nmol/kg b.w) for 21 days. Lean littermates were used for comparative purposes. 
Values are expressed as mean ± S.E.M for 6-8 mice per group. ***P < 0.001 
compared to saline normal group. 
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Figure 4.9 : Effects of once daily administration of [D-Ala
2
]GIP or Liraglutide 
on A) total bone mineral density (BMD) and B) total bone mineral content 
(BMC) in STZ-induced diabetic mice 
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Parameters were measured by dual energy X-ray absorption following 21 days once 
daily administration of saline (0.9%, w/v, NaCl), [D-Ala
2
]GIP or Liraglutide (each at 
25 nmol/kg b.w). Lean littermates were used for comparative purposes. Values are 
mean ± S.E.M for 6-8 mice.  
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Figure 4.10 : Effects of once daily administration of [D-Ala
2
]GIP or Liraglutide 
on lumbar A) bone mineral density (BMD) and B) bone mineral content (BMC) 
in STZ-induced diabetic mice 
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Parameters were assessed by dual energy X-ray absorption following 21 days once 
daily administration of saline (0.9%, w/v, NaCl), [D-Ala
2
]GIP or Liraglutide (each at 
25 nmol/kg b.w). Lean littermates were used for comparative purposes. Values are 
mean ± S.E.M for 6-8 mice. 
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Figure 4.11 : Effects of once daily administration of [D-Ala
2
]GIP or Liraglutide 
on femoral A) bone mineral density (BMD) and B) bone mineral content (BMC) 
in STZ-induced diabetic mice 
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Parameters were measured by dual energy X-ray absorption following 21 days once 
daily administration of saline (0.9%, w/v, NaCl), [D-Ala
2
]GIP or Liraglutide (each at 
25 nmol/kg b.w). Lean littermates were used for comparative purposes. Values are 
mean ± S.E.M for 6-8 mice. 
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Figure 4.12 : Effects of once daily administration of [D-Ala
2
]GIP or Liraglutide 
on tibial A) bone mineral density (BMD) and B) bone mineral content (BMC) in 
STZ-induced diabetic mice 
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Parameters were measured by dual energy X-ray absorption following 21 days once 
daily administration of saline (0.9%, w/v, NaCl), [D-Ala
2
]GIP or Liraglutide (each at 
25 nmol/kg b.w). Lean littermates were used for comparative purposes. Values are 
mean ± S.E.M for 6-8 mice. 
123 
 
Figure 4.13 : Effects of once daily administration of [D-Ala
2
]GIP or Liraglutide 
on femoral cortical bone mineral content in STZ-induced diabetic mice 
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Cortical bone mineral content was measured by quantitative x-ray microradiograph 
following 21 days once daily administration of saline (0.9%, w/v, NaCl), [D-
Ala
2
]GIP or Liraglutide (each at 25 nmol/kg b.w). Lean littermates were used for 
comparative purposes. A) Digital x-ray images of femoral cortical bone were 
measured 3-4 mm below growth plate. B) Mean grey level. Values are mean ± 
S.E.M for 6-8 mice. **P < 0.01 compared to saline normal group. 
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Figure 4.14 : Effects of once daily administration of [D-Ala
2
]GIP or Liraglutide 
on femoral cancellous bone mineral content in STZ-induced diabetic mice 
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Cancellous bone mineral content was measured by quantitative x-ray 
microradiograph following 21 days once daily administration of saline (0.9%, w/v, 
NaCl), [D-Ala
2
]GIP or liraglutide (each at 25 nmol/kg b.w). Lean littermates were 
used for comparative purposes. A) Digital x-ray images of femoral cancellous bone 
which was measured 2 mm below growth plate. B) Mean grey level. Values are 
mean ± S.E.M for 6-8 mice.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
127 
 
Figure 4.15 : Effects of once daily administration of [D-Ala
2
]GIP or Liraglutide 
on trabecular bone mass and microarchitecture in STZ-induced diabetic mice 
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Parameters were obtained from microtomography scan of tibia following 21 days 
once daily administration of saline (0.9%, w/v, NaCl), [D-Ala
2
]GIP or Liraglutide 
(each at 25 nmol/kg b.w). Lean littermates were used for comparative purposes. 
Values are mean ± S.E.M for 6-8 mice.  
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Figure 4.16 : Effects of once daily administration of [D-Ala
2
]GIP or Liraglutide 
on cortical bone geometry in STZ-induced diabetic mice 
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Images of cortical bone were obtained from a microtomography scan of tibia 
following 21 days once daily administration of saline (0.9%, w/v, NaCl), [D-
Ala
2
]GIP or Liraglutide (each at 25 nmol/kg b.w). Lean littermates were used for 
comparative purposes. Cortical bone was located 3 mm below growth plate and 
diameter of bone (A), diameter of bone marrow (B), cortical thickness (C) and cross-
sectional moment of inertia (D) were measured using ImageJ software and calculated 
as described in Section 2.7.3. Values are mean ± S.E.M for 6-8 mice. *P < 0.05, 
***P < 0.001 compared to normal saline group. 
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Figure 4.17 : Effects of once daily administration of [D-Ala
2
]GIP or Liraglutide 
on whole-bone mechanical properties of femoral cortical bone in STZ-induced 
diabetic mice 
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Parameters were obtained from 3-point bending test following 21 days once daily 
administration of saline (0.9%, w/v, NaCl), [D-Ala
2
]GIP or Liraglutide (each at 25 
nmol/kg b.w). Lean littermates were used for comparative purposes. Values are 
mean ± S.E.M for 6-8 mice. *P < 0.05, **P < 0.01 compared with saline normal 
group. 
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Figure 4.18 : Effects of once daily administration of [D-Ala
2
]GIP or Liraglutide 
on intrinsic mechanical tissue response of cortical bone in STZ-induced diabetic 
mice 
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Parameters were measured by nanoindentation following 21 days once daily 
administration of saline (0.9%, w/v, NaCl), [D-Ala
2
]GIP or Liraglutide (each at 25 
nmol/kg b.w). Lean littermates were used for comparative purposes. Values are 
mean ± S.E.M for 6-8 mice. *P < 0.05, **P < 0.01, ***P < 0.001 compared with 
STZ-induced diabetic control group. 
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Figure 4.19 : Effects of once daily administration of [D-Ala
2
]GIP or liraglutide 
on cortical bone mineral density distribution (BMDD) in STZ-induced diabetic 
mice 
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Bone mineralisation at cortical bone was measured by quantitative backscattered 
electron imaging following 21 days once daily administration of saline (0.9%, w/v, 
NaCl), [D-Ala
2
]GIP or Liraglutide (each at 25 nmol/kg b.w). Lean littermates were 
used for comparative purposes. Values are mean ± S.E.M for 6-8 mice. 
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Chapter 5 
 
Simultaneous activation of GIP, 
GLP-1 and glucagon receptors by 
[D-Ala
2
]GIP-oxyntomodulin 
positively affects cortical and 
trabecular bone properties and 
improves bone mechanical strength 
in genetically-induced C57 BL/KsJ 
diabetic (db/db) mice 
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5.1 SUMMARY 
 
Bone abnormalities have appeared as new complications of diabetes and although 
bone mineral density is unaffected or modestly increased in type 2 diabetes mellitus, 
patients are still prone to bone fracture. Gut hormones, glucose-dependent 
insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are primarily 
known to control glucose homeostasis but recently, the incretins are also suspected 
to participate in bone regulation. Stimulation of GIP and GLP-1 receptors 
ameliorates defective cortical bone strength by improving tissue material properties 
in animal models of STZ-induced insulin-deficient diabetes. However, the effects of 
co-activation of both receptors together with glucagon receptors on bone quality are 
unknown. This study assessed the effects of daily treatment of triple GIP, GLP-1 and 
glucagon acting agent, [D-Ala
2
]GIP-Oxyntomodulin ([D-Ala
2
]GIP-Oxm) on 
metabolic control, bone microarchitecture and strength in genetically-induced 
diabetic (db/db) mice. C57 BL/KsJ diabetic (db/db) mice received once-daily 
injection of saline (0.9% w/v NaCl) or [D-Ala
2
]GIP-Oxm (50 mmol/kg bw) for 21 
days. [D-Ala
2
]GIP-Oxm had no effect on body weight, water intake and 
accumulative food intake. Non-fasting plasma glucose was unchanged despite 
augmented insulin concentrations (3.5-fold, P < 0.01). No differences were seen in 
glucose tolerance and insulin sensitivity between treated and untreated diabetic 
groups. As compared to lean mice, db/db mice exhibited significant increases in total 
fat mass, reduced bone mineral density (BMD) and bone mineral content (BMC) and 
severe impairments in mechanical strength and microarchitecture at both cortical and 
trabecular bone. Administration of [D-Ala
2
]GIP-Oxm did not affect total, lumbar, 
femoral and tibial BMD and BMC in db/db mice. In addition, no modifications were 
observed in GLmean and absorbing material density between groups. As assessed by 
microCT, trabecular thickness (8% increase, P < 0.005) and cortical bone diameter 
(4% increase, P < 0.05) were significantly increased in [D-Ala
2
]GIP-Oxm mice. 
Bone mechanical assessments demonstrated that mice that were treated with [D-
Ala
2
]GIP-Oxm had augmented maximum displacement (65% increase, P < 0.05) and 
work-to-fracture (47% increase, P < 0.01), whilst bone matrix hardness (31% 
increase, P < 0.05) and indentation modulus (9% increase, P < 0.05) were also 
improved. The changes were independent of bone mineral density distribution. In 
conclusion, simultaneous activation of GIP, GLP-1 and glucagon receptors by [D-
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Ala
2
]GIP-Oxm analogue not only improved the material properties of bone matrix, 
but also the microstructure of cortical and trabecular bone, which in turn contributes 
to the overall improvement in mechanical response at the whole-bone level in leptin 
receptor-deficient diabetic (db/db) mice.  
 
5.2  INTRODUCTION 
 
Obesity has an impact on the quality of the skeleton and despite inconsistencies in 
reporting the effects of body mass on bone metabolism, bone impairments have been 
revealed in established rodent models of obesity and insulin resistance (Ealey et al. 
2006, Ionova-Martin et al. 2010, Patsch et al. 2011, Williams et al. 2011). Several 
bone-related hormones are altered in obesity including leptin, the important regulator 
of body weight (Friedmann & Halaas 1998, Thomas et al. 1999).  As such, leptin 
receptor-deficient (db/db) mice represent a genetic rodent model of spontaneous 
obesity as well as hyperglycaemia and hyperinsulinemia (Flatt et al. 1983). The 
leptin receptor is encoded by db gene and a recessive mutation in the gene has been 
shown to affect the intracellular domain of the single membrane-spanning receptor 
(Chen et al. 1996). Although leptin appears to bind to its receptor in db/db mice 
(Tartaglia et al. 1995), defective intracellular signal transduction attenuates leptin 
function, leading to a severe obesity and diabetes phenotype (Coleman 1978).  
 
In response to nutrient intake, glucose-dependent insulinotropic polypeptide (GIP) 
and glucagon-like peptide-1 (GLP-1) are released by the gastrointestinal tract. The 
physiological target of these gut hormones is on pancreatic β cells stimulatine insulin 
secretion and control blood glucose concentrations (Baggio & Drucker 2007) and as 
such, incretins provide therapeutic potential for the treatment of type 2 diabetes 
(Drucker 2003). Recently, emerging evidence on the importance of GIP and GLP-1 
signaling in normal bone regulation was revealed in genetically-modified knockout 
and transgenic mice (Mabilleau et al. 2013, Tsukiyama et al. 2006, Xie et al. 2005, 
Xie et al. 2007, Yamada et al. 2008, Chapter 3). Taken together, these data suggest 
beneficial effects of GIPR and GLP-1R signaling on bone. Nonetheless, endogenous 
incretins are a substrate of dipeptidyl peptidase-4 (DPP-4) and the gut hormones are 
rapidly cleaved by this serine protease enzyme, rendering the inactive truncated form 
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of these peptides. In order to circumvent DPP-4 activity, several stable long-acting 
incretin analogues were developed and examined for its glucose-lowering and 
insulin-releasing properties.  
 
Oxyntomodulin (Oxm) is a 37-amino acid gut molecule, derived from proglucagon 
family peptide and co-secreted with GLP-1 upon food intake. Oxm exerts its effects 
by binding to and co-activating both glucagon and GLP-1 receptors (Baggio et al. 
2004) to control insulin secretion (Schjoldager et al. 1988). Oxm is also involved in 
the regulation of energy expenditure and food intake (Cohen et al. 2003). In addition, 
several N-terminally modified stable GIP peptides have been examined for 
antidiabetic activity and [D-Ala
2
]GIP is one of the most promising molecules (Hinke 
et al. 2002). Based on these observations, [D-Ala
2
]GIP-Oxyntomodulin, is a recently 
characterised triple-acting peptide that interacts with GIP, GLP-1 and glucagon 
receptors has been generated by our research group and has proven to have 
antidiabetic potential (Bhat et al. 2013). Taking into consideration the capacity of 
this peptide to activate numerous peptide receptor pathways, [D-Ala
2
]GIP-
Oxyntomodulin is viewed as potential therapeutic agent in management of bone 
disease in diabetes.   
 
In Chapter 4, the link between diabetes and impairment in skeletal integrity was 
established in a chemically-induced mouse model. In the present study, we will 
assess the effects of prolonged and simultaneous activation of GIP, GLP-1 and 
glucagon receptors on metabolic parameters, bone morphology and strength in mice 
with genetically-induced obesity and diabetes, namely C57 BL/KsJ diabetic (db/db) 
mice. 
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5.3 MATERIALS AND METHODS 
5.3.1 Synthesis of [D-Ala
2
]GIP-Oxyntomodulin 
 
The triple-acting analogue, [D-Ala
2
]GIP-Oxyntomodulin was purchased from GL 
Biochem Ltd. (Shanghai, China) at 95% purity. The peptide was characterised by 
MALDI-TOF mass spectrometry as explained in Section 2.1.2.  
 
5.3.2 Animals and study design 
  
C57 BL/KsJ diabetes (db/db) mice (n=10, 11 weeks old) were divided into two 
groups that received [D-Ala
2
]GIP-Oxyntomodulin (50 nmol/kg bw) or saline vehicle 
(0.9%, w/v, NaCl) for 21 days. Lean mice (n=6) from the same genetic background 
were also treated with saline vehicle (0.9%, w/v, NaCl) for the same period of time 
and used for comparative purposes in bone quality assessment. Body weight, food 
consumption, fluid intake, non-fasting blood glucose and insulin concentrations were 
monitored regularly during the 21-day experimental period. Glucose tolerance (18 
mmol/kg bw, intraperitoneally, 18-h fast) and non-fasting insulin sensitivity tests (50 
U/kg bw, intraperitoneally) were carried out at the end of the study as described in 
Section 2.3.8 and 2.3.9, respectively. All experiments were conducted according to 
UK Home Office Regulations (UK Animals Scientific Procedures Act 1986). 
 
5.3.3 Measurement of plasma glucose and insulin 
 
Plasma glucose was measured using an Analox GM-9 glucose analyser as described 
in Section 2.4.1 and plasma insulin concentrations were determined by RIA 
experiment as outlined in Section 2.4.2. 
 
5.3.4 Measurement of body composition, bone density and mineral content by 
DEXA scanning 
 
Unconcious mice were placed on a specimen tray of the DEXA scanner and whole 
body scanning was performed. Bone mineral density (BMD), bone mineral content 
(BMC), total scanned area, lean mass, fat mass and percentage of total fat of ROIs 
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were measured as described in Section 2.5. Age-matched lean controls (n=6) with 
the same genetic background were included for comparative purposes. 
 
5.3.5 Assessment of bone quality and strength 
 
Bone microstructure and strength were assessed on excised femurs and tibias from 
all groups of mice at the end of the study.  
 
5.3.5.1 Quantitative x-ray Imaging (qXRI) 
 
The diameter of femurs was measured and recorded, followed by scanning 
processes. The femurs were imaged together with two standards, 1.5 mm-thick steel 
and polyester which represent grey level 255 and 0, respectively. Bone mineral 
content was determined as detailed in Section 2.6.1. 
 
5.3.5.2 X-ray microcomputed tomography (µCT) 
   
Tibias were positioned and tomographed as described in Section 2.6.2 and 
parameters that were obtained from the projections were trabecular bone volume, 
trabecular bone thickness, numbers of trabecular bone and trabecular separation. 
Images of cortical bone 3-4 mm below the growth plate were obtained and using 
ImageJ software, cortical bone diameter and marrow were measured, followed by 
determination of cortical thickness and cross-sectional moment of inertia as 
explained in Section 2.6.2. 
 
5.3.5.3 Three-point bending test  
 
Bones were individually kept in test tubes containing saline (NaCl, 0.9%) to 
rehydrate and left overnight at 4
o
C. The test was carried out as described in Section 
2.6.3 and four mechanical properties were computerised and evaluated; ultimate 
load, ultimate displacement, stiffness and total absorbed energy (work-to-failure). 
 
 
 
143 
 
5.3.5.4  Nanoindentation 
 
Prior to experimentation, polymethylmethacrylate blocks were polished with a 
diamond particle to remove the carbon layer previously coated for qBEI and the 
blocks were left in saline (NaCl, 0.9%) at 4
o
C for 15 h. Nanoindentation was 
performed as outlined in Section 2.6.4 and  maximum force, hardness, indentation 
modulus and dissipated energy were measured. 
 
5.3.5.5 Quantitative backscattered electron imaging (qBEI) 
 
The polymethylmethacrylate blocks were polished with diamond particles to give 1-
µm finishing, followed by carbon-coating process. Subsequently, the blocks were 
observed under scanning electron microscope as detailed in Section 2.6.5. 
 
5.3.6 Statistical analysis 
 
Data were analysed using repeated measures one-way or two-way ANOVA with 
Tukey’s post hoc tests or two-tailed t-tests using PRISM 5.0. Data are expressed as 
mean ± S.E.M and a P value < 0.05 was considered statistically significant. 
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5.4 RESULTS 
 
5.4.1  Effects of once-daily administration of [D-Ala
2
]GIP-Oxm on metabolic 
parameters in db/db mice. 
 
Treatment with [D-Ala
2
]GIP-Oxm for 21 days had no significant effect on body 
weight (Figure 5.1), food intake (Figure 5.2) and water intake (Figure 5.3) in db/db 
mice. Non-fasting plasma glucose concentrations in [D-Ala
2
]GIP-Oxm-treated 
diabetic mice were reduced from day 10 onwards, however the values did not reach 
statistical significant (Figure 5.4A). On the other hand, plasma insulin levels were 
significantly increased on day 20 (3.5-fold, P < 0.01) in mice treated with [D-
Ala
2
]GIP-Oxm compared to db/db saline controls (Figure 5.4B).  
 
5.4.2 Effects of once-daily administration of [D-Ala
2
]GIP-Oxm on glucose 
tolerance, glucose-induced plasma insulin release and insulin sensitivity in db/db 
diabetic mice. 
 
Once daily administration of [D-Ala
2
]GIP-Oxm had no significant effect on 
glycaemic response at every time point tested following glucose loading (Figure 
5.5A). From plasma glucose AUC (0-60 min) values, overall plasma glucose 
concentrations in db/db mice treated with [D-Ala
2
]GIP-Oxm were lowered compared 
to db/db controls, but the differences were not significant (Figure 5.5B). Glucose-
stimulated plasma insulin concentrations were slightly higher at every time point 
recorded (Figure 5.6A) in [D-Ala2]GIP-Oxm-treated mice when compared to 
controls and as a result, there was an increase in overall plasma insulin levels (Figure 
5.6B). Nonetheless, this increase did not reach significance. As seen in Figure 5.7, 
daily treatment of [D-Ala
2
]GIP-Oxm had no significant effect on plasma glucose 
concentrations following exogenous administration of insulin.  
 
5.4.3 Effects of [D-Ala
2
]GIP-Oxm on percentage body fat, bone mineral 
density and bone mineral content in db/db mice. 
 
Diabetic (db/db) mice had significantly higher percentage of body fat compared to 
lean littermates (70% increase, P < 0.001, Figure 5.8). Treatment with [D-Ala
2
]GIP-
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Oxm had no significant effect on total fat mass in db/db mice. There were no 
differences in BMD and BMC at regions of interest between [D-Ala
2
]GIP-Oxm and 
saline-treated diabetic mice (Figure 5.9-5.12). However, diabetic groups of mice 
exhibited a significant decrease in overall BMD and BMC (BMD: 24% decrease, P < 
0.001, Figure 5.9A; BMC: 50 - 59% decrease, P < 0.001, Figure 5.9B) as well as at 
lumbar (BMD: 33 - 38% decrease, P < 0.001, Figure 5.10A; BMC: 53 - 63% 
decrease, P < 0.001, Figure 5.10B), femur (BMD: 42% decrease, P < 0.001, Figure 
5.11A ; BMC: 72% decrease, P < 0.001, Figure 5.11B) and tibia (BMD: 21 - 26% 
decrease, P < 0.001, Figure 5.12A; BMC: 45% decrease, P < 0.001, Figure 5.12B) 
compared to normal mice.  
 
5.4.4 Effects of [D-Ala
2
]GIP-Oxm on cortical and trabecular bone mineral 
content in db/db mice. 
 
Assessment on bone mineral content was further investigated at both cortical and 
trabecular femur using quantitative x-ray microradiographs. As can be seen in Figure 
5.13, db/db mice had reduced GLmean (15% decrease, P < 0.001, Figure 5.13B) and 
absorbing material density (11% decrease, P < 0.001, Figure 5.13C) as compared to 
lean mice. Similarly, GLmean at trabecular bone was also reduced (19% decrease, P 
< 0.001, Figure 5.14B) which was accompanied by a decrease in absorbing material 
density (13% decrease, P < 0.001, Figure 5.14C). Treatment with [D-Ala
2
]GIP-Oxm 
induced no significant differences in cortical GLmean and absorbing material density 
of the treated and untreated db/db mice (Figure 5.13). The same parameters were 
also unchanged at trabecular bone (Figure 5.14).  
 
5.4.5 Effects of [D-Ala
2
]GIP-Oxm on trabecular bone microarchitecture and 
cortical bone geometry in db/db mice. 
 
Trabecular bone microarchitecture as well as geometry of cortical bone was 
determined by high resolution microCT. Bone volume was significantly reduced 
(70% decrease, P < 0.001, Figure 5.15A) in diabetic db/db mice compared to lean 
controls. This was accompanied by a reduction in trabecular thickness (15% 
decrease, P < 0.001). Additionally, there was a significant decrease in trabecular 
numbers (65% decrease, P < 0.001, Figure 5.15C) and in agreement, there was an 
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increase in trabecular separation (51% increase, P < 0.001, Figure 5.15D) in diabetic 
groups compared to normal mice. Treatment with [D-Ala
2
]GIP-Oxm for 21 days had 
no effect on trabecular bone volume, trabecular numbers and trabecular separation. 
Although other parameters were unchanged, trabecular thickness was significantly 
increased (7% increase, P < 0.05, Figure 5.15B) in mice treated with [D-Ala
2
]GIP-
Oxm compared to the diabetic control group. 
 
As seen in Figure 5.16, there were significant reduction in cortical bone diameter 
(21% decrease, P < 0.001, Figure 5.16A), bone marrow diameter (21% decrease, P < 
0.001, Figure 5.16B), cortical thickness (20% decrease, P < 0.01, Figure 5.16C) and 
CSMI (61% decrease, P < 0.01, Figure 5.16D) at cortical bone of db/db mice 
compared to normal controls. [D-Ala
2
]GIP-Oxm improved cortical bone diameter 
(4% increase, P < 0.05, Figure 5.16A) in db/db mice while other parameters were 
unaffected.  
 
5.4.6 Effects of [D-Ala
2
]GIP-Oxm on whole bone strength in db/db mice. 
 
Extrinsic mechanical properties of cortical bone were assessed by three-point 
bending. As shown in Figure 5.17, diabetic mice had significantly reduced maximum 
force (30% decrease, P < 0.01), maximum displacement (72% decrease, P < 0.01), 
stiffness (47% decrease, P < 0.001) and work-to-failure (71% decrease, P < 0.001) 
compared to lean controls. Administration of [D-Ala
2
]GIP-Oxm for 21 days in db/db 
mice markedly improved ultimate displacement (65% increase, P < 0.05, Figure 
5.17B) as compared to the saline-treated db/db group. The increase in maximum 
displacement was accompanied by an augmentation in work-to-failure (47% 
increase, P < 0.01, Figure 5.17D). However, no differences were observed in 
ultimate force and stiffness between db/db mice groups (Figure 5.17A & C).  
 
5.4.7 Effects of [D-Ala
2
]GIP-Oxm on cortical bone nanomechanical properties 
in db/db mice. 
 
As can be seen in Figure 5.18, mechanical properties evaluated at the tissue-level 
were reduced in leptin receptor-deficient db/db mice compared to lean controls. 
Although significant reductions were observed in hardness (14% decrease, P < 0.01), 
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indentation modulus (10% decrease, P < 0.05) and dissipated energy (39% decrease, 
P < 0.01), maximum force was unchanged (Figure 5.18C). Daily treatement of db/db 
mice with [D-Ala
2
]GIP-Oxm significantly increased bone hardness (31% increase, P 
< 0.05, Figure 5.18A) and indentation modulus  (9% increase, P < 0.05, Figure 
5.18B). In addition, there was slight improvement in dissipated energy (Figure 
5.18D), but it was not significant compared to saline-treated diabetic group. [D-
Ala
2
]GIP-Oxm had no effect on maximum force in db/db mice (Figure 5.18C). 
 
5.4.8 Effects of [D-Ala
2
]GIP-Oxm on cortical bone mineral density 
distribution in db/db mice. 
 
There were no differences seen in Capeak and Camean of diabetic and normal mice. 
However, diabetic db/db mice displayed significant increase in Cawidth (17% 
increase, P < 0.05, Figure 5.19C) compared to lean controls. Treatment of [D-
Ala
2
]GIP-Oxm over 21 day period in db/db mice did not affect these three 
parameters of mineral density distribution. 
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5.5 DISCUSSION 
 
In this study, an established genetically-induced mouse model of obesity and 
diabetes, the C57 BL/KsJ diabetic (db/db) mouse was employed to examine not only 
the glucose-lowering and insulinotropic properties of [D-Ala
2
]GIP-Oxm, but also 
other aspects that related to bone microstructure and strength. In agreement with 
earlier observations, db/db mice displayed progressive body weight gain, 
hyperglycaemia and hyperinsulinemia (Coleman 1978, Flatt et al. 1983). The 
increase in body weight was associated with a significant increase in fat mass. In 
contrast to a recent study in high-fat fed mice, [D-Ala
2
]GIP-Oxm administration for 
21 days had no effect on body weight in db/db mice (Bhat et al. 2013). On the other 
hand, non-fasting plasma insulin concentrations were noticeably increased on day 20 
in treated db/db mice.  
 
When comparison is made between non-fasting plasma insulin levels in the present 
study and STZ study (Chapter 4), insulin concentrations were surprisingly lowered 
in db/db mice to similar levels to STZ mice. An explanation for this could be due to 
insulin-producing beta cell degeneration as the db/db mice age. It is also well-
established that following STZ administration, pancreatic beta cells can undergo 
regeneration from replication of surviving intra-islet beta cells (Bonner-Weir et al. 
1981, Wang et al. 1994) and as a result, increased insulin production in STZ mice. 
[D-Ala
2
]GIP-Oxm therapy also failed to improve glycemic response to glucose load 
in db/db mice, unlike previous study in high-fat mice (Bhat et al. 2013). This 
difference is possibly due to the severity of the mouse model used in our study as 
even after food was withdrawn for 18 h, plasma glucose levels in db/db mice were 
still very high at around 22.5 mmol/L, whereas 18-h fasted high-fat fed mice in 
Bhat’s study (2013) had much lower plasma glucose concentrations of 
approximately 10.0 mmol/L. In order to standardize the data for metabolic 
parameters of db/db mice, lean group was not included. The lean controls were only 
used for comparative purposes in bone assessment. 
 
Insulin is known to induce bone formation (Cornish et al. 1996) and in Chapter 4, we 
clearly revealed that hypoinsulinemia in STZ-diabetic mice contributes to bone loss. 
Therefore, the leptin receptor-deficient model which exhibited hyperinsulinemia or 
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insulin resistance was used in this study. To date, only Bhat and colleagues have 
examined glucose-lowering and insulin-releasing activity of the recently-developed 
peptide, [D-Ala
2
]GIP-Oxm (Bhat et al. 2013) with no reports on the impact of the 
peptide on skeletal microstructure and strength. In the present study, we found that 
total, femur, tibia and lumbar bone mineral density and bone mineral content were 
significantly decreased in db/db mice and this supported earlier observations that 
also found reduced BMD and BMC in mice lacking leptin receptors (Ealey et al. 
2006). In agreement with DEXA scanning, GLmean and absorbing material density, 
which represents bone mineral content, were also reduced at both femoral cortical 
and trabecular bone.  
 
One of the possible contributing factors to the reductions of bone mass in db/db mice 
is loss in leptin signaling. Osteoblasts and adipocytes are derived from the same 
progenitors, marrow stromal cells (MSCs), and interestingly, leptin receptors were 
proven to be expressed on human MSCs (Thomas et al. 1999). In addition, the 
presence of leptin dose-dependently enhanced osteoblastic protein expression and 
reduced biomarkers for mature adipocytes in cultures of MSCs, emphasising the 
importance of leptin in controlling differentiation pathways of MSC precursors either 
into osteoblasts or adipocytes (Thomas et al. 1999). As a result of defective leptin 
signal transduction, differentiation of precursors is shifted to adipogenesis, hence 
grossly increased body weight and bone loss, leading to bone impairments. 
Furthermore, leptin has previously been reported to inhibit the production of bone-
resorbing osteoclast cells (Holloway et al. 2002). Thus, deficiency in leptin signaling 
may enhance generation of osteoclasts and increase osteoclastic bone resorptive 
activity, resulting in further bone loss. Once daily administration of [D-Ala
2
]GIP-
Oxm did not have a remarkable effect on BMD, BMC, GLmean or absorbing 
material density of db/db mouse bone when compared to saline-treated db/db 
controls. This is not surprising as examinations of bone by DEXA and qXRI were 
conducted at the macrostructure level of the skeleton and with the short period of 
treatment, any improvements in bone health may not be seen by these methods.  
 
Further assessments performed on the microstructure and morphology of specific 
areas of bone by microCT revealed that db/db mice had reduced trabecular bone 
volume, which contributed to a decrease in trabecular thickness. In line with 
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previous literature, bone mass reduction was also accompanied by less numbers of 
trabecular and higher trabecular separation (Williams et al. 2011). In addition, 
midshaft cortical diameter, bone marrow, cortical thickness and CSMI in db/db mice 
were all markedly reduced compared to lean littermates, suggesting that cortical 
bone was also severely compromised. Microstructural examination demonstrated 
that not only cortical bone diameter in db/db mice was increased with 21-day therapy 
with [D-Ala
2
]GIP-Oxm, but the regimen also significantly elevated trabecular 
thickness. Taken together, these improvements contribute to increased bone mass.  
 
In Chapter 4, cortical bone area, bone mechanical and intrinsic material properties 
were severely affected in STZ-diabetic mice. Importantly, material properties were 
restored in diabetic mice that received [D-Ala
2
]GIP or Liraglutide once daily. 
Similar to STZ-induced diabetic models, db/db mice displayed impaired cortical 
bone properties that lead to decreased bone strength. The effects of leptin receptor 
deficiency were further evaluated on whole-bone strength by three-point bending 
tests and femurs of db/db mice required less breaking force than lean control mice, 
indicating lower bone strength. Nanoindentation, which is independent of bone 
geometry and porosity (Rho et al 1997), was carried out to further strengthen the 
findings in three-point bending. Consistent with previous observations, hardness, 
indentation modulus and dissipated energy were reduced in db/db mice, suggesting 
that mechanical properties of bone matrix were adversely affected (Williams et al. 
2011). In order to determine if these modifications resulted from changes in calcium 
distribution, qBEI was performed, but no significant differences in Capeak and Camean 
was observed in all three groups. Athough db/db mice exhibited a significant 
increase in cortical Cawidth in comparison to lean mice, which represents 
heterogeneity of calcium deposition, no alteration of quantity or frequency of 
calcium mineral means overall mineralisation was unchanged.  
 
Most importantly, femurs excised from db/db mice that received [D-Ala
2
]GIP-Oxm 
appeared to have higher cortical resistance to fracture, supported by significant 
increments in maximum displacement at maximum force, and amount of work 
required to break the bone as compared to saline-treated db/db controls.  The 
increase in whole-bone strength was associated not only by elevations in hardness 
and stiffness at cortical tissue level, but also at organ level where there was 
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enhancement of bone mass from increases in cortical and trabecular bone diameter 
and thickness, respectively. Improvement in material properties of bone matrix is 
significant as intrinsic mechanical response was identical to the response in lean 
mice. Similar to what we have seen with [D-Ala
2
]GIP and Liraglutide therapy, the 
anabolic effects of [D-Ala
2
]GIP-Oxm on bone are independent of mineralisation 
distribution with respect to calcium content, as no differences were seen in bone 
mineral density distribution. Activation of GIPR or GLP-1R has beneficial effects on 
bone as discussed in Chapter 3 and 4 and therefore, it is not surprising to see that co-
activation of both incretin receptors had pronounced beneficial effects on restoration 
of bone quality in db/db mice. On the other hand, the effect of activation of glucagon 
receptors on bone is relatively unknown. Additionally, histomorphometrical and 
gene expression studies are needed to confirm the participation of osteoblasts and/or 
osteoclasts, and to establish the possible signaling pathways of this long-acting Oxm 
analogue on bone.  
 
In conclusion, this study reveals that both cortical and trabecular bone of db/db mice 
are detrimentally altered. Moreover, the DPP-4 resistant [D-Ala
2
]GIP-Oxm analogue 
elicits significant beneficial effects on both types of bone by increasing trabecular 
thickness, cortical diameter and bone strength at the tissue and organ level. The 
positive effects of triple-activation of GIPR, GLP-1R and glucagon receptors by [D-
Ala
2
]GIP-Oxm on bone quality in db/db mice provides additional evidence to 
include incretins in therapeutic strategies for bone-related diseases. Additionally, it 
would be interesting to study and characterise the potential actions of established 
incretin-based therapies on bone quality in other diabetic mouse models such as the 
high-fat dietary induced obesity and insulin resistance. 
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Figure 5.1 : Effects of once daily administration of  [D-Ala
2
]GIP-Oxm on body 
weight in db/db mice 
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Body weight was measured every 2 days, starting 4 days prior to treatment. Mice 
were treated once daily with saline vehicle (0.9%, w/v, NaCl) or (D-Ala
2
)GIP-Oxm 
(50 nmol/kg b.w) for 21 days (horizontal black bar). Values are mean ± S.E.M for 5-
6 mice.  
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Figure 5.2 : Effects of once daily administration of [D-Ala
2
]GIP-Oxm on 
cumulative food intake in db/db mice 
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Food intake was measured every 2-3 days, starting 4 days prior to treatment. Mice 
received daily treatment with saline vehicle (0.9%, w/v, NaCl) or (D-Ala
2
)GIP-Oxm 
(50 nmol/kg b.w) for 21 days. Values are mean ± S.E.M for 5-6 mice.  
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Figure 5.3 : Effects of once daily administration of [D-Ala
2
]GIP-Oxm on fluid 
intake in db/db mice 
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Water intake was measured 4 days prior to treatment. Mice were injected once daily 
with saline vehicle (0.9%, w/v, NaCl) or (D-Ala
2
)GIP-Oxm (50 nmol/kg b.w) for 21 
days (horizontal black bar). Values are mean ± S.E.M for 5-6 mice.  
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Figure 5.4 : Effects of once daily administration of [D-Ala
2
]GIP-Oxm on non-
fasting blood glucose and plasma insulin concentrations  in db/db mice 
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Mice were injected once daily with saline vehicle (0.9%, w/v, NaCl) or (D-
Ala
2
)GIP-Oxm (50 nmol/kg b.w) for 21 days (horizontal black bar). Blood was 
collected at 5-day intervals. Values are expressed as mean ± S.E.M for 5-6 mice. **P 
< 0.01 compared with db/db control group. 
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Figure 5.5 : Effects of once daily administration of [D-Ala
2
]GIP-Oxm on glucose 
tolerance in db/db mice 
 
A) 
0 15 30 45 60
0
10
20
30
40
db/db control
(D-Ala2)GIP-Oxm

Time (min)
P
la
s
m
a
 g
lu
c
o
s
e
 (
m
m
o
l/
l)
 
 
B) 
0
200
400
600
800
1000
db/db control
(D-Ala2)GIP-Oxm
P
la
s
m
a
 g
lu
c
o
s
e
 A
U
C
 (
m
m
o
l/
l.
m
in
)
 
 
Tests were conducted following 21 days once daily treatment with saline (0.9%, w/v, 
NaCl) or (D-Ala
2
)GIP-Oxm (50 nmol/kg b.w) in db/db mice. Glucose alone (18 
mmol/kg b.w) was intraperitoneally administered at time 0 (indicated by the arrow) 
in 18 h fasted mice and concentrations of plasma glucose recorded at 15, 30 and 60 
min post-injection. Plasma glucose AUC values (determined by using mean value at 
0 min as a baseline) are also shown (B). Values are mean ± S.E.M for 5-6 mice per 
group. 
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Figure 5.6 : Effects of once daily administration of [D-Ala
2
]GIP-Oxm on 
glucose-induced insulin release in db/db mice 
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Tests were conducted following 21 days once daily treatment with saline (0.9%, w/v, 
NaCl) or (D-Ala
2
)GIP-Oxm (50 nmol/kg b.w) in db/db mice. Glucose alone (18 
mmol/kg b.w) was intraperitoneally administered at time 0 (indicated by the arrow) 
in 18 h fasted mice and concentrations of plasma insulin recorded at 15, 30 and 60 
min post-injection. Plasma insulin AUC values (determined by using mean value at 0 
min as a baseline) are also shown (B). Values are mean ± S.E.M for 5-6 mice per 
group.  
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Figure 5.7 : Effects of once daily administration of [D-Ala
2
]GIP-Oxm on insulin 
sensitivity in db/db mice 
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Tests were performed after once daily treatment with saline (0.9%, w/v, NaCl) or (D-
Ala
2
)GIP-Oxm (50 nmol/kg b.w) for 21 days in db/db mice. A) Insulin (50 U/kg 
b.w) was administered at time 0 (indicated by the arrow) in non-fasted mice. B) 
Blood glucose AUC values (determined by using mean value at 0 min as a baseline) 
for 0-60 min post-injection. Values represent the means ± S.E.M for 5-6 mice per 
group.  
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Figure 5.8 : Effects of once daily administration of [D-Ala
2
]GIP-Oxm on total 
body fat in db/db mice 
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Body fat was measured by dual energy X-ray absorption after once daily 
administration of saline (0.9%, w/v, NaCl) or (D-Ala
2
)GIP-Oxm (50 nmol/kg b.w) 
for 21 days in db/db mice. Lean mice were used for comparative purposes. Values 
are expressed as mean ± S.E.M for 5-6 mice per group. ***P < 0.001 compared with 
lean control group. 
 
 
 
 
 
 
 
 
 
 
 
 
160 
 
Figure 5.9 : Effects of once daily administration of [D-Ala
2
]GIP-Oxm on A) 
total bone mineral density (BMD) and B) total bone mineral content (BMC) in 
db/db mice 
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Parameters were measured by dual energy X-ray absorption following 21 days once 
daily administration of saline (0.9%, w/v, NaCl) or (D-Ala
2
)GIP-Oxm (50 nmol/kg 
b.w) in db/db mice. Lean mice were used for comparative purposes. Values are mean 
± S.E.M for 5-6mice. 
***
P < 0.001 compared to lean control group. 
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Figure 5.10 : Effects of once daily administration of [D-Ala
2
]GIP-Oxm on 
lumbar A) bone mineral density (BMD) and B) bone mineral content (BMC) in 
db/db mice 
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Parameters were assessed by dual energy X-ray absorption following 21 days once 
daily administration of saline (0.9%, w/v, NaCl) or (D-Ala
2
)GIP-Oxm (50 nmol/kg 
b.w) in db/db mice. Lean mice were used for comparative purposes. Values are mean 
± S.E.M for 5-6 mice per group. ***P < 0.001 compared with lean control group. 
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Figure 5.11 : Effects of once daily administration of [D-Ala
2
]GIP-Oxm on 
femoral A) bone mineral density (BMD) and B) bone mineral content (BMC) in 
db/db mice 
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Parameters were measured by dual energy X-ray absorption following 21 days once 
daily administration of saline (0.9%, w/v, NaCl) or (D-Ala
2
)GIP-Oxm (50 nmol/kg 
b.w) in db/db mice. Lean mice were used for comparative purposes. Values are mean 
± S.E.M for 5-6 mice. ***P < 0.001 compared with lean control group. 
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Figure 5.12 : Effects of once daily administration of [D-Ala
2
]GIP-Oxm on tibial 
A) bone mineral density (BMD) and B) bone mineral content (BMC) in db/db 
mice 
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Parameters were measured by dual energy X-ray absorption following 21 days of 
once daily administration of saline (0.9%, w/v, NaCl) or (D-Ala
2
)GIP-Oxm (50 
nmol/kg b.w) in db/db mice. Lean mice were used for comparative purposes. Values 
are mean ± S.E.M for 5-6 mice. ***P < 0.001 compared with lean control group. 
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Figure 5.13 : Effects of once daily administration of [D-Ala
2
]GIP-Oxm on 
femoral cortical bone mineral content in db/db mice 
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Cortical bone mineral content was measured by quantitative x-ray microradiograph 
following 21 days once daily administration of saline (0.9%, w/v, NaCl) or (D-
Ala
2
)GIP-Oxm (50 nmol/kg b.w) in db/db mice. Lean mice were used for 
comparative purposes. A) Digital x-ray images of femoral cortical bone with 16-
color look-up table. B) Mean grey level. C) Cortical absorbing mineral density. 
Values are mean ± S.E.M for 5-6 mice. ***P < 0.001 compared with lean control. 
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Figure 5.14 : Effects of once daily administration of [D-Ala
2
]GIP-Oxm on 
femoral cancellous bone mineral content in db/db mice 
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Cancellous bone mineral content was measured by quantitative x-ray 
microradiograph following 21 days once daily administration of saline (0.9%, w/v, 
NaCl) or (D-Ala
2
)GIP-Oxm (50 nmol/kg b.w) in db/db mice. Lean mice were used 
for comparative purposes. A) Digital x-ray images of femoral cancellous bone with 
16-color look-up table B) Mean grey level. C) Trabecular absorbing mineral density. 
Values are mean ± S.E.M for 5-6 mice. ***P < 0.001 compared with lean control. 
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Figure 5.15 : Effects of once daily administration of [D-Ala
2
]GIP-Oxm on 
trabecular bone mass and microarchitecture in db/db mice 
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Parameters were obtained from microtomography scan following 21 days once daily 
administration of saline (0.9%, w/v, NaCl) or (D-Ala
2
)GIP-Oxm (50 nmol/kg b.w) in 
db/db mice. Lean mice were used for comparative purposes. Values are mean ± 
S.E.M for 5-6 mice. **P < 0.01, ***P < 0.001 compared with lean control group, 
Δ
P 
< 0.05 compared with db/db control group. 
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Figure 5.16 : Effects of once daily administration of [D-Ala
2
]GIP-Oxm on 
cortical bone geometry in db/db mice 
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Bones were scanned using high resolution microtomography following 21 days once 
daily administration of saline (0.9%, w/v, NaCl) or (D-Ala
2
)GIP-Oxm (50 nmol/kg 
b.w) in db/db mice. Lean mice were used for comparative purposes. Parameters were 
measured 3 mm below growth plate at cortical bone, A) Diameter of bone, B) 
diameter of bone marrow, C) cortical thickness and D) cross-sectional moment of 
inertia. Values are mean ± S.E.M for 5-6 mice. ***P < 0.001 compared with lean 
control. 
Δ
P < 0.05 compared to db/db saline control. 
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Figure 5.17: Effects of once daily administration of [D-Ala
2
]GIP-Oxm on 
mechanical properties of femoral cortical bone in db/db mice 
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Parameters were obtained from three-point bending test following 21 days once daily 
administration of saline (0.9%, w/v, NaCl) or (D-Ala
2
)GIP-Oxm (50 nmol/kg b.w) in 
db/db mice. Lean mice were used for comparative purposes. Values are mean ± 
S.E.M for 5-6 mice. **P < 0.01, ***P < 0.001 compared with lean control group, 
 Δ
P 
< 0.05, 
ΔΔ
P < 0.01compared with db/db control group. 
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Figure 5.18 : Effects of once daily administration of [D-Ala
2
]GIP-Oxm on 
intrinsic tissue properties of cortical bone in db/db mice 
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Parameters were measured by nanoindentation following 21 days once daily 
administration of saline (0.9%, w/v, NaCl) or (D-Ala
2
)GIP-Oxm (50 nmol/kg b.w) in 
db/db mice. Lean mice were used for comparative purposes. Values are mean ± 
S.E.M for 5-6 mice. *P < 0.05, **P < 0.01 compared with lean control. 
Δ
P < 0.05 
compared with db/db control. 
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Figure 5.19 : Effects of once daily administration of [D-Ala
2
]GIP-Oxm on 
cortical bone mineral density distribution (BMDD) in db/db mice 
 
A) 
0
5
10
15
20
25
Lean control
db/db control
[D-Ala2]GIP-Oxm
C
a
p
e
a
k
 (
%
 C
a
)
 
 
B) 
0
5
10
15
20
25
Lean control
db/db control
[D-Ala2]GIP-Oxm
C
a
m
e
a
n
 (
%
 C
a
)
 
 
 
 
 
 
177 
 
C) 
0
1
2
3
4
5
* **
Lean control
db/db control
[D-Ala2]GIP-Oxm
C
a
w
id
th
 (
%
 C
a
)
 
 
Bone mineralisation parameters were measured by quantitative backscattered 
electron imaging following 21 days once daily administration of saline (0.9%, w/v, 
NaCl) or (D-Ala
2
)GIP-Oxm (50 nmol/kg b.w) in db/db mice. Lean mice were used 
for comparative purposes. Values are mean ± S.E.M for 5-6 mice. *P < 0.05, **P < 
0.01 compared with lean control. 
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Chapter 6 
 
Effects of the GLP-1R agonist 
Exendin-4 and the DPP-4 inhibitor 
Sitagliptin on bone strength and 
quality in high-fat fed mice 
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6.1 SUMMARY 
 
Several currently available treatments for type 2 diabetes mellitus (T2DM) have 
been reported to negatively affect bone. The incretin-based therapies including, 
GLP-1 mimetics and DPPIV inhibitors, are new classes of drugs introduced for the 
treatment of T2DM. Although these agents are largely known to improve glycaemic 
control, their long-term effects on bone quality have not yet been fully established. 
This study examined the effects of daily treatment with the well-established GLP-1 
mimetic, Exendin-4 (25 mmol/kg bw, i.p) and DPP-IV inhibitor, Sitagliptin (50 
mmol/kg bw, orally) on metabolic control, bone mineral density, microarchitecture 
and strength inhigh-fat fed mice. Exendin-4 and Sitagliptin had no effect on body 
weight of high-fat fed mice. Reductions of non-fasting glucose (Exendin-4 : 58% 
decrease, P < 0.01; Sitagliptin : 41% decrease, P < 0.001) were accompanied by 
significant increases of non-fasting insulin (Exendin-4 : 83% increase, P < 0.01; 
Sitagliptin : 55% increase, P < 0.01) in treated compared to nontreated mice. 
Glucose tolerance (22-32%, decrease, P < 0.05) and insulin sensitivity (50-57% 
increase, P < 0.001) were improved with Exendin-4 and Sitagliptin treatment. As 
compared to lean mice, diabetic high-fat mice exhibited significant increases in total 
fat mass (27% increase, P < 0.01). However, no significant differences in fat mass of 
Exendin-4 or Sitagliptin treated mice when compared to high-fat controls. 
Administration of Exendin-4 or Sitagliptin did not affect on total, lumbar, femoral 
and tibial BMD and BMC in high-fat fed mice. In parallel, bone mineral content, as 
determined by GLmean and absorbing material density at both cortical and trabecular 
bones, did not change between Exendin-4- or Sitagliptin-treated and their saline-
treated diabetic controls. Administration of Exendin-4 marginally increased 
trabecular bone volume which contributed to the increase in trabecular numbers and 
reduction in trabecular separation. These changes however, did not reach statistical 
significance when compared to saline controls. Similarly, Sitagliptin treatment did 
not improve parameters measured at trabecular bone in high-fat fed mice. From 
assessment by microCT, high-fat diet altered cortical bone geometry resulting in 
marked increases in cortical bone diameter (10% increase, P < 0.05), bone marrow 
(18-25% increase, P < 0.001) and CSMI (49% increase, P < 0.05). These parameters 
were not improved by Exendin-4 or Sitagliptin therapy. In three-point bending tests, 
augmented resistance to fracture was observed (32% increase, P < 0.01) in diabetic 
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mice treated with Exendin-4 but not Sitagliptin, while ultimate force, ultimate 
displacement and stiffness remained unchanged in both treated groups. From this 
study, it is concluded that Exendin-4 improved whole-bone mechanical strength, 
whilst Sitagliptin has neutral effects on bone in high-fat fed mice. 
 
6.2  INTRODUCTION 
 
Bone remodeling is a continuous process throughout life and is coordinated by bone-
forming osteoblasts and bone-resorbing osteoclasts (Matsuo & Irie 2008). In this 
dynamic organ, maintenance of normal osteoblast-osteoclast communication is vital 
as imbalance in bone formation and resorption will reduce bone quality, leading to 
increased risk of fracture (Seeman 2002). Diabetes is closely associated with bone 
impairments and type 2 diabetes mellitus patients are highly susceptible to bone 
fragility fractures, despite having normal or elevated bone mineral density 
(Vestergaard, 2007). Emerging evidence on further bone loss with existing 
antidiabetic therapies such as thiazolidinediones (TZDs) (Schwartz et al. 2006) has 
lead to major concern on the safety of currently available diabetes treatment on bone. 
As newly-introduced class of antidiabetic drugs, the impact of incretin-based 
therapies on bone strength and quality remain largely unknown. 
 
Glucagon-like peptide-1 (GLP-1) is released in response to nutrient ingestion and 
stimulates glucose-dependent insulin secretion (Baggio & Drucker 2007). GLP-1 
also plays a role in delaying gastric emptying, inhibiting glucagon release and 
promoting satiety (Drucker & Nauck 2006). Furthermore, administration of GLP-1 
stimulates pancreatic beta-cells proliferation and reduces islet apoptosis (Li et al. 
2003, Xu et al. 1999). Therefore, the collective actions of GLP-1 make this molecule 
a promising therapeutic approach for type 2 diabetes mellitus (T2DM). As such, 
GLP-1-based therapies have now been developed for T2DM and the first approved 
drug in this class was Exendin-4 (Exenatide) (Lovshin & Drucker 2009). Exendin-4 
shares 53% sequence homology to mammalian GLP-1, and substitution of alanine 
with glycine at position 2 of the peptide protects the molecule from rapid 
degradation by the ubiquitous serine protease, dipeptidyl peptidase-4 (DPP-4). 
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DPP-4 inhibitor-based drugs were later developed to directly inhibit the actions of 
DPP-4 to degrade incretin hormones (Barnett 2006). As a result, this prolongs the 
glucoregulatory and insulinotropic actions of both incretin peptides, namely GLP-1 
and its sister incretin glucose-dependent insulinotropic polypeptide (GIP). Treatment 
with DPP-4 inhibitors enhances beta-cells regeneration and survival in STZ-induced 
diabetes model of mice (Pospisilik et al. 2003) and a more recent study found 
preservation of islet beta-cell mass and increase in pancreatic insulin content in 
isolated islets from high-fat fed mice treated with Sitagliptin (Mu et al. 2006). 
Sitagliptin (Januvia), was released onto the market in 2006 as orally administered 
drug for once-daily administration (Lovshin & Drucker 2009). Sitagliptin was 
proven to improve glycaemic control either in monotherapy or in combination with 
metformin or thiazolidinedione treatment (Aschner et al. 2006, Charbonnel et al. 
2006, Rosenstock et al. 2006). However, the effect of drugs such as Sitagliptin on 
bone turnover, strength and quality in diabetes remain largely unknown. 
 
In the present study we assessed the capacity of Exendin-4 and Sitagliptin to 
improve aspects of metabolic control, bone micromorphology and whole-bone 
mechanical strength in animal dietary-induced high-fat fed mice that present with 
overt obesity and insulin resistance. 
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6.3 MATERIALS AND METHODS 
 
6.3.1 Animals and study design 
 
Male NIH Swiss mice (n=16, 8 weeks old, Harlan Ltd., Blackthorn, UK) were 
individually housed in an air-conditioned room at 22 ± 2 with 12 h light : 12 h dark 
cycle, had free access to drinking water and high fat diet (45% fat, 20% protein, 35% 
carbohydrate; Special Diet Service, Essex, U.K.) for 16 weeks prior to the start of the 
studies. The mice were divided into two groups that received twice daily saline 
vehicle (0.9%, w/v, NaCl) or Exendin-4 (25 nmol/kg bw) intraperitoneally for 52 
days. For Sitagliptin studies, mice were maintained on high-fat diet for 20 weeks 
prior to start of the long-term studies. The mice were divided into two groups that 
received once daily saline vehicle (0.9%, w/v, NaCl) or Sitagliptin (50 nmol/kg bw) 
orally for 21 days. Lean mice also injected with saline vehicle and used for 
comparative purposes for both studies. Body weight, non-fasting blood glucose and 
insulin concentrations were observed at regular intervals. Glucose tolerance test (18 
mmol/kg bw, i.p, 18-h fast) and non-fasting insulin sensitivity test (25 U/kg bw, i.p) 
were performed at the end of the study as explained in Section 2.3.8 and 2.3.9, 
respectively. All experiments were performed according to UK Home Office 
Regulations (UK Animals Scientific Procedured Act 1986). 
 
6.3.2 Measurement of body composition, bone density and mineral content by 
DEXA scanning 
 
Unconcious mice were placed on a specimen tray and the whole body was imaged by 
DEXA scanner. Bone mineral density (BMD), bone mineral content (BMC), lean 
mass, fat mass and percentage of total fat of ROIs were measured as explained in 
Section 2.5. Age-matched lean controls (n=6-8) with the same genetic background 
were included for comparative purposes. 
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6.3.3 Assessment of bone mineral content by quantitative x-ray Imaging 
(qXRI) 
 
The diameter of femurs was measured and recorded, followed by the scanning 
processes. The femurs were imaged together with two standards, 1.5 mm-thick steel 
and polyester which represent grey 255 and 0, respectively. Bone mineral content 
was determined as detailed in Section 2.6.1. 
 
6.3.4 Assessment of trabecular bone morphology and cortical geometry by X-
ray microcomputed tomography (µCT) 
   
Tibias were tomographed as described in Section 2.6.2 and parameters that were 
obtained from the projections include bone mass, trabecular bone thickness, numbers 
of trabecular bone and trabecular separation. Cortical bone was located from a series 
of cross-sectional 3D images and ImageJ was used to determined cortical bone 
diameter and bone marrow diameter. Subsequently, cortical thickness and cross-
sectional moment of inertia were calculated based on equations given in Section 
2.6.2. 
 
6.3.5 Evaluation of extrinsic mechanical strength of bones  
 
Femurs were individually kept in test tubes containing saline (NaCl, 0.9%) and left 
overnight at 4
o
C. Three-point bending tests was carried out as described in Section 
2.6.3, and four mechanical properties were evaluated; ultimate load, ultimate 
displacement, stiffness and total absorbed energy (work-to-failure). 
 
6.3.6 Statistical analysis 
 
Data were analysed using repeated measures one-way or two-way ANOVA with 
Tukey’s post hoc tests or two-tailed t-tests using PRISM 5.0. Data are expressed as 
mean ± S.E.M and a P value < 0.05 was considered statistically significant. 
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6.4 RESULTS 
 
6.4.1  Effects of twice-daily administration of Exendin-4 on metabolic 
parameters, glucose tolerance and insulin sensitivity in high-fat fed Swiss TO 
mice. 
 
As shown in Table 6.1, twice-daily treatment of Exendin-4 for 52 days had no effect 
on body weight of high-fat fed mice. However, reduced non-fasting plasma glucose 
concentration (58% decrease, P < 0.01) and increased non-fasting insulin level (83% 
increase, P < 0.01) were observed in Exendin-4-treated high-fat mice compared to 
saline diabetic controls. In addition, significant improvement in glucose tolerance 
test (22%, P < 0.05) and insulin sensitivity (57%, P < 0.05) was also observed.  
 
6.4.2 Effects of once-daily administration of Sitagliptin on metabolic 
parameters, glucose tolerance and insulin sensitivity in high-fat fed Swiss TO 
mice. 
 
As seen in Table 6.2, once-daily treatment with Sitagliptin for 21 days had no effect 
on body weight of high-fat fed mice. Non-fasting plasma glucose concentrations 
were significantly reduced (41% decrease, P < 0.001) and this was accompanied by 
noticeable increases in non-fasting insulin levels (55% increase, P < 0.01) compared 
to diabetic controls. Improvement in glucose tolerance (32%, P < 0.001) and insulin 
sensitivity (50%, P < 0.001) was also observed.  
 
6.4.3 Effects of Exendin-4 and Sitagliptin on total body fat mass, bone mineral 
density and bone mineral content in high-fat fed NIH Swiss mice. 
 
High-fat diet significantly increased total body fat (27% increase, P < 0.01) of mice 
compared to lean littermate controls (Figure 6.1). Exendin-4 treatment for 52 days 
had no significant effect on percentage total body fat mass in high-fat diabetic mice. 
Bone densitometry which measured by bone mineral density (BMD) and bone 
mineral content (BMC) revealed that total BMD (Figure 6.2A) and BMD at lumbar 
(Figure 6.3A), femur (Figure 6.4A) and tibia (Figure 6.5A) were similar between 
high-fat diet and normal chow mice. Despite unchanged whole body BMC, tibial 
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BMC was markedly increased (14% increase, P < 0.01, Figure 6.5B) by high-fat 
feeding. Treatment with Exendin-4 had no effect on BMD and BMC of high-fat fed 
mice when compared with high-fat controls (Figure 6.2-6.5).  
 
Similar to high-fat mice in the Exendin-4 study, there was an increase (24% increase, 
P < 0.05, Figure 6.11) in percentage total body fat in mice consuming high-fat diet 
compared to mice feeding on normal chow in the Sitagliptin study. A modest 
reduction was seen in body fat mass of high-fat mice administered with Sitagliptin 
(Figure 6.11) but it was not significant when compared to saline high-fat controls. As 
compared to normal littermates, total BMD was unchanged in high-fat mice (Figure 
6.12A). However, high-fat diabetic mice had increased total BMC (12% increase, P 
< 0.05, Figure 6.12B). BMD at the lumbar region of high-fat diabetic mice was 
marginally higher than controls, however, the difference did not reach statistical 
significance (Figure 6.13A). On the other hand, lumbar BMC of high-fat mice was 
significantly increased (22% increase, P < 0.05, Figure 6.13B) when compared to 
lean controls. Femoral and tibial BMD and BMC were similar in high-fat and normal 
mice (Figure 6.14 & 6.15). Sitagliptin had no significant effect on BMD and BMC at 
whole body, femur, tibia and lumbar regions in high-fat mice (Figure 6.12-6.15).  
 
6.4.4 Effects of Exendin-4 and Sitagliptin on cortical and trabecular bone 
mineral content in high-fat fed NIH Swiss mice. 
 
As assessed by quantitative x-ray microradiographs, bone mineral content was not 
affected by high fat diet. GLmean and absorbing mineral density values at both 
cortical and trabecular were similar in lean and high-fat mice. In addition, treatment 
with either Exendin-4 (Figure 6.6 & 6.7) or Sitagliptin (Figure 6.16 & 6.17) did not 
show any significant differences when compared with high-fat controls. 
  
6.4.5 Effects of Exendin-4 and Sitagliptin on trabecular bone microstructural 
morphology and cortical bone geometry in high-fat fed NIH Swiss mice. 
 
Microarchitecture of tibia was assessed by microCT. For the Exendin-4 study, high-
fat mice exhibited significantly lowered bone volume (44% decrease, P < 0.01, 
Figure 6.8A), reduced trabecular numbers (45% decrease, P < 0.05, Figure 6.8C) and 
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increased trabecular separation (36% increase, P < 0.01, Figure 6.8D) compared with 
normal mice, while trabecular thickness (Figure 6.8B) was unchanged. Twice-daily 
administration of Exendin-4 slightly increased bone mass and trabecular numbers, 
while trabecular separation was reduced compared with high-fat fed control group 
(Figure 6.8). The differences however did not reach statistical significance (Figure 
6.8). At cortical bone, as shown in Figure 6.9, high-fat fed mice exhibited increased 
bone diameter (10% increase, P < 0.05, Figure 6.9A), bone marrow diameter (25% 
increase, P < 0.001, Figure 6.9B) and CSMI (49% increase, P < 0.05, Figure 6.9D) 
compared to lean mice, whilst cortical thickness (Figure 6.9C) was unchanged. 
Exendin-4 treatment had no effect on cortical bone geometry of high-fat mice 
(Figure 6.9A-D).  
 
In the Sitagliptin study, high-fat mice had a significant reduction in trabecular bone 
volume (28% decrease, P < 0.01, Figure 6.18A) and trabecular numbers (30% 
decrease, P < 0.01, Figure 6.18A), whilst trabecular thickness (Figure 6.18B) and 
separation (Figure 6.18D) were not significantly different than lean mice. Treatment 
with Sitagliptin did not change any of these parameters. As compared to lean 
controls, the high-fat mice displayed significantly increased cortical bone diameter 
(13% increase, P < 0.001, Figure 6.19A), bone marrow diameter (22% increase, P < 
0.01, Figure 6.19B) and CSMI (52% increase, P < 0.001, Figure 6.19D), whilst 
cortical thickness was not significantly different (Figure 6.19C). Cortical thickness 
and CSMI were slightly lowered (Figure 6.19C & 6.19D) in Sitagliptin-treated high-
fat mice, but the differences did not reach significance when compared to high-fat 
controls.  
 
6.4.6 Effects of Exendin-4 and Sitagliptin on mechanical properties of cortical 
bone in high-fat fed NIH Swiss mice. 
 
Mechanical properties of cortical bone were investigated using three-point bending 
tests. As seen in Figure 6.10, maintenance on high-fat diet did not affect ultimate 
force, ultimate displacement and stiffness in all three groups. However, work-to-
fracture was significantly reduced (34% decrease, P < 0.01) as compared to lean 
controls. Exendin-4 therapy increased (32% increase, P < 0.01) the work required to 
break the bone compared to diabetic controls (Figure 6.10D). Most importantly, the 
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improvement reached a similar work-to-failure level as lean mice. Similar to the 
Exendin-4 experiment, work-to-fracture in high fat controls from the Sitagliptin 
study was reduced although the reduction was not significantly different compared to 
lean mice (Figure 6.20D). Sitagliptin did not influence mechanical properties of bone 
tissue as no differences were observed during three-point bending tests (Figure 6.20). 
 
6.5 DISCUSSION 
 
Glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-
4) inhibitors are new classes of drugs introduced for treatment of type 2 diabetes 
mellitus (Lovshin & Drucker 2009). The target of incretin-based therapies is to 
sustain improvements in glycaemic control by prolonging or upregulating native 
incretin action (Drucker et al. 2010). Diabetic individuals are more susceptible to 
fractures as a result of decreased bone quality (Vestergaard 2011). Furthermore, 
short-term use of several existing antidiabetic drugs such as the thiazolidinediones 
(TZDs), are reported to cause bone mass deterioration in rodents (Rzonca et al. 2004, 
Soroceanu et al. 2004) and humans (Schwartz et al. 2006, Yaturu et al. 2007). 
However, little is known on the possible effects of clinically approved incretin-based 
treatments on bone strength and quality. Therefore, the present study assessed the 
impact of chronic administration of Exendin-4 and Sitagliptin on bone 
microstructure and mechanical strength in high-fat fed mice with dietary-induced 
obesity and insulin resistance.   
 
In agreement with previous observations, high-fat fed rodents exhibit significant 
body weight gain, developed mild hyperglycaemia and hyperinsulinemia with 
diminished glucose tolerance and insulin response to glucose loading (Porter et al. 
2010). Increase in body weight of high-fat mice is associated with a higher 
percentage of body fat mass as determined by DEXA. Chronic administration of 
Exendin-4 or Sitagliptin had no beneficial effect on body weight. However, the 
regimens significantly reduced non-fasting plasma glucose levels and augmented 
plasma insulin concentrations, as observed in previous studies (Gault et al. 2010, 
Gault et al. 2015). As compared to Sitagliptin study, non-fasting plasma glucose 
concentrations of HF control at the end of Exendin-4 study were doubled. Due to 
protocol of the separate studies, HF control group in Exendin-4 study had longer 
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access (36 weeks) to high-fat diet compared to HF controls in Sitagliptin study (24 
weeks). In general, excessive consumption of high-fat diet contributes to higher 
accumulation of saturated fats and increased release of inflammatory cytokines and 
other factors that can disrupt normal metabolic functions. As a result of extended 
intake of high-fat food, the HF mice in Exendin-4 study had deteriorated metabolic 
abnormalities and worsening of insulin resistance. Following administration of 
exogenous glucose or insulin, glucose tolerance and insulin sensitivity were also 
improved by Exendin-4 and Sitagliptin treatment, in agreement with others (Lamont 
& Drucker 2008).  
 
Diabetes-related bone loss compromises skeletal integrity and consistent with earlier 
observations, high-fat feeding also adversely affects bone microstructure and 
strength in mice (Cao et al. 2009, Ionova-Martin et al. 2010). Bone densitometry by 
DEXA showed that despite uchanged BMD, BMC in high-fat fed mice was actually 
increased compared to normal mice. Although we did not measure the length of 
long-bone, previous studies report that consumption of high-fat diet contributes to 
larger bone size, hence the increase in BMC (Ionova-Martin et al. 2010). However, 
estimation of bone mineral content and mineral density at trabecular and cortical 
bone of mice in the current study by qXRI revealed no significant differences. More 
importantly, neither Exendin-4 nor Sitagliptin therapy improved these parameters of 
bone mass. 
 
Bone microstructural assessment demonstrated that high-fat dietary-induced diabetic 
mice exhibited lower trabecular bone mass, which resulted from a reduction of 
trabecular bone volume and trabecular numbers, when compared with normal mice. 
Importantly, the impairments in trabecular bone have also been previously observed 
by Cao and colleagues and in their study, the reduction in structural parameters at 
trabecular bone was accompanied by increased RANKL to OPG ratio which was 
assessed in cultured osteoblasts derived from high-fat fed mice (Cao et al. 2009). 
RANKL plays major role in osteoclastogenesis by activating c-FOS and TRAF6 
molecular pathways (Lamothe et al. 2007, Takayanagi et al. 2002) and the function 
of RANKL is tightly regulated by a soluble decoy receptor secreted by osteoblasts, 
OPG (Kostenuik 2005). Increase in the RANKL to OPG ratio would enhance 
osteoclast activity and overall bone. The findings are further strengthened by 
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elevation of the serum biomarker for bone resorption, tartrate-resistant acid 
phosphatase (TRAP) in high-fat mice (Cao et al. 2009). 
  
Chronic administration of Exendin-4 or Sitagliptin failed to restore trabecular bone 
mass in high-fat diabetic mice. This is surprising as Exendin-4 has previously been 
shown to have significant beneficial effects on trabecular bone of streptozotocin-
induced and insulin-resistant diabetic mice (Nuche-Berenguer et al. 2010b). 
However, despite no significant differences in these trabecular bone parameters, 
cancellous bone of high-fat diabetic mice was improved by Exendin-4 therapy, as 
there were modest augmentations of bone volume and trabecular numbers as well as 
reduction in trabecular separation. Indeed, it is likely that if a longer period of 
Exendin-4 treatment was employed, normal trabecular bone mass may have been 
restored. The neutral effect of Sitagliptin on trabecular bone of high-fat fed male 
mice is unsurprising as similar observations have been reported previously (Kyle et 
al. 2011).  
 
As bone quality is determined by multiple factors, mechanical bone strength was 
also assessed. Mechanical testing is normally conducted at the bone midshaft of long 
bone which is mostly composed of cortical bone and this method directly evaluates 
the quality of compact bone. Previously, Cao and colleagues found that 14-week 
access to high-fat diet alters trabecular bone only, with no prominent changes at 
cortical bone (Cao et al. 2009). Interestingly, we found that cortical bone of high-fat 
diet mice was also detrimentally modified. Our findings support previous 
observations that reported a larger cortical femoral in high-fat fed mice (Ionova-
Martin et al. 2010) as also seen by the increase of outer cortical bone diameter in our 
study. The significant elevation of cortical bone diameter was accompanied by 
increased bone marrow diameter with unchanged cortical thickness when examined 
by microCT. In a previous study, histological examination demonstrated the 
presence of an abundance of adipocytes in the bone marrow area of high-fat mice, 
and it is possible that expansion of marrow cavity seen in our study is related to an 
increased number of adipocytes (Halade et al. 2010). 
 
However, there were small inconsistencies in the effects of high-fat diet on 
mechanical properties of cortical bone in the two separate studies within this 
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Chapter. As such, in the Exendin-4 study, untreated high-fat diabetic had general 
reduction in mechanical bone strength which associated with significantly reduced 
work to fracture as compared to normal mice. Although the same parameter was also 
slightly reduced in saline-treated diabetic mice with the Sitagliptin study, the 
reduction did not reach statistical significance. This is probably due to different 
durations the mice were maintained on the high-fat diet as the Exendin-4 study was 
longer, allowing further damage to cortical bone by high-fat feeding. As assessed by 
microCT, cortical bone increased in size, but despite having larger bone, size-
dependent bone strength as assessed by three-point bending test was diminished in 
diabetic mice, indicating decreased bone quality. 
 
Cortical bone from Exendin-4 treated high-fat mice was more resistant to fracture as 
compared to diabetic control mice and most importantly, the energy required to 
break femurs was similar to lean controls. In a study carried out by Nuche-Berenguer 
et al., they found that Exendin-4 treatment increased OPG to RANKL expression and 
that it also normalised the ratio of LRP5 to DKK1 (Nuche-Berenguer et al. 2010b). 
Elevation of OPG is associated with reduced osteoclastogenesis as it binds to key 
mediator for osteoclast differentiation, RANKL and thus, attenuating RANKL 
bioactivity (Khosla 2001). On the other hand, LRP5 is an activator of canocical Wnt 
signaling and its function is blocked by DKK1 (Johnson et al. 2004). Therefore, 
normalisation of LRP5 to DKK1 in diabetic mice could correct this Wnt signaling 
pathway together with downstream genes involved in osteoblastic bone formation. 
This could be the mechanism to explain the beneficial effect of Exendin-4 observed 
in the current study. Unlike Exendin-4, Sitagliptin treatment had no beneficial effect 
on whole-bone mechanical strength in high-fat dietary mice. This likely reflects the 
low circulating levels of incretin achieved with DPP-4 inhibitor, as opposed to 
exogenous injection of relatively large doses of stable incretin mimetics. 
 
In Chapter 4 and 5 of this thesis, pharmacologically- and genetically-induced 
diabetic mice exhibited bone impairments and once daily administration of stable 
GIPRs or/and GLP-1Rs agonists were shown to improve bone quality in those 
models of diabetes. The data in this Chapter show that induction of diabetes by  
prolonged feeding of high-fat diet also perturbs the microstructure of trabecular and 
cortical bone, leading to low bone strength. Despite lack of effects on trabecular 
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bone, there was cortical bone restoration with Exendin-4, but not Sitagliptin, 
treatment. However, further investigation is required to establish the mechanism of 
action and elucidate the anabolic effects of Exendin-4 on bone strength.  
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Table 6.1 Effects of twice-daily administration of Exendin-4 on metabolic 
parameters in high-fat fed mice 
 
Parameter 
 
HF control Exendin-4 Lean control 
Body weight (g) 
 
58.2 ± 2.53 54.1 ± 1.33 42.7 ± 2.08*** 
Non-fasting glucose 
(mM) 
 
22.5 ± 2.67  9.3 ± 2.16** 4.9 ± 0.19*** 
Non-fasting insulin 
(ng/ml) 
 
2.5 ± 0.37 4.6 ± 0.51** 1.8 ± 0.34 
Glucose Tolerance 
(AUC0-60min) 
(mmol/l.min) 
 
1042.8 ± 101.8 809.62 ± 24.95* 718.55 ± 72.88** 
Insulin Sensitivity 
(AAC0-60min) 
(% change plasma 
glucose) 
 
1166 ± 127.0 1828 ±155.4* 2192 ± 129.9*** 
 
Mice were maintained on high-fat diet for 16 weeks and parameters were recorded 
after twice daily administration of saline (0.9%, w/v, NaCl) or Exendin-4 (25 
nmol/kg b.w) for 52 days. AUC, area under curve; AAC, area above curve. Data 
represent means ± S.E.M for 8 mice per group. *P < 0.05, **P < 0.01, ***P < 0.001 
compared to saline high-fat group. 
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Figure 6.1 : Effects of twice-daily administration of Exendin-4 on total body fat 
in high-fat fed mice 
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Body fat was measured by dual energy X-ray absorption after twice daily 
administration of saline (0.9%, w/v, NaCl) or Exendin-4 (25 nmol/kg b.w) for 52 
days. Values are expressed as mean ± S.E.M for 8 mice per group. **P < 0.01 
compared to lean control group. 
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Figure 6.2 : Effects of twice-daily administration of Exendin-4 on A) total bone 
mineral density (BMD) and B) total bone mineral content (BMC) in high-fat fed 
mice 
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Parameters were measured by dual energy X-ray absorption following 52 days twice 
daily administration of saline (0.9%, w/v, NaCl) or Exendin-4 (25 nmol/kg b.w). 
Values are mean ± S.E.M for 8 mice.  
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Figure 6.3 : Effects of twice-daily administration of Exendin-4 on lumbar A) 
bone mineral density (BMD) and B) bone mineral content (BMC) in high-fat 
fed mice 
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Parameters were measured by dual energy X-ray absorption following 52 days twice 
daily administration of saline (0.9%, w/v, NaCl) or Exendin-4 (25 nmol/kg b.w). 
Values are mean ± S.E.M for 8 mice.  
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Figure 6.4 : Effects of twice-daily administration of Exendin-4 on femoral A) 
bone mineral density (BMD) and B) bone mineral content (BMC) in high-fat 
fed mice 
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Parameters were measured by dual energy X-ray absorption following 52 days twice 
daily administration of saline (0.9%, w/v, NaCl) or Exendin-4 (25 nmol/kg b.w). 
Values are mean ± S.E.M for 8 mice.  
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Figure 6.5 : Effects of twice-daily administration of Exendin-4 on tibial A) bone 
mineral density (BMD) and B) bone mineral content (BMC) in high-fat fed mice 
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Parameters were measured by dual energy X-ray absorption after twice daily 
administration of saline (0.9%, w/v, NaCl) or Exendin-4 (25 nmol/kg b.w) for 52 
days. Values are expressed as mean ± S.E.M for 8 mice per group. **P < 0.01 
compared to lean control group. 
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Figure 6.6 : Effects of twice-daily administration of Exendin-4 on femoral 
cortical bone mineral content in high-fat fed mice 
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Cortical bone mineral content was measured by quantitative x-ray microradiograph 
following 52 days twice daily administration of saline (0.9%, w/v, NaCl) or 
Exendin-4 (25 nmol/kg b.w) A) Digital x-ray images of femoral cortical bone with 
16-color lookup table B) Mean grey level C) Absorbing material density. Values are 
mean ± S.E.M for 8 mice.  
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Figure 6.7 : Effects of twice-daily administration of Exendin-4 on femoral 
cancellous bone mineral content in high-fat fed mice 
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Cancellous bone mineral content was measured by quantitative x-ray 
microradiograph following 52 days twice daily administration of saline (0.9%, w/v, 
NaCl) or Exendin-4 (25 nmol/kg b.w). A) Digital x-ray images of femoral cancellous 
bone with 16-color lookup table. B) Mean grey level. C) Absorbing material density 
Values are mean ± S.E.M for 8 mice. 
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Figure 6.8 : Effects of twice-daily administration of Exendin-4 on trabecular 
bone mass and microarchitecture in high-fat fed mice 
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Parameters were obtained from a microtomography scan following 52 days twice 
daily administration of saline (0.9%, w/v, NaCl) or Exendin-4 (25 nmol/kg b.w). 
Values are mean ± S.E.M for 8 mice. *P <0.05, **P < 0.01, compared with lean 
control. 
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Figure 6.9 : Effects of twice-daily administration of Exendin-4 on cortical bone 
geometry in high-fat fed mice 
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Bones were scanned using a high resolution microtomography scanner following 52 
days twice daily administration of saline (0.9%, w/v, NaCl) or Exendin-4 (25 
nmol/kg b.w). Parameters were measured 3 mm below growth plate at cortical bone, 
A) Diameter of bone, B) diameter of bone marrow, C) cortical thickness and D) 
cross-sectional moment of inertia.Values are mean ± S.E.M for 8 mice. *P < 0.05, 
***P <0.001 compared with lean control. 
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Figure 6.10 : Effects of twice-daily administration of Exendin-4 on mechanical 
properties of femoral cortical bone in high-fat fed mice 
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Parameters were obtained from three-point bending test following 50 days twice 
daily administration of saline (0.9%, w/v, NaCl) or Exendin-4 (25 nmol/kg b.w). 
Values are mean ± S.E.M for 8 mice. **P < 0.01 compared with high-fat control 
group. 
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Table 6.2 Effects of once-daily administration of Sitagliptin on metabolic 
parameters in high-fat fed mice 
 
Parameter 
 
HF control Sitagliptin Lean control 
Body weight (g) 
 
55.8 ±1.26 53.6 ± 0.94 45 ± 2.45*** 
Non-fasting glucose 
(mM) 
 
11.4 ± 1.25 6.7 ± 0.41*** 6.7 ± 0.59*** 
Non-fasting insulin 
(ng/ml) 
 
2.0 ± 0.43 3.1 ± 0.39** 1.7 ± 0.57 
Glucose Tolerance 
(AUC0-60min) 
(mmol/l.min) 
 
614.3 ± 40.1 418.2 ± 74.4*** 417.3 ± 31.9*** 
Insulin Sensitivity 
(AAC0-60min) 
(% change plasma 
glucose) 
 
1054.4 ± 180.7 1576.9 ±187.5*** 2239.7 ± 173.5*** 
 
Mice were maintained on high-fat diet for 20 weeks and parameters were recorded 
after once daily administration of saline (0.9%, w/v, NaCl) or Sitagliptin (50 
nmol/kg b.w) for 21 days. AUC, area under curve; AAC, area above curve. Data are 
presented as means ± S.E.M for 6 mice per group. **P < 0.01, ***P < 0.001 
compared to saline high-fat group. 
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Figure 6.11 : Effects of once daily administration of Sitagliptin on total body fat 
as measured by DEXA scanning in high-fat fed mice 
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Body fat was measured by dual energy X-ray absorption after once daily 
administration of saline (0.9%, w/v, NaCl) or Sitagliptin (50 nmol/kg b.w) for 21 
days. Values are expressed as mean ± S.E.M for 6 mice per group. *P < 0.05, **P < 
0.01 compared to lean control group. 
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Figure 6.12 : Effects of once daily administration of Sitagliptin on A) total bone 
mineral density (BMD) and B) total bone mineral content (BMC) in high-fat fed 
mice 
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Parameters were measured by dual energy X-ray absorption following 21 days once 
daily administration of saline (0.9%, w/v, NaCl) or Sitagliptin (50 nmol/kg b.w). 
Values are mean ± S.E.M for 6 mice. *P < 0.05, **P < 0.01 compared to lean control 
group. 
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Figure 6.13 : Effects of once daily administration of Sitagliptin on lumbar A) 
bone mineral density (BMD) and B) bone mineral content (BMC) in high-fat 
fed mice 
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Parameters were measured by dual energy X-ray absorption following 21 days once 
daily administration of saline (0.9%, w/v, NaCl) or Sitagliptin (50 nmol/kg b.w). 
Values are mean ± S.E.M for 6 mice. *P < 0.05 compared to lean control group. 
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Figure 6.14 : Effects of once daily administration of Sitagliptin on femoral A) 
bone mineral density (BMD) and B) bone mineral content (BMC) in high-fat 
fed mice 
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Parameters were measured by dual energy X-ray absorption following 21 days once 
daily administration of saline (0.9%, w/v, NaCl) or Sitagliptin (50 nmol/kg b.w). 
Values are mean ± S.E.M for 6 mice.  
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Figure 6.15 : Effects of once daily administration of Sitagliptin on tibial A) bone 
mineral density (BMD) and B) bone mineral content (BMC) in high-fat fed mice 
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Parameters were measured by dual energy X-ray absorption following 21 days once 
daily administration of saline (0.9%, w/v, NaCl) or Sitagliptin (50 nmol/kg b.w). 
Values are mean ± S.E.M for 6 mice.  
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Figure 6.16 : Effects of once daily administration of Sitagliptin on femoral 
cortical bone mineral content in high-fat fed mice 
 
A) 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
LEAN CONTROL HF CONTROL HF SITAGLIPTIN 
215 
 
B) 
0
50
100
150
200
Lean control
HF control
HF Sitagliptin
G
L
 m
e
a
n
 
 
C) 
0.0
0.2
0.4
0.6
0.8
1.0
Lean control
HF control
HF Sitagliptin
C
o
rt
ic
a
l 
A
M
D
 (
g
/c
m
3
)
 
 
Cortical bone mineral content was measured by quantitative x-ray microradiograph 
following 21 days once daily administration of saline (0.9%, w/v, NaCl) or 
Sitagliptin (50 nmol/kg b.w). A) Digital x-ray images of femoral cortical bone with 
16-color lookup table B) Mean grey level C) Absorbing material density. Values are 
mean ± S.E.M for 6 mice.  
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Figure 6.17 : Effects of once daily administration of Sitagliptin on femoral 
cancellous bone mineral content in high-fat fed mice 
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Cancellous bone mineral content was measured by quantitative x-ray 
microradiograph following 21 days once daily administration of saline (0.9%, w/v, 
NaCl) or Sitagliptin (50 nmol/kg b.w). A) Digital x-ray images of femoral cortical 
bone with 16-color lookup table. B) Mean grey level C) Absorbing material density. 
Values are mean ± S.E.M for 6 mice.  
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Figure 6.18 : Effects of once daily administration of Sitagliptin on trabecular 
bone mass and microarchitecture in high-fat fed mice 
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Parameters were obtained from microtomography scan following 21 days once daily 
administration of saline (0.9%, w/v, NaCl) or Sitagliptin (50 nmol/kg b.w). Values 
are mean ± S.E.M for 6 mice. *P < 0.05, **P < 0.01, compared to lean control group.  
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Figure 6.19 : Effects of once daily administration of Sitagliptin on cortical bone 
geometry in high-fat fed mice 
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Parameters were obtained from microtomography scan following 21 days once daily 
administration of saline (0.9%, w/v, NaCl) or Sitagliptin (50 nmol/kg b.w). Values 
are mean ± S.E.M for 6 mice. *P < 0.05, **P < 0.01, ***P < 0.001 compared to lean 
control group. 
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Figure 6.20 : Effects of once daily administration of Sitagliptin on mechanical 
properties of femoral cortical bone in high-fat fed mice 
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Parameters were obtained from 3-point bending test following 21 days once daily 
administration of saline (0.9%, w/v, NaCl) or Sitagliptin (50 nmol/kg b.w). Values 
are mean ± S.E.M for 6 mice.  
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General discussion 
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7.1  Introduction 
 
Diabetes mellitus is now considered as one of the world’s major health problems as 
rapidly increasing numbers are reported and the burden that this metabolic disorder 
imposes on society is becoming more severe (International Diabetes Federation 
2015). Diabetes is characterised by high blood glucose levels, resulting from 
defective insulin production and/or utilisation. While T1DM is associated with 
inability of pancreatic beta cells to produce insulin, T2DM is largely due 
abnormalities in the secretion and action of insulin (Zimmet et al. 2001). Diabetes 
has detrimental effects on many other organs, including bone (Bouillon 1991). 
T1DM patients consistently have low BMD and in contrast, BMD of T2DM patients 
is either modestly elevated or unchanged (Vestergaard 2007). Nevertheless, both 
types of diabetes have been linked to increased risk of fragility fractures (Rakel et al. 
2008, Vestergaard 2007). With the growing prevalence of diabetes, many diabetic 
patients will develop bone metabolic abnormalities, leading to increased bone 
fracture risk (Janghorbani et al. 2007). 
 
Bone impairments have been reported in rodents and humans with diabetes 
(Vestergaard 2011). Recently, there has been growing interest in understanding 
diabetes-related metabolic disturbances in bone and discovering new approaches to 
deal with diabetic bone loss (Moseley 2012). The identification of several risk 
factors that are associated with bone health in diabetes has been discussed in 
Sections 1.2.1. Further, it is clear that common molecular signaling contributing to 
the pathogenesis of bone disorders can be exploited in the development of potential 
therapeutics. The beneficial actions of GIP and GLP-1 on bone suggest that incretin 
hormone mimetics can be useful in managing bone abnormalities in diabetes 
(Ceccarelli et al. 2013, Irwin et al. 2010).  
 
In this thesis, we investigated the potential beneficial effects of incretin-based 
therapies on bone abnormalities in diabetes. In vitro studies with GIP and its stable 
analogue on osteoblastic bone cells were conducted in Chapter 3. Additionally, 
preliminary studies on the effects of GIP and GLP-1 genetic deficiency on bone 
mass were also carried out in incretin receptor knock-out mice. In subsequent 
Chapters, the potential effects of different DPP-4 resistant incretin analogues, and a 
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DPP-4 inhibitor on bone quality, including bone mass, microstructure, geometry and 
strength was examined in three different types of diabetic mouse models, namely 
chemically-induced, genetically-induced and environmentally-induced diabetes.  
  
7.2  In vitro studies with GIP  
 
GIP is one of the well-characterised incretin hormones that promotes insulin-
releasing activity from pancreatic beta-cells in response to food ingestion. In 
addition to this, functional GIPRs are evidenced on normal human bone, osteoblast-
derived cell lines and osteoclasts, indicating direct bone actions of GIP (Bollag et al. 
2000, Zhong et al. 2007). Further studies have shown that GIP increased bone 
formation and reduced bone resorption, suggesting an anabolic effect of GIP on bone 
(Bollag et al. 2000, Ding et al. 2008, Tsukiyama et al. 2006, Zhong et al. 2003, 
Zhong et al. 2007). In Chapter 3, the potential effects of native GIP and the stable 
[D-Ala
2
]GIP analogue in stimulating bone formation in SaOS-2 cells was assessed. 
Both peptides significantly increased bone-related growth factors, TGF-β and IGF-1 
and the bone formation biomarker, alkaline phosphatase activity. In line with 
previous studies, cAMP production was also enhanced with native GIP and stable 
[D-Ala
2
]GIP, indicating activation of cAMP signaling pathways with GIPR ligands. 
More importantly, [D-Ala
2
]GIP was observed to be more potent than the native 
peptide. Preliminary studies on the effects of incretins on bone mass were also 
conducted in mice lacking GIP and/or GLP-1 receptors. It was found that bone mass 
was significantly reduced in GIPR and DIR KO mice, whilst BMD and BMC in 
GLP-1R KO mice were comparable with lean littermates. In vivo bone assessment in 
KO mice studies further confirmed the beneficial actions of GIP on bone 
(Mieczkowska et al. 2013, Xie et al. 2005).     
 
For future studies, other osteoblastic-like cell lines could be employed for in vitro 
studies with GIP peptides, namely MG-63 (human osteoblastic-like cell line) (Pautke 
et al. 2004) and MC3T3-E1 (mouse osteogenic cell line) (Sudo et al. 1983). 
Moreover, MG-63 has already been proven to express functional GIP receptors 
(Bollag et al. 2000). During bone formation, osteoblasts make unmineralised osteoid, 
which mainly consists of collagen, which is then followed by bone mineralization. 
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One of the determinants for bone strength is the degree of bone mineralisation and 
with the aforementioned cell lines, assessment on the effects of these peptides on 
mineral deposition could be performed as explained previously (Fratzl-Zelman et al. 
1998, Gregory et al. 2004). There are inconsistencies in reports on the presence of 
receptors of the other well-known incretin, GLP-1 on osteoblasts (Bollag et al. 2000, 
Mabilleau et al. 2013, Nuche-Berenguer et al. 2010a). However, these contradictory 
observations are not surprising as they used different osteoblastic cell lines in their 
studies. Therefore, future work could include receptor binding studies to determine 
and confirm GLP-1R expression on bone cells, followed by assessment on the 
potential impact of GLP-1 and its stable mimetics in vitro. 
 
Bone remodeling is a continuous process coordinated by osteoblasts and osteoclasts 
(Matsuo & Irie 2008). Maintenance of normal molecular signaling in this complex 
process is vital as imbalance in bone formation and bone resorption may cause bone 
loss or brittleness, leading to lower bone strength (Seeman 2002). Our studies, 
together with others have shown that GIP has positive effects on bone-forming 
osteoblasts (Bollag et al. 2000, Ding et al. 2008, Tsukiyama et al. 2006, Zhong et al. 
2003). However, studies on the effects of GIP on osteoclasts in vitro are lacking as 
only one previous study by Zhong and colleagues report the expression of GIPR on 
osteoclasts and the direct inhibition of bone resorptive activity by GIP (Zhong et al. 
2007). In agreement, another group revealed in a histomorphometrical study that 
bone formation biomarkers were reduced, coupled with a significant increase in the 
number of mature osteoclasts in GIPR KO mice, thereby confirming beneficial dual-
action of GIP signaling on bone (Tsukiyama et al. 2006). Further examination to 
establish the potential effects of activation of GIPR and GLP-1R signaling pathways 
in bone could include determination of osteoclastic proliferation, differentiation, cell 
death and changes in bone resorption biomarkers in osteoclastic cell cultures. 
 
7.3  Activation of GIPR or GLP-1R on bone quality in pharmacologically 
induced insulin-deficient diabetic mice 
 
Deficiency in insulin has adverse effects on bone growth (Thrailkill et al. 2005b). In 
animal studies, a chemical substance that is toxic to islets beta cells such as 
streptozotocin (STZ), has been readily used to induce insulin-deficient diabetes 
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models (Coe et al. 2013, Motyl & McCabe 2009). Incretin hormones, with primary 
physiological action to stimulate insulin secretion from pancreatic beta-cells, have 
been shown to have beneficial effects on bone (Mabilleau et al. 2013, Xie et al. 
2005, Xie et al. 2007, Yamada et al. 2008). The native forms of these peptides have a 
short half-life as they are rapidly degraded by DPP-4 (Baggio & Drucker 2007). In 
order to overcome DPP-4 activity, structurally-modified GIPR or GLP-1R agonist 
such as [D-Ala
2
]GIP or Liraglutide have been developed (Hinke et al. 2002, 
Knudsen et al. 2000).  
 
In Chapter 4 of this thesis, normal mice were injected with a single high dose (150 
mg/kg bw) of STZ to induce diabetes. Blood glucose concentrations were measured 
after 2 days to confirm the development of diabetes. Five days post-STZ 
introduction, diabetic mice received once-daily treatment with DPP-4 resistant [D-
Ala
2
]GIP or Liraglutide for 21 days. The effects of this regimen on metabolic 
parameters and bone quality were assessed and evaluated. Once-daily administration 
of [D-Ala
2
]GIP or Liraglutide had no significant effects on body weight, water 
intake, non-fasting plasma glucose and insulin concentrations in diabetic mice. 
Glucose tolerance had tendency to be improved, whilst no augmentation in insulin 
sensitivity was seen. No prominent changes observed in bone mass, 
microarchitecture and whole-bone strength with [D-Ala
2
]GIP or Liraglutide  therapy 
were observed. However, mechanical properties of bone matrix were remarkably 
improved with both treatments, indicating recovery of bone quality at the tissue 
level. It is worth highlighting that the target in GIPR or GLP-1R signaling may be on 
material properties in bone matrix, and that the positive effects of both long-acting 
analogues are independent of the insulin axis. Overall, this Chapter reveals the 
potential effects of the GIPR and GLP-1R agonists, [D-Ala
2
]GIP and Liraglutide, in 
attenuating insulin-deficient bone impairments in mice.     
 
Additional studies are required to further elucidate the impact of stable GIPR and 
GLP-1R agonists on bone. These include assessment of bone matrix with other 
techniques such as Fourier transform infrared imaging (FTIR), which allows 
investigation of modifications of collagen and minerals status (Paschalis 2012). 
Furthermore, bone histomorphometry can be performed to examine molecular 
activities in the bone (e.g osteoblasts and osteoclasts numbers, bone mineralisation) 
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(Erben & Glosmann 2012). In parallel, changes in the levels of bone formation and 
bone resorption serum biomarkers (osteocalcin, PINP, RANKL/OPG and C-terminal 
telopeptide) as well as protein expression in bone remodeling-associated signaling 
pathways (Wnt, RUNX2, MMP, amylin and calcitonin) could be assessed. 
Additionally, a similar long-term study could be conducted with additional groups of 
diabetic mice treated with the first line drug for osteoporosis and diabetes, a 
bisphosphonate and metformin, respectively, so that comparison in the efficacy of 
incretins can be made. 
 
7.4 Simultaneous activation of GIPR and GLP-1R by [D-Ala
2
]GIP-Oxm on 
bone quality in leptin receptor-deficient C57 BL/KsJ (db/db) mice 
 
Obesity has a detrimental impact on skeleton quality and impaired bone has been 
revealed in established rodent models of obesity and insulin resistance (Ealey et al. 
2006, Ionova-Martin et al. 2010, Patsch et al. 2011, Williams et al. 2011). Single 
activation of GIPR or GLP-1R has been shown to improve material properties of 
bone matrix in STZ-induced insulin-deficient diabetic mice in Chapter 4. However, 
the effects of co-activation of these receptors on bone quality are uncertain. Chapter 
5 of this thesis investigated the effects of simultaneous activation of GIP and GLP-1 
receptors by [D-Ala
2
]GIP-Oxm on metabolic parameters, bone micromorphology 
and strength in genetically-induced diabetic (db/db) mice. However, it also needs to 
be borne in mind that [D-Ala
2
]GIP-Oxm will also activate glucagon receptors. 
Administration of [D-Ala
2
]GIP-Oxm for 21 days had no effect on body weight, 
water intake and accumulative food intake. Non-fasting plasma glucose levels 
remained high despite a significant increase in insulin concentration on day 20. 
Additionally, no significant improvements were observed in glucose tolerance and 
insulin sensitivity between treated and nontreated diabetic groups.  
 
With regards to bone, [D-Ala
2
]GIP-Oxm therapy had no effects on bone mass as 
examined radiographically by DEXA and qXRI. However, further studies on bone 
microarchitecture found that trabecular thickness and cortical bone diameter were 
significantly elevated in diabetic mice treated with the stable triple-acting peptide. 
Assessment of biomechanical strength of whole-bone revealed increases in work 
required to resist fracture and displacement at maximum load applied. This was in 
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parallel with augmented tissue-level hardness and indentation modulus. From 
micromorphology and biomechanical evaluation, it was shown that [D-Ala
2
]GIP-
Oxm exerts its effect on both trabecular and cortical bone and that simultaneous 
activation of both incretin receptors improved not only the material properties of 
bone matrix, but also bone strength at the organ level. Nonetheless, these 
improvements were not associated with changes in mineral density distribution as no 
prominent changes were seen in the frequency, quantity or heterogeneity of calcium 
concentrations in teated and nontreated db/db mice. To summarise Chapter 5, the 
triple-acting agonist [D-Ala
2
]GIP-Oxm has beneficial actions on trabecular bone 
microarchitecture and cortical bone strength at the organ- and tissue-level.  
 
Further studies are needed to investigate possible molecular processes that are 
activated or inactivated by the binding of [D-Ala
2
]GIP-Oxm to incretin and glucagon 
receptors. This could be achieved through use of specific GIP, GLP-1 or glucagon 
antagonists, which have been characterised (Gault et al. 2003b, Peterson & Sullivan 
2001). Furthermore, additional FTIR studies together with gene and protein 
expression analysis, as suggested in Section 7.3, would be of interest.  
 
7.5 Effects of current incretin-based therapies for human T2DM on bone 
quality in high-fat fed mice 
 
Accumulating evidence has revealed the adverse effects of several existing 
antidiabetic therapies for T2DM, such as rosiglitazone and pioglitazone on the 
quality of the skeleton (Rzonca et al. 2004, Schwartz et al. 2006, Soroceanu et al. 
2004, Yaturu et al. 2007). As a new class of antidiabetic drugs, the glucose-lowering 
and insulin-stimulating properties of incretin-based therapies are well established 
(Ahren 2007, Lovshin & Drucker 2009, Lund et al. 2011). However, less well 
known are the potential effects of these drugs on bone integrity. Chapter 6 employed 
well-characterised high-fat diet-induced mouse model of obesity and diabetes to 
investigate the effects of the GLP-1 mimetic, Exendin-4 and DPP-4 inhibitor, 
Sitagliptin on bone mass, microarchitecture, geometry and strength. Chronic 
treatment with Exendin-4 (52 days) or Sitagliptin (21 days) had no effect on body 
weight and fat mass of high-fat fed mice. However, glycaemic control was improved 
as seen by the reduction of non-fasting glucose level. This was accompanied by a 
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significant increase in non-fasting insulin in Exendin-4- or Sitagliptin-treated 
compared to nontreated mice. Additionally, glucose tolerance and insulin sensitivity 
were improved with Exendin-4 and Sitagliptin therapy. 
 
In agreement with previous studies, mice fed on high-fat had impaired bone 
microarchitecture and strength (Cao et al. 2009, Ionova-Martin et al. 2010). 
Administration of Exendin-4 or Sitagliptin did not affect bone mass. On the other 
hand, a modest increase in trabecular bone volume, which was contributed by an 
increase in trabecular numbers and reduction in trabecular separation was observed 
with Exendin-4, whilst Sitagliptin treatment did not improve any of parameters 
measured at trabecular bone in high-fat fed mice. Examination of cortical bone 
geometry revealed no beneficial effect of Exendin-4 or Sitagliptin therapy. In three-
point bending tests, remarkable increased in resistance to bone failure was observed 
in diabetic mice treated with Exendin-4, but not Sitagliptin, whilst ultimate force, 
ultimate displacement and stiffness remained unchanged in all treatment groups. 
From these two separate studies, it is concluded that Exendin-4 improves mechanical 
bone strength and exerts its main effect at cortical bone, whilst Sitagliptin had 
neutral effects on bone. 
 
Smaller-scale tissue-level assessment such as nanoindentation could be performed to 
confirm the findings of the three-point bending test. Similar to previous chapters, 
FTIR and gene and protein expression studies would also add value to the present 
studies.  
 
7.6 Strengths and weaknesses 
 
Three different types of diabetic mouse model were employed in this study; STZ-
induced insulin-deficient, genetically-induced leptin receptor-deficient (db/db) and 
finally, the high-fat diet-induced diabetic model. The most significant point to note is 
that no single animal model can accurately mimic diabetes in man, so it is therefore 
necessary to study various aetiologies. STZ-induced and HFD-induced diabetic mice 
came from Swiss TO background, whilst db/db mice were derived from C57 BL/KsJ 
colony. In comparison to bone density of STZ-induced diabetic mice (Figure 4.9), 
db/db mice had a significant drop in bone density with respect to its normal 
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littermates (Figure 5.9). Bone develops in a relatively short period of time in mouse 
and at the end of first postnatal month, skeletons are almost completely formed 
(Zoetis et al. 2003). Due to its genetic background, bone formation in db/db mice has 
been disrupted since gestation and furthermore, deficiency in postnatal bone 
osteogenesis as a loss of leptin signaling has been shown in a previous db/db mice 
study (Roszer et al. 2014). In contrast, Swiss TO mice were allowed to grow under 
normal condition and induction of insulin deficiency in STZ-mice was performed 
after bone modelling was completed. Therefore, bone loss in db/db was more severe 
than Swiss TO STZ-diabetic mice.  
 
As discussed in Chapter 5, deficiency in leptin signaling negatively affects skeletal 
integrity (William et al. 2011). Leptin directly enhances osteoblast and chondrocyte 
proliferation and differentiation in vitro and in vivo (Cornish et al. 2002, Thomas et 
al. 1999) while inhibiting formation of multinucleated mature osteoclast (Cornish et 
al. 2002, Holloway et al. 2002). Leptin exerts its positive effects on bone through the 
specific leptin receptor, which has been evidenced on both osteoblasts and 
chondrocytes (Cornish et al. 2002, Steppan et al. 2000). In vivo, peripheral 
administration of leptin increases bone mass and reduces bone fragility (Cornish et 
al. 2002, Steppan et al. 2000) in agreement with observations in leptin deficient 
db/db mice in this thesis.  
 
In contrast, Karsenty groups reported that intracerebroventricular infusion of leptin 
in mutant and wild-type mice inhibits osteoblastic bone formation (Ducy et al. 2000) 
and induces bone resorption (Elefteriou et al. 2005), suggesting a central inhibitory 
role of leptin on the skeleton. These contradictory findings may be a result of 
different types of mice used in the studies or route of administration. Of note, leptin 
is a systemic hormone produced by adipocytes and is abundantly found in human 
bone marrow environment (Laharrague et al. 1998), proposing that it has important 
effects on bone. Furthermore, leptin is positively correlated with fat mass, which in 
turn, has been reported to protect individuals from skeletal fracture (Holecki & 
Wiecek 2010, Pasco et al. 2001). Regardless of the nature of leptin in bone, those 
aforementioned experiments establish that leptin can affect bone quality either 
through the hypothalamus or directly. 
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In the present study, incretin-based analogues were administered by the 
intraperitoneal route. Unlike intravenous route which bypasses the need for molecule 
absorption, intraperitoneal injection of drug into peritoneal cavity is primarily 
absorbed into portal vein system (Turner et al. 2011). The compounds eventually 
pass through the liver and undergo hepatic metabolism like oral delivery, before 
reaching other organs. In terms of incretin effect, intraperitoneal route of 
administration does not involve gastrointestinal tract and therefore, this method is 
more similar to intravenous delivery as the incretin effect is avoided. This means that 
our results are not influenced by possible activation of the incretin axis in these mice. 
 
There is a possibility of cross-reactivity between GIP and GLP-1 agonists, although 
it is unlikely to occur (Brubaker & Drucker 2002, Thorens 1992). This theory could 
be tested through use of specific GIP and GLP-1 receptor antagonists (Gault et al. 
2003b), or that the analogues could be studied in GIP and GLP-1 receptor transfected 
cells (Gremlich et al. 1995, Thorens 1993) or receptor KO animals (Preitner et al. 
2004, Scrocchi et al. 1996). These mechanistic type studies fall somewhat outside 
the scope of the current thesis but nevertheless could be very interesting.   
 
7.7 Summary of future studies 
 
This thesis presented data from in vitro studies with GIP and its stable analogue in 
osteoblastic-derived cells, as well as total and regional bone masses from single or 
double incretin receptor knock-out mice. In addition, bone quality after chronic 
treatment with incretin mimetics or DPP-4 inhibitor in three established mouse 
models of different aetiologies of diabetes was presented. While the data strongly 
suggests a beneficial effect of incretins on bone, further assessment is required to 
provide more evidence for the development of incretin-based therapies in the 
management of bone abnormalities in diabetes. Below is a summary of potential 
future work :  
 
1) Investigate the effects of GIPR and GLP-1R agonists in different 
osteoblastic-like cells such as MG-63 (human) and MC3T3-E1 (mouse) cell 
lines. 
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2) Assess effects of stable incretins on generation and differentiation of bone-
resorbing osteoclastic cells.  
 
3) Establish the mechanisms of action of long-acting GIP and GLP-1 analogues 
on bone.  
 
4) Conduct long-term studies with DPP-4 resistant GIP and GLP-1 peptides and 
compare against first line osteoporotic and antidiabetic drugs such as 
bisphosphonates and biguanides on bone quality in different models of 
diabetes.   
 
5) Conduct additional ex vivo bone assessments such as Fourier Transform 
Infrared (FTIR) spectroscopy and histology that have not been covered in this 
thesis.   
 
6) Evaluate frequency of bone abnormalities in patients treated with GLP-1 
mimetic or DPP-4 inhibitor versus other therapies. 
 
7) Assess direct effects of incretin receptor activation on bone characteristics in 
patients with diabetes. 
 
In conclusion, this thesis highlights incretin-based mimetics as new approach for the 
management of bone impairments in diabetes. Additionally, this thesis will hopefully 
provide useful knowledge that can be utilised in future investigations on diabetic 
bone loss, and in the development of potential therapeutics that will be beneficial for 
bone-related diseases in general. Ultimately this thesis will act as a forerunner 
towards clinical trials to reveal the utility of incretin-based drugs for people with 
diabetes and related bone disorders.  
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